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Imade E. Imasuen Williams 
LOSS OF TIP30 ACCELERATES PANCREATIC CANCER PROGRESSION 
AND METASTASIS 
Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading 
cause of cancer-related death in the United States, and is characterized by key 
driver mutations (e.g. KRAS, TP53, CDKN2A, and SMAD4), elevated expression 
of growth factors such as TGF-βs and the EGF receptor (EGFR), a markedly 
desmoplastic stroma, and a propensity to develop multi-organ metastases and 
chemoresistance. Consistent with its aggressive nature, the 5-year survival rate 
for PDAC is 8-9%, which demonstrates an urgent need to develop novel therapies. 
High expression levels of microRNA-10b (miR-10b) in PDAC tissues are 
associated with decreased patient survival and earlier appearance of metastatic 
disease following neoadjuvant chemoradiotherapy. miR-10b downregulates the 
expression of transcription coactivator Tat-Interacting Protein 30 (TIP30) by 
targeting its 3’UTR. TIP30 has multiple reported functions. TIP30 suppresses 
tumor formation and metastasis, forms a complex that regulates EGFR trafficking 
and degradation, and transcriptionally upregulates pro-apoptotic genes. 
Alterations in TIP30 have been reported in multiple human cancers, including 
pancreatic cancer. We hypothesized that Tip30-deficiency accelerates PDAC 
progression and metastasis in a murine model of PDAC. To test this hypothesis, 
we crossed mice with oncogenic Kras (KC) localized to the pancreas epithelium, 
with Tip30-deficient mice (K30C). We compared PDAC histopathology between 
Tip30-heterozygous (K30+/-C) and Tip30-null (K30-/-C) mice. Tip30-heterozygosity 
x 
accelerated PDAC-lesion-associated pancreatic cancer cell (PCC) pulmonary 
seeding. By contrast, total loss of Tip30 enhanced PCC micrometastatic seeding 
to the liver and hepatic metastasis. K30+/-C mice also presented with an early, 
increased penetrance of lung lesions and lung adenocarcinoma; and PCCs 
isolated from K30+/-C pancreata exhibited increased EGFR protein levels. These 
findings suggest that TIP30 deficiency can have a dose-dependent effect on 
organotropic metastasis and EGFR levels in PCCs. Future studies will delineate 
the molecular consequences of TIP30 loss in PDAC and contribute to a broader 
understanding of pancreatic cancer metastasis. 
 
       Thomas Hurley, Ph.D., Chair  
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CHAPTER 1. INTRODUCTION 
Cancer is the second leading cause of death in the United States (US), and 
the leading cause of death among Hispanics and Asian Americans (Heron et al., 
2016). As described by Hanahan and Weinberg in their seminal review, Hallmarks 
of Cancer, cancer, is the permanent alteration in a normal cell’s physiology 
(Hanahan and Weinberg, 2011). These alterations can allow uncontrolled cell 
proliferation and malignant growth of various tissues in the body. According to 
Hanahan and Weinberg, the six original hallmarks include: 
 evasion of apoptosis (programmed cell death)  
 the ability to produce growth signals 
 resisting anti-growth signals  
 an ability to promote the growth of new blood vessels  
 a capacity for tissue invasion and metastasis 
 unlimited capacity for replication (Hanahan and Weinberg, 
2000). 
 
In 2011, four additional hallmarks were added, including 1) hijacking cellular 
metabolism, 2) harboring genetic mutations and genomic instability, 3) evading the 
immune response, and 4) inflammation (Hanahan and Weinberg, 2011). 
Cancer death rates have declined by 26% since 1991, and as of 2016, more 
than 15.5 million cancer survivors were living in the United States (American 
Cancer Society, 2018). Research and technological strides have contributed to an 
improvement in cancer detection methods. These strides have impacted early 
diagnosis and the development of therapies for some cancers, such as testicular, 
prostate, thyroid, skin, and breast cancers. These five cancers currently have a 
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survival rate of greater than 90% (American Cancer Society, 2018). This statement 
is based on cases diagnosed between 2007-2013 and followed through 2014. 
Despite these advances for the general population, not all populations have 
seen the broad benefits. Survival rates are lower in Black Americans compared to 
White Americans for many cancers (“Cancer Disparities”, 2018). Since the late 
1980s, testicular cancer has had near-cure survival rates, at greater than 95%. In 
addition, the five-year survival rate for breast cancer is currently 91%, for all races. 
However, the survival percentages drop drastically for patients diagnosed at later 
stages (American Cancer Society, 2018). It should also be noted that 
epidemiological statistics above are based on data collected by the Surveillance 
Research Program in the National Cancer Institute’s Division of Cancer Control 
and Population Sciences (“Surveillance, Epidemiology”, 2010). However, data 
availability and underreporting limit the broad utility of the data, as these studies 
represent only one-third of the population of the United States (Yu et al., 2009). 
Continued research and collaborations between clinicians and translational and 
basic scientists in fields of surgery, radiation oncology, immunology, genetics, 
biochemistry, chemistry, and molecular and cellular biology, will one day allow for 
similar advances for other cancers, including one the most deadly: pancreatic 
cancer, where the survival rate has only increased by a few percentage points, 
since the 1970s (American Cancer Society, 2018). 
1.1 Pancreatic Ductal Adenocarcinoma (PDAC) 
Pancreatic cancer is currently the fourth leading cause of cancer-related 
death in the United States and is projected to become the second by 2020 (Rahib, 
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2014). In 2018, there were roughly 55,000 new pancreatic cancer cases, and 
roughly 44,000 estimated deaths (Siegel et al., 2018). Although the risk of 
developing pancreatic cancer is rare, it is almost always fatal. The median survival 
for PDAC is six months, with an overall five-year survival rate of 8-9% (Siegel, 
2014; Siegel et al., 2018; American Cancer Society, 2018). This poor prognosis is 
due in large part to its high metastatic prevalence. The most common sites of 
metastasis are the liver, followed by the lung (Hezel et al., 2006). More than 80% 
of patients have non-localized disease at diagnosis and are not eligible for surgery 
(Li et al., 2004; Hezel et al., 2006; American Cancer Society, 2018). 
Pancreatic ductal adenocarcinoma, PDAC, makes up approximately 94% 
of all pancreatic cancers (Warshaw et al., 1992, American Cancer Society, 2018). 
PDAC is characterized by heightened desmoplasia (Pandol et al., 2009), a hypoxic 
tumor environment (Koong et al., 2000), pancreatic cancer cell (PCC) 
chemoresistance, a high frequency of key driver mutations [KRAS (95%) (Raphael 
et al., 2017; Almoguera et al., 1988), SMAD4 (55%), TP53 (70%), and CDKN2A 
(90%) (Rozenblum et al., 1997; Kern, 2000; Hruban et al., 2000)], and upregulation 
of growth factors including transforming growth factor-betas (TGF-βs) (Friess et 
al., 1993) and epidermal growth factor (EGF) receptor (Navas et al, 2012; Barton 
et al., 1991; Korc et al., 1992; Friess et al., 1996; reviewed by Bardeesy and 
DePhino, 2002). The complexity of the tumor microenvironment, the heterogeneity 
of the disease, the lack of useful biomarkers for early detection, and inadequate 
therapeutic response makes PDAC a challenging cancer to treat (Siegel et al., 
2018). 
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There are seven distinct stages of PDAC progression (0-IV), with stage IV 
being the most advanced. Stages I and II have two sub-stage classifications: A 
and B (Alteri et al., 2017). Disease stage is determined by tumor size, lymph node 
involvement, and metastasis to distant organs. The American Joint Committee on 
Cancer determined this tumor-node-metastasis classification system (Edge et al., 
2010). In Stage 0, or carcinoma in situ, cancer is confined to the pancreatic duct 
cells and the pancreas (Alteri et al., 2017). In Stage IA, the tumor is 2 cm or less, 
while in Stage IB, the tumor is between 2 and 4 cm. In Stage IIA, the tumor is 
bigger than 4 cm across. In Stage IIB, the tumor size can be anywhere between 
that as described in Stage I-IIA but also involves spread to a few lymph nodes 
(Hidalgo, 2010; Saka et al., 2016). In Stage I or II, the tumor is classified as 
resectable (Varadhachary et al., 2006). Stage III cancer may or may not be 
confined to the pancreas and varies in size, and lymph node involvement, but 
spread to distant sites is not detected; this stage is classified as locally advanced 
and unresectable (Varadhachary et al., 2006; Hidalgo, 2010). In Stage IV, or 
metastatic disease, PDAC has spread to either the liver, peritoneum (lining of the 
abdominal cavity), lungs and/or bones (Peixoto et al., 2015). It is important to note 
that in humans diagnosed with Stage IV cancer, both the cancer size and lymph 
node spread can vary (Alteri et al., 2017; Hidalgo, 2010). This variability highlights 
the heterogeneity of the disease and challenges the prevailing paradigm that tumor 
invasion precedes metastasis. 
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1.1.1 Pancreas Anatomy and Physiology 
Pancreas is derived from Greek, meaning “all flesh”. The human pancreas 
is a glandular organ that lies in the abdomen just behind the stomach (reviewed in 
Williams, J, 2012). The pancreas is in direct proximity to the portal vein (PV), aorta, 
celiac axis (CA), and the superior mesenteric vein (SMV) and artery (SMA) 
(Longnecker, 2014; Figure 1). The head of the pancreas sits in a crevice of the 
duodenum, and the tail of the pancreas connects to the spleen. The majority of the 
pancreas tissue is exocrine, and aids in the digestion of proteins and 
carbohydrates. The exocrine pancreas is comprised of acinar and ductal 
compartments that are responsible for pro-enzyme secretion and release of 
pancreatic juices into the duodenum of the small intestine (Kern, 1993). The major 
pancreatic duct, which connects with the common bile duct, allows pancreatic 
secretions to reach the duodenum. Key enzymes produced by the pancreas are 
trypsin, which aids in protein digestion, and amylase and lipase, which aid in the 
breakdown of carbohydrates and fats, respectively. Additional enzymes stored in 
the pancreas are DNase and RNase (Pandol, 2011).  
The remaining pancreatic tissue is endocrine in function and is responsible 
for releasing hormones into the bloodstream. The islet compartment of the 
pancreas (Figure 1), or the islets of Langerhans house the endocrine function of 
the pancreas. Somatostatin, growth inhibitory hormone, is one such hormone 
released by the pancreas (Longnecker, 2014), in addition to the hormones insulin 
and glucagon that are released from alpha and beta cells, respectively. Insulin and 
glucagon regulate the responses to the fed and fasting states relative to circulating 
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Figure 1. The pancreas with neighboring arteries and blood vessels 
  
A depiction of the human pancreas with a tumor (PDAC), sitting in the groove of the duodenum. 
CA-Celic Axis, HA-Hepatic Artery, PV-Portal Vein, SA-Splenic Artery. SMA-Superior Mesenteric 
Artery. SMV-Superior Mesenteric Vein. The head and tail of the pancreas are marked.
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blood glucose levels. Glucagon stimulates the breakdown of the energy reserve 
glycogen in the liver in order to maintain blood glucose levels. Decreased insulin 
production or resistance to insulin is linked to type 1 or 2 Diabetes Mellitus 
(reviewed by Kharroubi and Darwish, 2015). 
1.1.2 PDAC Presentation and Risk Factors 
Patients diagnosed with pancreatic cancer often present late in the disease 
stage. The clinical presentation for PDAC includes unexplained weight loss, 
jaundice, acute onset of diabetes, and can include acute pancreatitis, floating 
stools, pain, nausea, and vomiting (Tempero et al., 2017). However, these 
symptoms often appear only during advanced disease stages (American Cancer 
Society, 2018). Early stage disease symptoms can be vague and non-specific, 
further contributing to late diagnoses. By the time most patients reach the clinic, 
their cancer has already metastasized to distant organs.  
Jaundice is associated with patients with tumors in the head of the pancreas, 
while patients with tumors in the tail or body of the pancreas are more likely to 
present with symptoms only late in the development of the disease (reviewed in 
Tempero et al., 2017). As a consequence, only 15% of PDAC patients present with 
resectable disease (Hidalgo et al., 2015). Furthermore, 
 75% of patients experience recurrence in approximately 2.5 years 
(Groot et al., 2018) 
 
 ~35% of PDAC patients present with locally advanced disease 
(Stage III) (Hidalgo et al., 2015) 
 
 50-60% of PDAC patients present with metastatic disease (Stage 
IV) (American Cancer Society, 2017; Varadhachary, 2006; Hidalgo 
et al., 2015). 
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In locally advanced disease, a pancreatic tumor can fall under the category of 
borderline resectable where the tumor partially wraps around vital blood vessels 
(Figure 2A) or locally advanced surgically unresectable disease. A borderline 
resectable tumor either encases the hepatic artery without extending to the celiac 
axis (and without SMA encasement) or some distortion or narrowing of the SMV is 
present, but safe resection and reconstruction are feasible (Al-Hawary et al., 
2013). If a tumor makes venous or arterial vessel contact that exceeds 180° in 
circumference, it is classified as “vessel encasement” (Figure 2B). In the case of 
unresectable disease, the relationship and proximity between the tumor and vein 
or artery decrease the safety for surgical removal of the tumor. Unresectable 
PDAC involves tumor encasement of the celiac axis, more than 180° around the 
superior mesenteric artery (SMA), or occlusion of the superior mesenteric vein 
(SMV), the portal vein (PV), or the superior mesenteric-portal vein (SMPV) 
(Varadhachary, 2006; Al-Hawary et al., 2014, Figure 2C). This would result in an 
unreconstructable SMV or PV, and the patient’s disease is therefore considered 
inoperable.  
PDAC is associated with a variety of different risk factors. The demographic 
factors associated in developing pancreatic cancer include age (> 50 years), male 
gender, and ethnicity (black populations have the highest mortality) (reviewed in Li 
et al., 2004). Outside of these demographic factors, lifestyle risk factors include 
tobacco, obesity and heavy alcohol use. The latter of which is defined as more 
than 20 drinks per week (Alsamarrai et al., 2014) or >60 mL ethanol/day (Hassan 
et al., 2007). In a different report and meta-analysis of 117 pooled datasets,
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Figure 2. PDAC tumor contact with arterial or venous wall influences surgical resection 
 
(A) Tumor contact is less than 180°. No arterial or vein encasement or distortion. (B) Tumor contact 
is 180°. Tumor is encasing the artery or vein. (C) Tumor contact of greater than 180° with arterial 
or venous occlusion and distortion. Black arrow notes an example of distortion. X, Artery or Vein, 
T, Tumor. Dashed line, 180° lumenal circumference. Image reproduced with permission from 
reference Al-Hawary et al., 2014. 
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tobacco smoking was one of the highest associated risk factors (Maisonneuve and 
Lowenfels, 2014). The risk of developing pancreatic cancer is two-fold higher in 
smokers as compared to non-smokers (Lin et al., 2002; Iodice et al., 2008). Lastly, 
genetic predisposition, Diabetes Mellitus, a history of pancreatitis (Hassan et al., 
2007; American Cancer Society, 2017), Helicobacter pylori infection (moderate 
risk, Maisonneuve and Lowenfels, 2014), smokeless tobacco use, Lynch 
syndrome, presence of mutations in BRCA1 and/or BRCA2, more than four cups 
of coffee per day (American Cancer Society, 2017, Lin, Y, 2002), low fruit and 
vegetable intake, and the consumption of charred food from grilling (Li, D., 2004) 
are additional reported risk factors. Epidemiology studies demonstrate that 1 in 62 
individuals can expect to be diagnosed with pancreatic cancer at least once in their 
lifetime (Noone, 2018). 
Most PDAC cases result from somatic mutations. However, roughly 10% of 
cases result from germline or familial mutations. To be considered at risk for 
familial PDAC, the patient must have at least two immediate relatives (parent, 
sibling, or child) diagnosed with the disease (Petersen, 2016). Genetic risk factors 
and medical conditions that contribute to pancreatic cancer predisposition are 
hereditary pancreatitis, hereditary non-polyposis colorectal cancer, ataxia-
telangiectasia, Peutz-Jeghers syndrome, familial breast cancer, familial atypical 
multiple mole melanoma, chronic pancreatitis, diabetic mellitus, gastrectomy and 
deficiencies in carcinogen metabolism and DNA repair (reviewed in Li et al., 2004). 
Common genes involved in hereditary pancreatic cancer are BRCA2, CDKN2A, 
PALB2, and ATM (Roberts et al., 2016). The time between a diagnosis of chronic 
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pancreatitis and onset of PDAC is 10-20 years (Bang et al., 2014). Chronic 
pancreatitis, although a risk factor, is considered to confer very low risk for PDAC, 
with only 4-6% of chronic pancreatitis patients presenting with PDAC over 20 years 
(Bang et al., 2014). To reduce the risk of pancreatic cancer, a tobacco- and a 
smoke-free lifestyle, lower body mass index (BMI), and a diet consisting of fruit 
and whole grains is recommended (Pericleous et al., 2014).  
When compared to age-matched controls, PDAC patients had at least a 
40% higher prevalence of diabetes compared to breast, colon, lung or prostate 
cancer patients (Andersen et al., 2017). Although PDAC arises in the exocrine 
pancreas, alterations in the endocrine compartment may predispose people to 
disease development and vice versa. Type 3c diabetes (T3cDM) is used to 
describe diabetic patients that developed diabetes after first being diagnosed with 
exocrine pancreatic disease (reviewed in Andersen et al., 2017). It is also referred 
to as PDAC-associated diabetes or new-onset diabetes associated with PDAC 
(reviewed in Andersen et al., 2017). Although pancreatic disease and PDAC are 
believed to cause diabetes in a subset of patients, the mechanism for this is not 
yet known. The causation-association between the two are based on findings that 
in PDAC patients with diabetes, the diagnoses for the latter occurred less than 24 
months before the diagnosis of PDAC (Pannala et al., 2008; Andersen et al., 
2017). Researchers have even encouraged clinicians to use new-onset diabetes 
as a biomarker for PDAC diagnosis. 
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1.1.2.1 Pancreatic Cancer Disparities 
Non-Hispanic Blacks (NHBs) and African Americans have the highest 
cancer incidence and mortality rates compared to other races (Siegel et al., 2018). 
In the most recent report, African Americans (AA) had both the highest incidence 
and mortality rates for cancers of the kidney and renal pelvis, the liver and 
intrahepatic bile duct, the lung and bronchus (male), the prostate, the stomach, 
and the uterine cervix (Siegel et al., 2018). Although the incidence for patients with 
breast cancer were similar in both non-Hispanic Black (NHB) and non-Hispanic 
White (NHW) women, NHB breast cancer patients had a higher mortality rate. 
Overall cancer deaths in NHBs were 14% higher than NHWs and were 
independent of gender (Siegel et al., 2014; Siegel et al., 2018); the racial disparity 
was more substantial for individuals 65 years old or younger. These and other 
disparities were attributed to lower access to quality healthcare (Siegel et al., 
2018). Emerging studies point to the impact of genetic ancestry on the biology and 
disease course in breast cancer, a field where disparities in breast cancer have 
been well established. For instance, the observation that US Hispanic women have 
the second lowest breast cancer incidence compared to NHW, AA, Asian 
American, and Indigenous American women is attributed to their mixed European 
and Indigenous American ancestry (reviewed in Fejerman et al., 2008). Fejerman 
et al., (2008) found that after adjusting for place of birth and known risk factors, the 
association between higher European ancestry and breast cancer risk was 
statistically significant. In contrast, there is disproportionate presentation of an 
aggressive subtype of breast cancer in women of African descent. Young women 
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of African descent have a higher incidence of triple-negative breast cancer 
(reviewed in Jenkins et al., 2019). According to Jenkins et al. (2019), these women 
are reported to have tumors with a distinct genetic signature. An example is the 
DARC/ACKR1 mutation, which is known as the duffy variant and is restricted to 
populations with West African Ancestry (Jenkins et al., 2019). This recent study 
shows that the West African-specific duffy variant strongly associates with an 
increase in proinflammatory chemokines involved in cancer progression.   
The incidence of pancreatic cancer is 25% higher in NHBs compared to 
NHWs (American Cancer Society, 2018). A multi-institutional study based out of 
Houston, Texas, reported that African American (AA) PDAC patients had a lower 
survival status compared with Caucasian PDAC patients (after adjusting for age, 
sex, and stage at diagnosis). They further suggested that the factors that attributed 
to these differences included financial pressures, cultural differences, and 
underlying comorbidities that prevented therapy (Wray et al., 2012). These factors 
also decreased the probability of receiving treatment, Wray et al. (2012) reported. 
In a review by Khawja et al. (2015), AA patients were younger at the time of 
diagnosis, and had more difficult-to-treat tumors, specifically tumors found in the 
tail or body of the pancreas. Although the percentage of patients with mutations at 
codon 12 in KRAS were not significantly different in AA PDAC patients, the 
presence of the KRASG12V mutation was more than double that of Caucasian 
patients (Pernick et al., 2003). Additional studies into the impact of genetic 
ancestry on PDAC incidence and patient survival are needed in the pancreatic 
cancer research field. 
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Health disparity studies are limited based on self-reporting of race without 
mapping of genetic ancestry (Mersha and Abebe, 2015). As reviewed by Mersha 
and Abebe in Human Genomics, race refers to a person’s physical appearance, 
i.e., skin color. Ethnicity can refer to a person’s cultural heritage. However, these 
groupings do not account for the variability in genetic ancestry and the specific 
percent of African or European ancestry in an individual, uncovered by genetic 
analysis (Mersha and Abebe, 2015). Research studies should account for 
commonalities in single nucleotide polymorphism (SNP) variants to more 
accurately identify and group populations of individuals (Mersha and Abebe, 2015). 
This approach could improve treatment options for people of color diagnosed with 
PDAC. Bridging gaps identified in health disparities research may also include 
more representation of minorities in clinical trials and stages of drug development, 
and in the use of human samples for research. Addressing these concerns, 
especially for PDAC, could help advance the field and translate to the broader 
population within the United States.  
1.1.3 Current Therapy 
PDAC is currently detected by endoscopic ultrasound-guided fine-needle 
aspiration (EUS-FNA) (Hewitt et al., 2012). This method, however, cannot be used 
to exclude the presence of cancer and EUS-FNA cannot distinguish between 
PDAC and chronic pancreatitis (Hartwig et al., 2009, Fritscher-Ravens et al., 
2002). The current standard of care for PDAC is gemcitabine plus nanoparticle 
albumin-bound (nab)-paclitaxel (a microtubule inhibitor) or the combination of 
leucovorin, 5-fluorouracil (5-FU), irinotecan and oxaliplatin (FOLFIRINOX) 
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(reviewed in Hidalgo et al., 2015). Surgery and radiation therapy, with a 
combination of any of the three chemotherapies, are also current treatment options 
for patients diagnosed with pancreatic cancer. For patients with borderline 
resectable pancreatic cancer, the standard of care is a chemotherapeutic as a 
neoadjuvant, followed by chemoradiation therapy after surgery (Varadhachary et 
al., 2006). 
1.1.3.1 Surgery 
Surgery and removal of the tumor is currently the only way to cure 
pancreatic cancer (reviewed in Bardeesy and DePinho, 2002; Ducreux et al., 
2015). Unfortunately, due to the typically late presentation, only about 20% of 
patients are candidates for surgery. During the surgical process, resection of the 
tumor is difficult and must be accompanied by clear disease-free margins. Positive 
margins after surgery can result in disease re-occurrence and translate to poor 
survival outcome (reviewed in Varadhachary, 2006). In addition, the reported five-
year survival rate for surgery-eligible candidates is still only 20% (Ahrendt and Pitt, 
2002). A computed tomography (CT) scan, using submillimeter (0.5-1 mm) axial 
(horizontal plane) sections, is used to stage the tumor and determine resectable 
or non-resectable tumor classification (stage I or II) (Lu et al., 1997). CT is the 
preferred method for pancreas imaging and staging; however, pathological 
diagnosis is not required before surgery (Tempero et al., 2017). 
The relationship between the pancreatic tumor and any nearby vessel or 
arterial wall, introduced in section 1.1.2, is especially critical in determining what 
type of surgery, if any, can be performed (Tempero et al., 2017). Degree of contact 
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with either the vessel or arterial wall as well as vessel or arterial deformity or 
narrowing are two criteria that surgeons must take into account to determine if a 
pancreatic tumor can be resected (Tempero et al., 2017, Figure 2). A pancreatic 
tumor is resectable when fat planes are present around the celiac axis and superior 
mesenteric (SMA) and hepatic arteries without superior mesenteric (SMV) or portal 
vein distortion (Al-Hawary et al., 2013). Venous or arterial vessel contact that 
exceeds 180° in circumference precludes surgical removal of the tumor (Figure 
2C, Al-Hawary et al., 2013). Aortic encasement or invasion (Figure 1) would also 
hinder the surgical resection of a tumor (Al-Hawary, 2014). Negative resection 
margins (the outer edge of tissue devoid of cancer cells) are imperative for 
improved prognosis after surgery (Sohn et al., 2000). If the pancreatic tumor is 
ever in an inaccessible location that may potentially prevent vasculature 
reconstruction or leave negative margins, then surgeons will not operate. 
Tumors in the pancreas tail and body are typically not eligible for surgical 
resection due to advanced disease at the time of diagnosis. However, if eligible 
then a pancreatectomy is performed (surgical excision of the tail and body of the 
pancreas and spleen). A total pancreatectomy is performed if the cancer is not 
confined to just one region of the pancreas. These surgeries also typically include 
removal of a portion of the small intestine, a portion of the stomach, the common 
bile duct, the gallbladder, the spleen, and nearby lymph nodes. Patients that 
present with tumors in the head of the pancreas receive a minimally invasive 
pancreaticoduodenectomy termed a “Whipple” which is a complex technique 
required to be performed only by highly skilled and trained surgeons. The Whipple 
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is a form of laparoscopic surgery that was performed first by Walter Kausch and 
then Allen Whipple in the early 1900s (reviewed in Gagner and Palermo 2009). 
This procedure results in the removal of the head of the pancreas, the duodenum, 
the gallbladder, and the bile duct resulting in resection and reconstruction in one 
step (Tempero et al., 2017; reviewed in Masiak-Segit et al., 2018). 
1.1.3.2 Chemotherapy  
Current therapeutic modalities for PDAC are gemcitabine plus nab-
paclitaxel or FOLFIRINOX. Before administration of neoadjuvant therapy, a fine-
needle aspiration (FNA) biopsy guided by endoscopic ultrasound (EUS) or CT is 
required. The biopsy is used to confirm malignancy and for pathological staging. 
Neoadjuvant therapy is administered first to shrink the tumor before surgery. 
Gemcitabine is recommended for patients with either metastatic or locally 
advanced disease, as well as good performance status (Tempero et al., 2017). In 
a large phase 3 clinical trial of gemcitabine-treated patients, the median disease-
free survival (DFS) was 13.4 months for the gemcitabine-treated group compared 
to only 6.7 months in the control group (Oettle et al., 2013).  
Although, gemcitabine and gemcitabine combinations are recommended as 
first-line treatment for PDAC, fixed-dose-rate gemcitabine or other gemcitabine 
combinations are also acceptable forms of treatment for patients with advanced or 
metastatic disease. Some combinations include gemcitabine plus cisplatin, 
gemcitabine plus erlotinib (an epidermal growth factor receptor (EGFR) inhibitor), 
and gemcitabine plus capecitabine. However, these latter combination therapies 
did not result in a median DFS that was better than gemcitabine alone. An 
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exception is the case of gemcitabine plus cisplatin, which did provide benefit to a 
certain subgroup of patients. All combinations also were associated with extreme 
toxicities, such as in the case of gemcitabine plus capecitabine (Tempero et al., 
2017). The most recent chemotherapy regimen for patients with metastatic 
pancreatic cancer includes cocktail leucovorin (folinic acid), 5-FU (fluorouracil), 
irinotecan, and oxaliplatin (FOLFIRINOX). In a randomized phase 3 clinical trial 
patients treated with FOLFIRINOX exhibited a significant three-four month 
progression-free survival (PFS) and median overall survival (OS) advantage 
compared to patients treated with gemcitabine alone (Conroy et al., 2011). 
FOLFIRINOX is also used as a second-line treatment for patients that have been 
previously treated with gemcitabine.  
1.1.3.3 Radiation Therapy 
Patients with pancreatic cancer are given radiation therapy in combination 
with chemotherapy. Chemotherapy is used to sensitize cancer cells to radiation 
(Tempero et al., 2017); this maximizes the impact of the radiation. To date, the 
addition of radiation therapy only results in a modest survival advantage at best 
when compared to treatment with chemotherapeutic regimens alone (reviewed in 
Tempero et al., 2017). Advances in radiation therapy will be beneficial for those 
patients with localized PDAC and poor performance status: patients who cannot 
tolerate surgery and are inoperable due to age. Stereotactic body radiation 
therapy (SBRT) is one such approach that delivers precise radiation therapy via 
cyberknife and linear-accelerator-based methods (Ryan et al., 2018).  
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1.1.4 PDAC Pathobiology and Tumor Microenvironment 
In addition to heterogeneous, PDAC tumors are often described as 
desmoplastic, which means they are dense and abundant in fibrous or connective 
tissue (reviewed in Hezel et al., 2006). PDAC tumor tissue, also referred to as 
stroma, makes up 80% of the pancreatic tumor mass and plays an important role 
in carcinogenesis (Erkan et al., 2010). PDAC stroma is rich in type I collagen and 
fibronectin (Mollenhauer et al., 1987). In addition to collagen and fibronectin, the 
PDAC tumor microenvironment is also abundant in hyaluronic acid (Provenzano 
et al., 2012; Olive et al., 2009; Jacobetz et al., 2013; Chen et al., 2015). Cancer 
heterogeneity describes the cell population diversity commonly found within a 
tumor and the distinct molecular signatures of those cell populations (Dagogo-Jack 
and Shaw, 2017). The extracellular matrix (ECM) of a PDAC tumor is the molecular 
network that connects the various cell types within the tumor (Feig et al., 2012). 
These cells include cancer epithelial cells, stromal cells (stellate cells), fibroblasts, 
a variety of cancer-associated fibroblasts (CAFS), endothelial cells, and all 
immune cells (Öhlund et al., 2017).  
In addition to being widely fibrotic as a result of desmoplastic reaction 
(Pandol et al., 2009), the PDAC tumor microenvironment is hypovascular, which 
leads to a low oxygen or a hypoxic - environment (Koong et al., 2000). Hypoxia is 
reported to increase pancreatic stellate cell activity (Couvelard et al., 2005). 
Indeed, vessels in PDAC tumors appear collapsed (Longo et al., 2016) which is a 
phenomenon attributed to the interstitial fluid pressure in solid tumors. The 
decreased vasculature adversely impacts drug delivery and is a factor in chemo-
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resistance (Jacobetz et al., 2013). Reports on the role of the vasculature in PDAC 
tumors are conflicting. Although blood vessels are compressed, in a recent report, 
35% of human PDACs (hPDACs) exhibit an up-regulation of an angiogenic gene 
signature (Craven et al., 2016). Targeting lymphangiogenesis using a 
combinatorial therapy approach has also led to tumor growth and metastasis 
suppression in an orthotopic model of PDAC (Gore et al., 2016). These and other 
reports of high vascular endothelial growth factor (VEGF) expression in PDAC 
tumors challenge the current dogma that angiogenesis does not actively play a 
role in PDAC (Itakura et al., 1997; Seo et al., 2000). 
Another characteristic of the PDAC tumor microenvironment is its highly 
immunosuppressive nature. Immunosuppression is one way that tumor cells 
evade immune surveillance, which typically serves to destroy pathogens (reviewed 
in Vinay et al., 2015). Understanding the relationship between the immune system 
and PDAC tumor biology will be necessary for developing effective 
immunotherapies. Immune infiltrates of PDAC tumors include high numbers of M2-
type tumor-associated macrophages (TAMs), a subset of neutrophils, regulatory 
T-cells (Treg), and T helper 17 (TH17) cells (reviewed in Protti and De Monte, 2013; 
Clark et al., 2007; Zou and Restifo, 2011), and myeloid-derived suppressor cells 
(MDSCs) (Zhang et al., 2014). Although the number of CD68+ macrophage 
infiltrates in human PDAC tumors vary, one study demonstrated that an increase 
in CD163+ and CD204+ M2-type TAMs were associated with invasion and lymph 
node metastasis (reviewed in Protti and De Monte, 2013). In an inducible 
genetically engineered mouse model (GEMM) of PDAC, macrophages and a 
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second subset of myeloid cells, MDSCs, were found to inhibit CD8+ T-cell anti-
tumor activity by activating PD-L1 expression through an EGFR/MAPK signaling 
axis (Zhang et al., 2016). Targeting CD11b myeloid cells in this model restored 
anti-tumor immunity. The emerging field of tumor immunology, as it applies to 
PDAC is an area that warrants further investigation, and may allow for a better 
understanding of PDAC pathobiology and the complex tumor microenvironment.  
1.1.5 PDAC Initiation, Progression, and Maintenance 
The head of the pancreas is the most common site of PDAC formation 
(Hezel et al., 2006). However, tumors are also found in the organ’s tail or body. If 
tumors of the body or tail of the pancreas go undetected, it results in more 
aggressive tumor formation and poorer patient outcome (Dreyer et al., 2018). In 
addition to a desmoplastic stromal reaction, other histological features of PDAC 
include abnormal gland formation and well-to-poorly-differentiated tumors (Hansel 
et al., 2003). Of the three identified PDAC precursor lesions: pancreatic 
intraepithelial neoplasia (PanIN), mucinous cystic neoplasm (MCN), and 
intraductal papillary mucinous neoplasm (IPMN), PanIN is the most common and 
widely studied (reviewed in Hezel et al., 2006). PanIN lesions are microscopic and 
progress stepwise, from PanIN-1A/B to PanIN-2 to PanIN-3, accumulating genetic 
alterations as they progress to PDAC (reviewed in Hruban, 2000; Bardeesy and 
DePinho, 2002; Brosens et al., 2015). As PanIN lesions progress in histological 
stage they exhibit increasing architectural and nuclear atypia (Kern et al., 2001). 
High-grade PanIN, such as PanIN-3, are found less frequently in human pancreas 
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tissues from individuals who have not been diagnosed with PDAC and are 
associated with invasive PDAC (Konstantinidis et al., 2013; Hruban et al., 2004). 
There are four key genetic driver mutations of PDAC. These are genetic 
mutations that predominate and are found at high frequency in PDAC patients. 
These drivers are KRAS, p16INK4A, SMAD4/DPC4, and TP53 alterations (Kern, 
2000; Yachida and Iacobuzio-Donahue, 2009), and all can contribute to PDAC 
initiation and progression (Bardeesy and DePinho, 2002). PDAC formation is 
believed to follow a genetic progression model, and telomere shortening 
contributes to this genomic instability (Bardeesy and DePinho, 2002; Hruban et al., 
2000). Additionally, telomere shortening is an event that is detected beginning in 
early grade PanIN (van Heek et al., 2002), and contributes to PDAC when coupled 
with inflammatory conditions (Brosens et al., 2015).  
Low-frequency driver mutations of PDAC include alterations in the 
retinoblastoma gene (RB1) (Kern, 2000) and hyperphosphorylation and 
inactivation of its protein product, RB (Gore et al., 2013) and the overexpression 
of growth factors such as transforming growth factor-βs (TGF-βs) (Friess et al., 
1993) and the epidermal growth factor (EGF) family of receptors (R) and their 
ligands (Barton et al., 1991; Korc et al., 1992; Friess et al., 1996). Alterations in 
TGFβR2 are also seen at lower frequency (Goggins et al., 1998). Dysregulation in 
pathways such as these promotes uncontrolled proliferation in human and murine 
pancreatic cancer cell lines (Gore et al., 2013; Jaganathan et al., 2010).   
The specific cell of origin in PDAC is still unclear. PDAC was initially thought 
to originate from ductal cells due to the duct-like histology of PanIN precursor 
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lesions. However, attempts to transform normal ductal cells into PanIN precursor 
lesions or PDAC were unsuccessful (Brembeck et al., 2003). A vast body of 
literature supports the acinar cell as the PDAC cell of origin (Wagner, 2001; 
Carrière et al., 2007; reviewed in Guerra and Barbacid, 2013). Acinar to ductal 
metaplasia (ADM) is reported to precede PanIN formation and PDAC (Crawford et 
al., 2002), and PanIN precursor lesions are thought to originate through the 
transdifferentiation of acinar cells (reviewed by Stanger and Dor, 2006; Guerra and 
Barbacid, 2013). However, pancreata, resected for reasons other than PDAC have 
a 50% incidence of PanIN-1 (Konstantinidis et al., 2013), challenging a definitive 
association between early lesions and stepwise progression to PDAC. The 
concept of pancreas insult or injury either through inflammation, a genetic event, 
or an environmental oxidative stress event is widely accepted as an associated 
event for PDAC initiation (reviewed by Kolodecik et al., 2013). Although a 
combination of one or more of these events is a likely initiator of the disease, it is 
generally perceived that “inflammatory-driven pancreatic carcinogenesis” is a 
significant contributor (reviewed in Neesse et al., 2015). In this model, a damaged 
acinar cell releases inflammatory cytokines such as interleukin-6 (IL-6) or tumor 
necrosis factor (TNF) in response to pancreatic injury. The immune system then 
attempts to clear the cells, albeit unsuccessfully. Additional pro-inflammatory 
cytokines are released into the parenchyma and inadvertently result in an increase 
in the population of pre-malignant and malignant pancreatic cells (reviewed in 
Neesse et al., 2015).  
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Cancer cell and cancer cell-associated fibroblast (CAF) cross-talk 
contributes to the formation of a pancreatic tumor and disease progression. 
Pancreatic stellate cells are a small population of initially quiescent cells in the 
periacinar pancreas parenchyma (Erkan et al., 2010). They have a myofibroblast-
like morphology and are responsible for depositing extracellular matrix (ECM) 
protein into the periacinar space upon activation (Erkin et al., 2009). The sole 
purpose of activated stellate cells, in the context of PDAC, is to facilitate cancer 
progression by interacting with pancreatic cancer cells (PCCs).  
Pancreatic cancer cells interact with stellate cells and stimulate stellate cell 
activation (Bachem et al., 2005). Although PCCs express a few of the ECM 
components such as type I, III, and IV collagen, fibronectin, laminin, vitronectin, or 
undulin (Löhr et al., 1994), activated stellate cells secrete excessive amounts of 
ECM proteins to produce the stromal reaction or fibrosis (Xu et al., 2010). Stellate 
cells are therefore critical in establishing a web that allows for inflammatory, acinar, 
and cancer cell association and cross-talk that could then initiate tumor formation.  
1.1.5.1 KRAS, EGFR and other Drivers of PDAC 
Mutations in KRAS are one of the four key drivers of hPDAC (Guerra et al., 
2003; Hingorani et al., 2003; Collins et al., 2012; Ying et al., 2012); and genetic 
KRAS aberrations have been detected as early as pancreatic intraepithelial lesion 
(PanIN)-1 (Kanda et al., 2012). KRAS is a proto-oncogene and belongs to a family 
of small GTPases involved in the regulation of cell growth and proliferation. An 
oncogenic KRAS mutation is not only necessary for the initiation of PDAC, but 
continuous KRAS signaling has been proven to be essential for PDAC progression 
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and maintenance in inducible mouse model studies (Collins et al., 2012). Activating 
point mutations in codon 12 of KRAS make up 98% of all KRAS mutations in PDAC 
(Eser et al., 2014). EGFR induction appears close to the same time as a mutation 
in KRAS in the genetic progression model of human PDAC (Bardeesy and 
DePhino, 2002). EGFR or other receptor tyrosine kinases can influence KRAS 
activity via autocrine and paracrine stimuli (Eser et al., 2014). This process is 
initiated when ligand binds to the EGFR’s extracellular domain and promotes 
receptor dimerization and transactivation of the receptor’s tyrosine kinase 
domains. Kinase activation then promotes downstream activation of Ras through 
GDP/GTP exchange. An activated Ras binds to its effector protein Raf to elicit 
downstream signaling responses through the canonical mitogen-activated protein 
kinase signaling pathway, RAF-MEK1/2-ERK1/2, or through PI3K-AKT pathways 
(reviewed in Downward, 2002, Figure 3). Studies by Navas et al. (2012) show that 
Kras-driven PDAC is dependent on EGFR signaling, except in the case of 
complete p53 loss (p53lox mouse) which led to EGFR-independent, Kras-driven 
PDAC formation (Navas et al., 2012). In addition, ablation of EGFR decreases 
ERK and PI3K activity in an oncogenic Kras model of murine PDAC (reviewed in 
Crawford et al., 2019; Ardito et al., 2012). 
The remaining three driver mutations of PDAC (TP53, CDKN2A (p16INK4A), 
and SMAD4 or DPC4) have tumor-suppressive properties (Rozenblum et al., 
1997). Tumor-suppressor loss, through genetic mutation and epigenetic silencing, 
as in the case of CDKN2A (p16INK4A) (Fukushima et al., 2002), results in aberrant 
signaling. p16INK4A, encoded by CDKN2A, is a cell-cycle inhibitor of G1-S transition  
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Figure 3. EGFR-KRAS signaling in PDAC 
 
Alterations in the microenvironment that are pro-tumor contribute to PDAC initiation, progression 
and maintenance. Oncogenic KRAS (KRAS*) activity can be enhanced by other upstream receptor 
tyrosine kinases (RTKs), the epidermal growth factor receptor (EGFR) and its family members, and 
downstream effectors such as PI3K and AKT. Image adapted from (Eser et al., 2014). 
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and is dysregulated in cancer (Romagosa et al., 2011). TP53 is one of the most 
widely studied tumor suppressor genes (Muller and Vousden, 2014), and point 
mutations in TP53 provide a growth advantage to cancer cells (Muller and 
Vousden, 2014). One such example is the R175H point mutation (Morton et al., 
2010), Trp53R172H in mouse models (Hingorani et al., 2005). Inactivating point 
mutations in either p53 or p16(Ink4a) accelerated pancreatic lesion formation in a 
murine PDAC model of oncogenic Kras (Bardeesy et al., 2006a). Hingorani et al. 
(2005) were the first to show that Trp53-mutant mice succumbed to disease at five 
months and had high metastatic burden in a KrasG12D mouse PDAC model 
(Hingorani et al., 2003). In contrast, mice with both oncogenic Kras and an Ink4a 
tumor suppressor deletion formed PanIN lesions early and died due to metastatic 
disease by 11 weeks of age (Aguirre et al., 2003).  
Mothers against decapentaplegic homolog 4 (SMAD4), also known as 
deleted in pancreatic cancer, locus 4 or DPC4, is the gene that encodes a 
transcription factor involved in canonical TGF-β signaling and message transport 
to the cell nucleus (Shi and Massagué, 2003). SMAD4 inactivating mutations make 
up around 50% of PDAC cases (Kern, 2000). While Smad4-deficient mice do not 
develop pancreatic tumors, Smad4 loss combined with oncogenic Kras also 
accelerated PDAC development (Bardeesy et al., 2006b). This mouse model 
utilizes a pancreas-specific promoter to drive germline expression of an activating 
KrasG12D point mutation and deletion of Smad4 exons 8 and 9 (Bardeesy et al., 
2006b).  
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Numerous studies in mice demonstrate the relevance of oncogenic Kras in 
the initiation, progression and maintenance of PDAC (Hingorani et al., 2003, 
Hingorani et al., 2005; Bardeesy et al., 2006a, Bardeesy et al., 2006b; Aguirre et 
al., 2003; Collins et al., 2012). The progression model for human PDAC is limited 
by the uncertainty of the temporal sequence of each genetic event subsequent to 
the initiating KRAS mutation (Bardeesy and DePhino, 2002; Pasca di Magliano 
and Logsdon, 2013). Over the last 16 years, and with the use of genetically 
engineered mouse models (GEMMs) of PDAC that recapitulate human pancreatic 
neoplasia, substantial advances have been made in the field. Continued rigorous 
experimentation of the biochemical and cellular components of these genetic 
alterations and their contributions to disease progression are still intensely 
underway in the field. 
1.1.6 PDAC Metastasis  
Metastasis allows a tumor to spread and kill its host organism (reviewed in 
Gupta and Massagué, 2006). Almost 90% of all cancer deaths are the result of 
metastasis, or the malignant spread of a tumor to a secondary site, or sites (Chaffer 
and Weinberg, 2011). Metastasis requires cancer cell detachment from the primary 
tumor site, followed by cancer cell motility and intravasation into the circulatory 
system. Next, bypass of immune surveillance, extravasation at capillary beds, 
followed by invasion at the secondary site precedes colonization of a distant organ 
(reviewed in Gupta and Massagué, 2006). Epithelial to mesenchymal transition 
(EMT) was initially believed to be a requirement for cancer invasion and metastasis 
(Kang and Massagué, 2004). However, the concept that a cancer cell needs to 
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undergo EMT in order to metastasize and become invasive was challenged in the 
pancreas field when the Raghu Kalluri laboratory reported that the deletion of two 
common EMT inducers, Snail and Twist, did not alter PDAC invasion, 
dissemination or metastasis (Zheng et al., 2015). A study in the breast cancer field 
found that EMT was not essential for tumor initiation (Xie et al., 2014). Although 
EMT in PDAC differs from that in breast cancer, others reported that EMT and 
pancreatic cancer cell dissemination preceded pancreatic tumor formation (Rhim 
et al., 2012). These discrepancies in the field could be due to variations among 
model systems (Hruban et al., 2006) and/or differences in genomic-aberration-
associated EMT dependencies. PDAC is a disease laden with genetic alterations. 
Consequently, certain subtypes of PDAC may influence genetic aberrations that 
are more prone to an EMT-dependent metastatic progression. Delineating the 
EMT program in the context of specific genomic aberrations may help to resolve 
the role of EMT in PDAC progression and metastasis.  
More than 50% of PDAC patients (Hidalgo et al., 2015) present with 
metastatic disease. In a separate report, 20% of PDAC patients were classified as 
having resectable disease presentation with hepatic or peritoneal metastasis at the 
time of laparoscopy or laparotomy (Varadhacary et al., 2006). This reflects the 
limitations of PDAC detection by CT. The liver is the most frequent site of PDAC 
metastasis, although distant metastases have been found at almost all anatomical 
sites (Yachida and Iacobuzio-Donahue, 2009). A review of autopsy data from four 
different reports that combined 413 autopsies in which PDAC was the primary 
tumor found that the liver is involved in 80% of metastatic PDAC cases (Yachida 
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and Iacobuzio-Donahue, 2009). For the one-third of PDAC patients reported not 
to have liver metastases at autopsy, those patients instead have lung and 
abdominal lymph node metastasis (Yachida and Iacobuzio-Donahue, 2009). The 
lung is the third most commonly involved site of metastasis with a frequency of 
45% total involvement at autopsy (reviewed in Yachida and Iacobuzio-Donahue, 
2009; Embuscado et al., 2005). The reported percentages take into account 
autopsies in which multiple sites of metastasis were identified in some patients 
with a primary neoplasm in the pancreas (diSibio and French, 2008).  
Distant metastases occur late in the clonal evolution of PDAC (with the first 
subclone with metastatic potential appearing roughly seven years after the 
appearance of the founder cell of the parental clone) (Haeno et al., 2012). Based 
on sequencing and evolutionary mapping of primary and metastatic clonal 
populations from seven rapid autopsy patients, a computational analysis 
suggested that primary pancreatic cancers and their matched metastases shared 
only a weak relationship (Haeno et al., 2012). The presence of large tumors without 
metastases at autopsy and small tumors with metastases at autopsy support that 
an increase in tumor size does not necessarily have to influence metastatic 
burden. Metastatic cells can also exist in a dormant state and bypass detection 
(Obenauf and Massagué, 2015; Giancotti, 2015). Requirements for colonization of 
metastatic cells are site-specific (Obenauf and Massagué, 2015).  
The TGF-β signaling pathway relies on the SMAD4 transcription factor and 
additional SMAD cofactors; this pathway can be anti-mitogenic or cause pancreatic 
cancer cells to have a cell growth advantage and EMT (Massagué, 1998). For 
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these reasons, TGF- β actions are considered to be context dependent (see Friess 
et al., 1993), and can be cancer-metastasis promoting (Padua and Massagué, 
2008). SMAD4 inactivation disrupts canonical TGF-β signaling (Massagué, 1998). 
In addition, TGβR2-deficient mice develop oncogenic Kras-driven PDAC and liver 
metastases as early as seven to ten weeks (Ijichi et al., 2006). In a compound 
Smad4-deficient/Ink4a+/-/Kras-mutant mouse model of PDAC, 37.5% of mice 
developed liver invasion or metastases (Bardeesy et al., 2006b). The Sonic 
Hedgehog signaling pathway, initially discovered for its role in embryogenesis, is 
an additional signaling pathway associated with PDAC metastasis. Misregulation 
of the Hedgehog signaling pathway is common in PDACs (Berman et al., 2003; 
Thayer et al., 2003). Together with Notch (another embryonic signal transduction 
pathway) signaling, Hedgehog can promote pancreatic cancer initiation and 
maintenance if left unchecked (Mullendore et al., 2009). Primary and metastatic 
cell lines established from a murine PDAC model have sustained activation of 
Hedgehog signaling (Thayer et al., 2003). Lastly, hypoxia-inducible factors 1 and 
2, when elevated, are associated with increased metastasis in multiple cancers 
including pancreatic cancer (Rankin and Giaccia, 2016). Therefore both the 
hypovascular and hypoxic PDAC tumor environment may promote metastatic 
disease (reviewed in Tuveson and Neoptolemos, 2011). Since these factors and 
aforementioned signaling pathways contribute to metastatic disease, additional 
studies delineating the biochemical processes and therapies targeting this 
signaling may be extremely valuable in improving patient outcome.  
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Due to their self-renewal properties, cancer stem cells (CSCs) have been 
linked to the origin of cancer metastasis. CSCs contribute to intratumoral 
heterogeneity and are also a mechanism of tumor resistance to therapy (Shibue 
and Weinberg, 2017). Pancreatic CSCs play a significant role in the promotion and 
dissemination of PDAC (Lee et al., 2008; Zhu and Yuan, 2015; Valle et al., 2018). 
In 2007, studies in Diane Simeone’s laboratory led to the identification of 
CD44/CD24/epithelial specific antigen (ESA)-positive pancreatic cancer cells with 
self-renewal properties and the capacity to produce progeny that can fully 
differentiate (Li et al., 2007). Additional CSC studies found that migratory CD133- 
and CXCR4-positive human pancreatic cancer stem cells are essential for PDAC 
metastasis (Hermann et al., 2007). Depletion of this pool prevented PDAC 
metastasis but not tumor initiation. More recently, highly metastatic pancreatic 
cancer cells have tested positive for EpCAM, CD24, CD44, CD133, and SCA1 
markers (Ischenko et al., 2014).  
1.1.7 Advances and Progress  
According to a study reliant on data from the Survival, Epidemiology and 
End Results (SEER) Database of human metastatic PDAC cases from 1993 to 
2013, the percent of patients that died within two months of PDAC diagnosis 
decreased from 63.5% to 50.6% (Golan et al., 2017). In addition, patient survival 
(12 months after diagnosis) increased from 4.9% to 12.7% (Golan et al., 2017). 
These improvements have been linked to advances in chemotherapy. 
Gemcitabine increased the 12-month survival rate for PDAC from 2% to 18%, 
when compared to the first chemotherapeutic used for the treatment of PDAC (5-
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FU) (Burris et al., 1997). Single therapeutic targeting of the most frequently 
mutated genes in PDAC has not proven successful. However, combinatorial 
targeting of signaling molecules such as phosphoinositide 3-kinase (PI3K), with 
MEK, and AKT inhibitors is being investigated in clinical trials (reviewed in Hidalgo 
et al., 2014). The combinatorial approach has been used in the development of 
more efficacious chemotherapeutics for the treatment of pancreatic cancer, for 
example, FOLFIRINOX and gemcitabine/nab-paclitaxel. FOLFIRINOX 
significantly improved patient outcome, by increasing the median OS of PDAC 
after treatment to 11.1 months (Conroy et al., 2011). The median overall survival 
of gemcitabine, when compared to FOLFIRINOX in this study, was 6.4 months 
(Conroy et al., 2011). 
 The majority of PDAC patients are deemed inoperable at the time of 
diagnosis due to late presentation and advanced stage by the time they reach the 
clinic. A recent study that focused on identifying circulating tumor cells (CTCs) in 
the blood of PDAC patients had promising results. The investigators detected 
CTCs in 62.5% of patients with a 94.4% specificity rate (Ankeny et al., 2014). In a 
follow-up study, three or more CTCs per 4 mL of blood was a prognostic marker 
and an accurate identifier of patients with metastatic disease (Court et al., 2018). 
To detect pancreatic cancer efficiently and effectively, one needs to have a 
pancreatic cancer-associated (CA) antigen, also referred to as a biomarker that is 
specific to the disease. In order for a cancer-associated antigen to be reliable, it 
needs to be specific for PDAC patients. The utility of serum carbohydrate and 
carcinoembryonic antigens have proven to be useful when distinguishing PDAC 
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from healthy tissues; however, these antigens prove useful only in Stage III PDAC 
or greater (Chen et al., 2015). In a comprehensive meta-analysis that included 
2,316 participants, carbohydrate antigen 19-9 (CA 19-9), a candidate biomarker 
for the diagnosis of pancreatic cancer, was found to have a sensitivity of 0.8 and 
a specificity of 0.8. These findings translate to an 80% detection rate for pancreatic 
cancer patients using this marker, with 80% accuracy (Huang and Liu, 2014). 
 Since the vast majority of PDAC tumor consists of stroma (Erkan et al., 
2010), efforts to target the stroma have been made. The reasoning behind stromal 
targeting was to allow for better delivery of chemotherapeutic agents into the 
tumor. Surprisingly, investigators found that targeting stromal elements of PDAC 
resulted in a more aggressive and undifferentiated cancer (Rhim et al., 2014). 
These studies utilized a genetically engineered mouse model (GEMM) of PDAC 
with a deletion in sonic hedgehog (Shh) (Rhim et al., 2014). Shh was targeted due 
to its notable involvement in PDAC tumor stroma development according to Rhim 
et al. (2014). Their findings were consistent with human trial data in which stromal 
targeting was not successful (Ozdemir et al., 2014). The HALO 202 phase II clinical 
trial explored targeting elevated hyaluronan levels, in a subset of PDAC patients, 
and demonstrated a modest increase in survival when combined with nab-
paclitaxel/gemcitabine therapy (Hingorani et al., 2018). Consequently, additional 
studies need to be conducted in the area of combined stromal and epithelial 
targeting to establish whether this is a therapeutic option. 
Quantitative analysis using a mathematical model predicted a window of 
roughly 20 years between the initiation of PDAC tumorigenesis and the metastatic 
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lesion presentation in the clinic (Yachida et al., 2010). The last three years of the 
timeline were attributed to the birth of a metastatic subclone. This subclone would, 
therefore, hold the capacity to give rise to a liver or lung metastatic lesion (Yachida 
et al., 2010). These findings highlight a 17-year window of opportunity where 
further biomarker and targeted therapy could help save the lives of a vast majority 
of PDAC patients.  
Although endoscopic and radiographic imaging technologies still have 
limitations for diagnosis of PDAC and pancreatitis, especially for early-stage 
disease, significant improvements have been made. Endoscopic ultrasound (EUS) 
and endoscopic retrograde pancreatography (ERP) methods have the potential to 
aid in early diagnosis and delivery of therapeutic agents to the tumor site. ERP 
was first used to image the pancreatic duct, but advances have since improved the 
outcomes for this device (Coté et al., 2013). Some advances include 
pancreatoscopy which allows for more straightforward and direct visualization of 
both the bile duct and the pancreas duct. Albeit, biopsy during this process is not 
feasible due to a time limitation. There have also been advances in resolution and 
high-definition video imaging. High-resolution microendoscopy allows for the 
visualization of PanIN precursor lesions of PDAC, and tissue at a cellular level 
(reviewed by Coté et al., 2013). 
1.1.8 Cre-loxP Technology: Site-Specific Recombination for Genetically 
Engineered Mouse Models (GEMMs) of PDAC 
Cre is a 38-kDa tyrosine recombinase enzyme that is derived from the P1 
bacteriophage (Sauer and Henderson, 1988). Sternberg and Hamilton (1981) 
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coined the term Cre, which means causes recombination. Sernberg and Hamilton 
(1981) proved that the P1 bacteriophage contained a hot spot for recombination 
and natural ability to resolve its genome using Cre recombinase proteins and target 
locus of crossing over (x)-bacteriophage P1 (loxP) sites (Sternberg and Hamilton, 
1981; Hoess and Abremski, 1984). LoxP and the cre gene were confirmed to be 
separate yet adjacent segments of EcoR1-7 DNA (Sternberg and Hamilton, 1981). 
Cre-loxP-mediated site-specific homologous recombination (specific transgene 
deletion) was developed by Brian Sauer and is used in transgenic mouse model 
systems to control the expression of transgenes of interest (Sauer and Henderson, 
1988). Since Cre is a site-specific DNA recombinase, it only relies on the location 
and orientation of its direct target: loxP sites, which are short strands of DNA with 
Cre-specific binding sites. LoxP sites are 34-bp in length and consist of two 13-bp 
palindromic DNA sequences separated by an 8-bp spacer region. The spacer 
region is where the cleavage event occurs (Lakso et al., 1992). When LoxP sites 
are oriented in the same direction (in cis) around or flanking a specific gene, it 
allows for deletion of that gene; loxP sites in opposite orientation result in inverted 
floxed genetic sequences (Kuzminov et al., 2011).  
Cre uses a topoisomerase mechanism to introduce site-specific cuts and 
ligations in DNA sequences. Cre’s conserved tyrosine residue participates in 
nucleophilic attack and linkage formation with a phosphate group on the targeted 
DNA strand (Van Duyne, 2001). This results in a DNA-protein complex and 3’-
phosphotyrosine linkage (Van Duyne, 2001). This homologous recombination 
event allows for controlled expression of genetic mutations in tissues or cells of 
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interest. Through an adenoviral vector, Cre can be introduced close to the targeted 
organ (Jackson et al., 2001) or can be introduced by cell- or tissue-specific 
promoters introduced and passed down in the germline. Since the two loxP DNA 
regions are positioned on the same chromosome, the homologous recombination 
event occurs through the formation of a circle (Kuzminov et al., 2011). This leaves 
one resolved linear strand of DNA with a loxP site, and one deleted circular DNA 
strand holding the genetic region targeted for deletion and the other loxP. 
Investigators have found that recombination efficiency between two loxP sites on 
the same chromosome decreases with increasing genetic distance (Zheng et al., 
2000).  
Genetic engineering of tissue and cell-specific mutations in animal model 
systems allows scientists to understand the development and progression of 
human disease. Genetically engineered mouse models (GEMMS) have been 
precious and critical for expanding the knowledge base for pancreatic ductal 
adenocarcinoma (PDAC) development and progression, mostly due to the 
similarity in disease progression shared between Homo sapiens and Mus 
musculus (house mouse). Studies in mice are performed only when necessary and 
can lead to the development of novel patient therapies. The advantage of using 
autochthonous mouse models of PDAC is that they allow for spontaneous tumor 
formation in the mouse’s own pancreas (Tao et al., 2018). Using Cre-loxP 
technology and systems, conditional (restrictive) mutations in the pancreas of 
genetically engineered mice can be spatially controlled through the introduction of 
pancreas-specific promoters (reviewed in Walrath et al., 2010). In addition to 
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spatial control, temporal control of a specific mutation can be employed using a 
Cre fused to the hormone-binding domain of the estrogen receptor (Cre-ER) (Feil 
et al., 2009). Cre-ER technology in mice exposed to the ligand tamoxifen through 
feed or drink allows activation of the ER and drives Cre to the nucleus where it can 
recombine DNA (Feil et al., 2009; Walrath et al., 2010). These GEMMs are referred 
to as inducible models. 
Pancreatic duodenal homeobox 1 (Pdx1) is a transcription factor involved 
in the development of the pancreas. It is expressed early during embryogenesis at 
embryonic day 8.5 (E8.5) (Offield et al., 1996). In transgenic mouse models of 
pancreatic cancer, the Pdx1 promoter is commonly used to drive preferential 
expression of a mutation of interest to the pancreas epithelium. Pdx1-Cre-
transgenic mice (Gu et al., 2002) will express the Cre recombinase protein, which 
will facilitate a site-specific DNA recombination event in all cells that express the 
Pdx1 transcription factor. P48 is a second transcription factor expressed around 
E9.5 essential for pancreas fate (Hingorani et al., 2003). Together, Pdx1 and P48 
double-positive expressing cells give rise to all of the cells of the mature pancreas 
(Hingorani et al., 2003).  
The KC mouse model (LoxP-STOP-LoxP (LSL)-KrasG12D;Pdx1-Cre or LSL-
KrasG12D;P48-Cre) of pancreatic cancer utilizes the Cre-loxP technology via a Pdx1 
or P48 promoter. The recombination event that occurs results in the excision of a 
synthetic transcriptional/translational ‘stop’ cassette (STOP) (Lakso et al., 1992; 
reviewed in Dragatsis and Zeitlin, 2001) that sits just upstream of the mutant Kras 
sequence. Thus, one copy of oncogenic Kras (G12D) (KrasG12D/+ or KrasG12D) is 
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driven to the pancreas epithelium during embryogenesis (Hingorani et al., 2003). 
In addition to the pancreas epithelium, Pdx1-Cre has been detected in the antral 
stomach and duodenum in neonates and the adult islet (Hingorani et al., 2003). 
While Pdx1-Cre results in a reported stochastic pattern of expression in pancreas 
tissues, P48-Cre results in a more uniform distribution of Cre in the pancreas when 
assessed in the background of a ROSA26 (R26) Cre reporter. This is thought to 
be potentially due to the knock-in-strategy used to develop the transgenic mouse 
model (Hingorani et al., 2003; Kawaguchi et al., 2002). The ROSA26 gene locus 
is ubiquitously and constitutively expressed in all tissues, and during embryonic 
development in mice. The ROSA26 reporter line is used to monitor Cre expression 
by detection of beta-galactosidase expression (Soriano, 1999-Seidler, et al., 2008; 
Friedrich and Soriano, 1991). KC mice develop a full range of pre-malignant 
lesions in the pancreas, similar to the human PDAC with long latency to PDAC 
(Hingorani et al., 2003). The Pdx1-Cre;LSL-KrasG12D mouse can develop 
metastatic disease as early as 6.25 months to both the liver and the lung (Hingorani 
et al. 2003; reviewed in Guerra and Barbacid, 2013).  
  Another group of investigators developed a temporal oncogenic Kras 
mouse model of PDAC using a R26-tetracycline transactivator transgene to control 
KrasG12D expression in the pancreas epithelium (Collins et al., 2012). Using this 
model, they were able to show that oncogenic Kras is required for PDAC initiation 
and tumor maintenance (Collins et al., 2012). The investigators reported “rare 
areas of ADM and low-grade PanIN in 1 of 3 mice” at three weeks of age (Collins 
et al., 2012, p.641). At five weeks of age, 2 of 3 mice had areas of ADM and low-
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grade PanIN formation. A more even distribution of PanIN precursor lesions of 
PDAC and areas of fibrosis was detected in mice 18 weeks of age, and at six 
months 1 of 2 mice developed PDAC (Collins et al., 2012). 
1.2 MicroRNAs and miR-10b in PDAC  
MicroRNAs (miRs) are small non-coding ribonucleic acids (RNAs), that are 
between 18-25 nucleotides long, and are commonly overexpressed in PDAC 
(Garzon et al., 2010; Szafranska et al., 2007; Bloomston et al., 2007). miR-10b is 
one of the most frequently upregulated miRs in PDAC (Bloomston et al., 2007; 
Preis et al., 2011). High miR-10b levels in human hPDAC are associated with 
decreased therapeutic response to neoadjuvant therapy, shorter time to 
metastasis, and decreased patient survival (Preis et al., 2011). miR-10b was 
significantly overexpressed in cytokeratin (CK)-19 positive pancreatic cancer cells 
(PCCs) in human PDAC tissues (Preis et al., 2011). CK-19 is a marker used to 
identify pancreatic cancer cells in precursor lesions and PDAC in tissues. In 
addition, an analysis of plasma samples from a patient cohort undergoing 
evaluation for PDAC indicated that high plasma miR-10b levels distinguish PDAC 
from chronic pancreatitis (CP) and patients without pancreatic pathology (Ouyang 
et al., 2017). miR-10b enhances pancreatic cancer cell (PCC) invasion in vitro by 
suppressing Tat-interacting protein 30 (TIP30) gene expression, which leads to 
sustained epidermal growth factor (EGF) signaling (Ouyang et al., 2017). 
microRNA-dependent mechanisms are an example of epigenetic alterations, or 
alterations in gene expression that do not result from modification of the DNA 
sequence itself (reviewed by McCleary-Wheeler et al., 2014). 
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1.3 TIP30, Direct Target of miR-10b 
In a recent PDAC study, miR-10b-overexpressing PCCs had a significant 
decrease in TIP30 gene expression levels (Table 1, Ouyang et al., 2013). In both 
PDAC and esophageal squamous cell carcinoma (ESCC), miR-10b is reported to 
directly target the 3’ untranslated region (UTR) of TIP30 mRNA and lead to 
decreased TIP30 expression (Ouyang, 2013; Dong et al., 2014). miR-10b and 
TIP30 expression were also inversely correlated in 15 human ESCC cases (Dong 
et al., 2014). As noted in Table 1, TIP30 is not the only target of miR-10b (Ouyang 
et al., 2013, Supplemental). A microarray analysis by Ouyang et al. (2013, 
Supplemental) revealed that 55 genes were down-regulated in a human pancreatic 
cancer cell line engineered to overexpress miR-10b (pMir-10b). A miR can have 
more than a hundred different targets (Brennecke et al., 2005). In addition to 
HTATIP2 or TIP30, and genes listed in Table 1, miR-10b is reported to target 
kruppel like factor 4 (KLF4) (Tian et al., 2010) and RAS-signaling modulator NF1 
(Chai et al., 2010) among others (Ouyang et al., 2013). In addition to a reported  
tumor-suppressive function, Klf4 overexpression induced PanIN formation in the 
presence of oncogenic Kras (Wei et al., 2016). 
1.3.1 TIP30 
Tat-interacting-protein (TIP) 30 or (30 kilodaltons (kD)) [also known as 
Human Immunodeficiency Virus-1 (HIV-1) TAT-Interactive Protein 2 (HTATIP2) or 
CC3 in the literature] is a small transcriptional coactivator, metastasis suppressor 
and antiangiogenic factor that predisposes cells to apoptosis (Shtivelman, 1997; 
Xiao et al., 1998; Baker et al., 2000; NicAmhlaoibh and Shtivelman, 2001). 
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Table 1. Genes down-regulated by miR-10b 
Gene symbol pMir-10b/ctrl FC p-value 
FBXO45 0.58 0.002801 
RAB15 0.51 0.014403 
AGR2 0.50 0.039114 
SDC1 0.45 0.001458 
CDK6 0.38 0.024854 
SKA1 0.38 0.024388 
HTATIP2 (TIP30) 0.38 0.034162 
EPHB2 0.35 0.022975 
 
Adapted from Ouyang et al. (2013, Supplemental). FC, fold change
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The name HTATIP2 came from a 1998 study, in which investigators reported a 
transcription cofactor that accelerated tat-mediated transcription by binding the C-
terminal domain of RNA polymerase II and enhancing Tat-activated transcription 
of HIV-1 (Xiao et al., 1998). Around the same time, and in a separate study, loss 
of a gene by the name of CC3, was reported in an RNA differential display analysis 
of highly metastatic variant small cell lung cancer (v-SCLC) cell lines compared to 
non-metastatic cell lines (Shtivelman, 1997). Shtivelman found that CC3-low or -
absent v-SCLC cells were resistant to apoptosis (Shtivelman, 1997). CC3 and 
HTATIP2 were found to be the same gene and gene product, and the role of TIP30 
as a metastasis suppressor through proapoptotic properties were further 
examined. A role for TIP30 kinase activity was even postulated (Xiao et al., 2000). 
However, the kinase activity of TIP30 is highly unlikely due to the lack of an ATP-
binding site (Omari et al., 2005).  
TIP30, located on chromosome 11 in humans, and chromosome 7 in mice 
is ubiquitously expressed in normal tissues, including the pancreas (Figure 4, 
Shtivelman, 1997). The TIP30 protein has been found in both the nucleus (Xiao et 
al., 1998; Ito et al., 2003; Jiang et al., 2004; Zhao et al., 2008; Li et al., 2013) and 
cytoplasm (Ito et al. 2003; King and Shtivelman, 2004; Zhao et al., 2007; Zhao et 
al., 2008; Tong et al., 2009; Li et al., 2013; Guo et al., 2014) as well as localized 
to the nuclear envelope (King and Shtivelman, 2004; Guo et al., 2014). Ito et al. 
(2003) reported that 90% of TIP30 is found in the cytoplasm, and 10% in the 
nucleus. Three isoforms of TIP30 have been reported in human cell lines: isoforms 
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Figure 4. Ubiquitous expression of TIP30  
 
TIP30 (HTATIP2) tissue-specific gene expression from BioGPS database (Wu et al., 2016). Probe-
based microarray data (GeneAtlas U133A). Expression values are units of fluorescence intensity. 
M = mean fluorescent intensity of 41.3 (baseline). Image retrieved from 
http://biogps.org/#goto=genereport&id=1055 on November 14, 2018.   
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1 and 3 weigh 27 kD and 30 kD, respectively. Isoform 1 is considered to be the 
canonical form and is associated with TIP30’s proapoptotic and antiangiogenic 
properties (Shtivelman, 1997). Isoform 3 was isolated as a binding cofactor of Tat 
in pull-down assays (Xiao et al., 1998). Isoform 2, 14.9 kD, referred to as TC3 or 
alternatively spliced product of CC3 (Whitman et al., 2000), is missing amino acids 
134-242 [according to the National Center for Biotechnology Information database 
(NCBI)] (Greer et al., 2009, Shtivelman, 1997). Although this study did not focus 
on isoform 2, TC3 is reported to have an antiapoptotic effect and protect cells from 
apoptosis. This isoform is also reported to be highly unstable and susceptible to 
degradation (Whitman et al., 2000). TIP30 is mutated or lost in a vast majority of 
human cancers including hepatocellular (Ito et al., 2003), breast (Zhao et al., 
2007), colorectal (Chen et al., 2010), lung (Tong et al., 2009), and brain (Hu et al., 
2016). Loss of TIP30 has also been associated with EMT and enhanced 
invasiveness of both hepatocellular carcinoma (HCC) and pancreatic cancer cells 
(Zhu et al., 2015; Ouyang et al., 2013). Furthermore, TIP30 loss was associated 
with lymph node metastasis and poor survival outcome in PDAC patients (Guo et 
al., 2014). TIP30 loss was also correlated with lymph node metastasis in a lung 
cancer study (Tong et al., 2009). 
1.3.2 TIP30 Functions 
TIP30 is most closely related to the enzymatic family of short-chain 
dehydrogenases/reductases or SDRs (Baker, 1999). Oxioreductases catalyze 
oxidation-reduction reactions and are commonly dependent on nicotinamide 
adenine dinucleotide phosphate (NAD(H) or NADP(H)) coenzymes (Kallberg et al., 
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2002). Indeed, NADPH is the preferred cofactor for TIP30. However, X-ray 
crystallography studies have failed to identify substrate-binding or associated 
enzyme activity (Omari et al., 2005). TIP30 shares the greatest sequence identity 
with the E. Coli SDR UDP galactose-4 epimerase and has the common Tyr143-
Lys147Ser132 motif found in SDR catalytic domains (Baker, 1999). However, 
unlike SDRs, the dimer interface does not involve typical packing of two pairs of 
helices. Consequently, the catalytic tyrosine is not positioned appropriately for 
catalysis (Omari et al., 2005). SDRs are typically active only as dimers or 
heterodimers (Jornvall et al., 1995) and have identified substrates. However, 
TIP30 is reported to interact with other proteins, including importin-β2 to inhibit 
nuclear import and ACSL4 to mediate endosomal trafficking. TIP30 also interacts 
with the estrogen receptor alpha-interacting coactivator CIA to repress c-Myc 
transcription (Jiang et al., 2004).  
In the STRING consortium and database for protein interactomes 
(Szklarczyk et al., 2015), TIP30 interactors are mostly NAD(P)H dehydrogenases,  
synthetases, including ATP synthase, and involve mitochondrial proteins (Figure 
5). The TIP30 interactors that are labeled as “known” in Figure 5 were identified 
in curated databases or were experimentally determined (Szklarczyk et al., 
2015).Zhang et al. (2011), report that TIP30 forms a complex with ACSL4, 
endophilin B1, and Rab5a that is essential for receptor-mediated endocytosis and 
helps to regulate EGFR signaling and degradation. Endophilin B1 maintains 
mitochondrial membrane compartmentalization and architecture (Karbowski et al., 
2004). The mitochondria are not only the powerhouse of the cell, but upon  
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Figure 5. Gene and protein interaction network for TIP30 
 
HTATIP2 is the query node for TIP30 in the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (Szklarczyk et al., 2015). 
Nodes surrounding HTATIP2 are the first shell of interactors. Empty nodes are those proteins with unknown 3D structures. Image retrieved from 
STRING v11, https://string-db.org/ on July 7, 2018.
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membrane permeabilization, this organelle is responsible for reported TIP30-
mediated release of proapoptotic factors such as cytochrome c and second 
mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding 
protein (Smac/DIABLO) (Shi et al., 2008). Mitochondrial-associated proteins Bax 
and Bcl-2 are also involved in cell death response and were found to work in 
concert with TIP30 to induce apoptosis (Shi et al., 2008). Given these multiple roles 
for TIP30 in literature, the overarching theme of its activity is that of a redox sensor. 
As such, TIP30 would be involved in processes that affect gene transcription in 
addition to some of the other properties identified in the literature such as 
coactivation, apoptosis and nuclear import as described below. 
1.3.2.1 Coactivation  
Coactivators play an important role in regulating biological processes by 
regulating gene expression (Puigserver and Spiegelman, 2003; Spiegelman and 
Heinrich, 2004). In a protein affinity chromatography assay, TIP30 was one of the 
two proteins identified to bind the activation domain of tat, a nuclear regulatory 
protein encoded by HIV-1 that enhances HIV-1 transcription (Xiao et al., 1998; 
reviewed in Jones and Peterlin, 1994). The role of tat in HIV-1 transcription is to 
increase the efficiency of RNA polymerase II transcription elongation (Jones and 
Peterlin, 1994). As mentioned previously, neither oxioreductase nor kinase activity 
has been confirmed for TIP30. There have been reports of serine and threonine 
kinase activity, autophosphorylation, as well as direct phosphorylation of the serine 
and threonine residues on the C-terminal domain of RNA polymerase II (Xiao et 
al., 2000); however, an ATP-binding site was not found in TIP30 (Omari et al., 
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2005). One speculation for the discrepancy has been potential kinase 
contamination from the baculovirus expression system preparations used in the 
original studies (Omari et al., 2005). Xiao et al. (2000) also reported that TIP30 did 
not behave as a global transcription factor. TIP30 depletion did not affect basal 
transcription or Gal-VP16-activated transcription (Xiao et al., 1998). Gal-VP16 is a 
class of transcriptional activators involved in activating yeast, plant, insect and 
mammalian cell transcription (reviewed in Sadowski et al., 1988). With the lack of 
confirmed catalytic activity, classification of this protein as a coactivator may be 
more appropriate. Although TIP30 cannot act as a transcriptional regulator, it may 
still be involved in regulating transcription by interacting with other coactivators 
and/or acting as a sensor.  
1.3.2.2 Apoptosis 
TIP30’s metastasis suppressor and proapoptotic functions were first 
identified by the lack of expression of TIP30 in a differential display of highly 
metastatic variant-small cell lung cancer (v-SCLC) compared to classic small-cell 
lung cancer cell lines. Reintroduction of TIP30 in v-SCLC cells sensitized cells to 
apoptosis both in vitro and in vivo and upregulated an apoptotic pathway that may 
have involved down-regulation of anti-apoptotic factor Bcl-2 (Shtivelman, 1997). In 
a separate study, TIP30 overexpression led to an increase in NIH 3T3 and v-SCLC 
cell death as detected in a trypan blue exclusion assay and the upregulation of an 
apoptotic gene signature (Xiao et al., 2000). Overexpression of TIP30 in v-SCLC 
cells led to increased levels of the apoptotic genes Bad and Siva (Xiao et al., 2000). 
Shi et al. (2008), found that TIP30 triggers the release of cytochrome c from the 
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mitochondrial intermembrane space into the cytosol and the release of second 
mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding 
protein (Smac/DIABLO). Cytochrome c and Smac/DIABLO are two well-known 
precursors and initiators of a mitochondrial apoptotic pathway, leading to cell death 
(Shi et al., 2008; Arnoult et al., 2002; Martinez-Ruiz et al., 2008). TIP30 regulated 
the translocation of Bax through a TIP30-P53-Bax signaling cascade ending with 
activation of Caspase-9 and -3 (Shi et al., 2008). 
1.3.2.3 Nuclear Import 
Another explanation for TIP30-mediated apoptosis is demonstrated through 
studies of its role in nuclear import. Inhibition of nuclear import by TIP30 induces 
cell death according to King and Shtivelman (2004). TIP30 is reported to bind 
importin betas and inhibit the nuclear import in vitro and in vivo of classic nuclear 
localization signal- (NLS) or M9-tagged proteins (King and Shtivelman, 2004). The 
addition of purified TIP30 cytosol [transport buffer] to permeabilized HeLa cervical 
cancer cells decreased nuclear import rates in in vitro nuclear import assays; while 
the addition of recombinant protein from TIP30 (G28V) and (G31A) mutants 
decreased cell-binding interactions with transportin (importin β2) and the nuclear 
pore complex (King and Shtivelman, 2004). These TIP30-mutant conditions further 
led to a decrease in nuclear import inhibition (King and Shtivelman, 2004). The 
physiological implications of these findings still need to be elucidated.  
1.3.3 TIP30 in Cancer, Metastasis, and PDAC 
The seminal work on TIP30 in cells derived from small cell lung cancer 
(SCLC) as well as in other tumor cells in vitro support its anti-metastatic properties 
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(Shtivelman, 1997, Xiao et al., 2000). In 1997, and under the name CC3, TIP30 
gene expression was absent in highly metastatic variant-SCLC (v-SCLC) cell lines; 
the reintroduction of CC3 suppressed metastasis in vivo in a tail vein assay 
(Shtivelman, 1997). Similar results were obtained with highly metastatic 
hepatocellular carcinoma (HCC) cell line LM3 after intratumoral injection of TIP30-
overexpressing adenovirus (Zhao et al., 2008). The majority of the literature 
supports TIP30 as a metastasis suppressor and tumor suppressor. However, most 
of these studies are cell-line based (Ito et al., 2003; Zhao et al., 2007; Chen et al., 
2010; Tong et al., 2009). There is also literature that reports TIP30 overexpression 
in Her-2/neu-positive breast cancer tissues and in metastatic prostate cancer 
(Zhang et al., 2005; Zhang et al., 2008). The impact of both TIP30 loss and 
overexpression in cancer is not understood and will need further elucidation. 
GEMMs with full-body Tip30 loss develop hepatocellular carcinoma (Ito, et 
al., 2003) or lung adenocarcinoma (Li, et al., 2013) with long latency. TIP30 loss 
has also been shown to enhance cytoplasmic and nuclear epidermal growth factor 
receptor (EGFR) signaling and to promote human lung cancer tumorigenesis (Li 
et al., 2013). In HeLa cervical cancer cells, TIP30 silencing enhanced 
mitochondrial respiration and glycolysis (Chen and Shtivelman, 2010). TIP30 loss 
is relevant across multiple cancer subtypes and may also play a role in the 
metabolic regulation of various cancer cells. Given the contrasting results obtained 
with cell line based studies, a meta-analysis was performed by Xu et al. (2016) to 
determine the prognostic value of TIP30. Analysis of 1705 cancer patients with 
high versus low TIP30 expression determined that patients with high TIP30 levels 
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showed favorable overall/recurrence-free survival whereas lack of TIP30 
expression was associated with lymph node and tumor metastasis (Xu et al., 
2016).  
The relationship between TIP30 expression and cancer is a subject of 
intense investigation. Ouyang et al. (2013), reported that TIP30 is a direct target 
of microRNA (miR)-10b, one of the most frequently upregulated microRNAs (miRs) 
in PDAC (Bloomston et al., 2007; Preis et al., 2011). In these studies, pancreatic 
cancer cells that overexpressed miR-10b had decreased TIP30 mRNA levels. 
These levels were reversed when the 3’UTR of TIP30 was mutated and unable to 
be recognized by miR-10b (Ouyang et al., 2013). Pancreatic cancer cells with 
decreased TIP30 levels by miR-10b overexpression or by direct silencing of TIP30 
mRNA showed an increase in EGF- and TGF-β-mediated invasion as well as an 
increase in epithelial-mesenchymal transition (EMT)-associated gene expression 
levels (Ouyang et al., 2013). TIP30 is also involved in EGFR endocytic trafficking 
and degradation by associating with Rab5a when complexed with endophilin B1 
and ACSL4 to modulate EGFR endocytosis and signaling (Zhang et al., 2011; Li 
et al., 2013). While Rab5 is a GTPase involved in the fusion of the vesicles with 
the early endosome (Gorvel et al., 1991), endophilin B1 maintains mitochondrial 
morphology and organization in addition to its involvement in receptor trafficking 
(Karbowski et al., 2004). One study points to the association between decreased 
TIP30 protein expression and increased lymph node metastasis and poor 
prognosis in pancreatic cancer patients (Guo et al., 2014). It is therefore not fully 
understood if and how TIP30 loss exerts an essential role in PDAC pathobiology. 
 55 
To summarize, TIP30 is a putative metastasis suppressor, whose current 
function is not yet fully understood. Although classified as an oxioreductase, it does 
not act as an oxioreductase or as a kinase, but has been reported to bind proteins 
that enhance transcription. What is clear, is that TIP30 alterations are prominent 
in multiple different cancers including PDAC, and loss of TIP30 has been reported 
to associate with poor survival outcome. Further research is needed in this regard, 
and for the role of TIP30 loss in PDAC specifically, due to the connection made 
between miR-10b overexpression in PDAC and miR-10b-TIP30 targeting in human 
pancreatic cancer cells (Ouyang et al., 2013). To this end, we generated a novel 
genetically engineered mouse model to study the role of Tip30 loss in the 
autochthonous model of oncogenic Kras-driven PDAC. We hypothesized that 
Tip30 loss accelerates pancreatic cancer progression and metastasis.  
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Mice 
B6.FVB-Tg(Ipf1-Cre)1Tuv (Pdx1-Cre) mice were obtained from the National 
Cancer Institute (NCI) Repository, Stock No. 01XL5 (mouse ID’s TP427 or 
greater). Mouse ID’s preceding TP427 received the Pdx1-Cre transgene from The 
Jackson Laboratory (B6.FVB-Tg(Pdx1-cre)6Tuv/J, Stock No. 014647. 
B6.129S4/SvJae-KrasTm4Tyi/J (LSL-KrasG12D/+) and C.129P2(B6)-Htatip2tm1Hx/J 
(Tip30-/-) were purchased from The Jackson Laboratory, Stock No. 008179 and 
018767, respectively, and have been previously described (Jackson et al., 2001; 
Hingorani et al, 2003; Ito et al., 2003). A mouse ID “TP” ear tag and mouse 
identification system (National Band & Tag, Newport, KY, and Style No. 1005-1P) 
was used to identify each mouse subject. To expand the Tip30 mouse colony 
(“TP”), founders were crossed with Pdx1-Cre from an existing colony in our 
laboratory from the background Stock Rb1<tm2Brn>/J. Mice used for these 
experiments were therefore of mixed background, with more than four identified 
strains, and LSL-KrasG12D/+;Tip30+/+;Pdx1-Cre (K30+/+C), and Tip30-deficient 
(K30+/-C or K30-/-C) and wild-type controls were generated internally and rigorous 
genotyping was performed. Introduction of only one Pdx1-Cre and one LSL-
KrasG12D allele was controlled by breeding with parents that were positive for only 
one mutant allele between the two parents. Brother-sister mating was employed. 
Mice were born with near-expected Mendelian genetic ratios, but ratios varied 
between litters. For example, in one litter the Tip30 transgene was distributed as 
follows: 0 Tip30-/-; 6 Tip30+/-; and 3 Tip30+/+ (for a litter whose parents were K30+/- 
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and 30+/-C); and in another litter from a different pair of breeders, but with the same 
genotype: 2 Tip30-/-; 5 Tip30+/-; and 1 Tip30+/+. LSL-KrasG12D was passed on at a 
rate of roughly 50%, as was the Pdx1-Cre transgene in both of these litters. Three 
mice from both litters received both a LSL-KrasG12D and Pdx1-Cre transgene. In a 
breeding cross of 30+/- and 30-/- the Tip30 transgene was distributed as follows: 4 
Tip30-/-; 5 Tip30+/-; and 0 Tip30+/+. As reported previously, the Tip30 gene was not 
essential for mouse development (Ito et al., 2003). Animal experiments were 
approved by the Institutional Animal Care and Use Committee (IACUC) at Indiana 
University School of Medicine, Indianapolis, IN, and were cared for by Laboratory 
Animal Resource Center (LARC) per the IACUC protocol No. 10785 and 11344.  
2.2 Tail DNA Extraction  
Tail snips were taken when pups were two weeks of age, in accordance 
with IACUC and LARC standards. Tails snips, measuring approximately three to 
four millimeters in length, were digested in 150 microliters of tail lysis buffer (50 
mM NaOH + 2 µM EDTA) for 45 minutes at 95°C using a Perkin Elmer Thermal 
Cycler. The reaction was stopped using a 10 microliter neutralization solution of 1 
mM tris(hydroxymethyl)aminomethane (Tris) in ultrapure laboratory grade double 
deionized water (ddH2O), pH 8.2. One microliter of tail DNA was used in 
genotyping reactions. These steps amounted to roughly 200-300 ng of DNA. Tail 
DNA was stored at -20°C. 
2.3 Tissue and Cell Line DNA Extraction  
Proteinase K and Phenol DNA extraction method was used to extract DNA 
from tissues and cell lines. Phenol/chloroform/isoamyl alcohol, pH 6.7 (Fisher 
 58 
BP17521) and 0.3 mL digestion buffer for cell lines per well (6-well plate, in 
duplicate) or 0.5 mL tissue dust was used. Digestion Buffer was composed of 100 
mM NaCl, 10 mM Tris [pH 8.0], 25 mM EDTA [pH 8.0], 0.5% SDS, and 0.1 mg/mL 
proteinase K (Roche #03115836001). Digests were incubated at 50°C for 12-18 
hours, rotating to activate Proteinase K. DNA was precipitated with 1/10 volume of 
3 M sodium acetate (pH 5.2) ammonium acetate and 2 volumes of 100% ethanol, 
then washed with 70% ethanol. DNA pellets were dissolved in ultrapure, deionized, 
nuclease-free H2O (Fisher Scientific BP2819-1). For DNA sequencing, a DNA and 
RNA purification kit was used to purify DNA (Qiagen 80204). For whole genome 
sequencing, DNA was extracted using the DNA purification kit (Qiagen 80204) 
from cell lines and outsourced to Novogene (Sacramento, CA) for library 
preparation, sequencing, and alignment to the mm10 mouse reference genome. 
Sequencing results were viewed in the Integrative Genomics Viewer (retrieved 
from https://software.broadinstitute.org/software/igv/ and accessed June 13, 2018. 
Dr. Francis Enane, a member of our laboratory with expertise in genomic analysis, 
assisted with the interpretation of the whole genome sequencing data. 
2.4 Genotyping 
For genotyping, genomic DNA isolated from mouse tails, pancreas, lung, or 
liver tissues or from murine cell lines isolated from primary tissue was subjected to 
polymerase chain reaction (PCR) using recommended sequence-specific 
oligonucleotide primers and agarose gel electrophoresis. HotStarTaq polymerase 
(Qiagen 203607), PCR (dNTPs) Nucleotide Mix (Roche 04638956001), Coral Red 
10X PCR buffer, 15 mM MgCl2 (Qiagen N1032568), 25 mM MgCl2 (Qiagen 
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1018999), and ultrapure laboratory grade deionized water (ddH2O) from a Milli-Q 
IQ 7000 water purification system (EMD Millipore) was used as listed in Section 
2.27. Oligomers used and thermocycler conditions were performed as instructed 
by The Jackson Laboratory, and are listed in Section 2.28. Oligomers were 
reconstituted to 100 µM stock solutions and used at a final concentration of 0.5µM, 
unless otherwise indicated. PCR products were separated over 1.5%-3% agarose 
(Lonza 50004)/1X TAE gel. A 1% ethidium bromide (Fisher BP1302-10) solution 
was added to the gel at a ratio of 1:15,000 during gel preparation for the purposes 
of DNA fragment detection. DNA fragments (visualized as bands) were imaged 
using a Bio-Rad ChemiDoc MP Imaging System. Genotyping was also outsourced 
to TransnetYX (Cordova, TN, USA) for genomic DNA from tail and pancreas to 
confirm in-house genotyping. Methods sections 2.26-2.28 describe PCR primers, 
reactions, and cycling conditions for the KrasG12D transgene (Kras), “Cre” of the 
Pdx1-Cre transgene (PDX), the Tip30 transgene: Tip30 wild-type (WT) versus 
Tip30 mutant (MT), and the EGFP of the tdTomato-EGFP transgene. Pdx1-Cre 
genotyping was confirmed using primers that spanned both Pdx1 and Cre regions 
in one reaction (see Methods 2.26, “Pdx1-Cre (NCI)”. Genotyping of additional 
transgenes commonly used in GEMM research of PDAC (Westphalen and Olive, 
2012) and previously used by the Korc Laboratory (Trp53R172H or mp53 (Hingorani 
et al, 2005), Rb (Carrière et al., 2011), miR-155 (The Jackson Laboratory 007745), 
Bmal (The Jackson Laboratory 007668), miR-21 (Hatley et al., 2010), Smad7 
(Snider et al., 2010), Ink4a (Aguirre et al., 2003), Agr2 (Norris et al., 2013; Park et 
al., 2009), human HER3, Smad4L/L (Bardeesy et al., 2006b), p16 (Bardeesy et 
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al., 2006a), and Syndecan 4 mouse models as well as genotyping for other 
transgenes related to research studies by the developers of the Tip30-deficient 
mouse model [MMTV-Neu (Zhang et al., 2010), NCOA5 (S. Gao et al., 2013), and 
IL-6 (S. Gao et al., 2013) mouse models] was also completed to exclude 
contamination and the presence of other genes than what is reported in the “TP30” 
mouse colony generated for these studies (Appendix A).  
2.4.1 The Kras G12D Conditional PCR Method 
The PCR reaction for Kras G12D Conditional PCR can be used to confirm 
successful recombination of the LSL-KrasG12D transgene with Cre recombinase 
(Jacks, 2017). This protocol, published by the The Jacks Lab (Jacks, 2017) and 
utilized in Hingorani et al. (2003), results in the detection of three bands: an 
unrecombined LSL cassette (a 500-bp PCR product also referred to as 
“Unrecombined 2lox”), the wild-type Kras sequence (a 622-bp PCR product), and 
a third 650 base pair product confirming the presence of a remaining loxP site and 
the KrasG12D mutation (“Recombined 1loxP” PCR product). For this assay, one 
primer recognizes the upstream region of the Kras sequence (LSL-FP1), a second 
primer anneals downstream of primer one and recognizes the first coding exon of 
Kras (LSL-RP2), and a third primer anneals to a portion of the LSL cassette (LSL-
FP3). The positioning of primers LSL-FP1 and LSL-RP2 will result in a PCR 
product whose size reflects the presence or absence of the recombination event, 
through the insertion of a loxP site (roughly 34 bp) on the KrasG12D sequence. A 
mouse with just a LSL-KrasG12D transgene and no Pdx1-Cre will test positive for 
the unrecombined 2-loxP PCR product and the 622 bp wild-type Kras product, and 
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has both one copy of a wild-type allele in addition to one copy of a the LSL-KrasG12D 
transgene. A LSL-KrasG12D;Pdx1-Cre (KC, Hingorani et al., 2003) mouse that has 
undergone successful recombination in the pancreas tissue will also be positive 
for the third PCR product, 1-loxP-KrasG12D at around 650 bp (Hingorani et al., 
2003). This recombination event will not be 100% efficient in pancreatic tissues, 
however, due to the stochastic expression of Pdx1 (Hingorani et al., 2003). If 
recombination was 100%, then one would also observe the complete loss of the 
500 bp unrecombined 2-LoxP PCR product. 
2.5 Tissue Preparation  
Necropsies were performed and tissues were harvested in accordance to 
our IACUC protocol. First, a small piece of pancreas tissue was quickly excised 
and snap frozen in liquid nitrogen after quick gross examination to prevent 
autolysis. Following removal, pancreas tissue is reported to undergo rapid 
autolysis (Hruban et al., 2006). In situ and ex vivo images of tissues were taken 
with a Sony DSLR-A390 camera. In addition to pancreas tissue, a sample of the 
liver, lung and muscle were snap frozen into separate cryovials, stored at -80°C, 
and used for protein, mRNA, and DNA analysis. A sample from pancreas, lung, 
and liver tissues were also excised and establish cell lines as indicated (see 
Methods 2.13, 2.14). The remaining tissue from these organs, as well as whole 
kidney, spleen, and muscle were placed in 10% neutral buffered formalin (VWR 
International BDH0502) for paraffin embedding and histological analysis (see 
Methods 2.11). A second sampling of the tail was taken at sacrifice to confirm 
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genotyping. Fluorescent tissues from the K30Ctd mouse model were frozen in 
optimal cutting temperature (OCT) compound without fixation. 
2.6 Tissue Pulverization for Protein, mRNA, or DNA 
Snap frozen pancreata or tissues were pulverized using liquid nitrogen-
cooled tissue guns in RNAase-free conditions (Ambion AM9780) to a fine dust 
substance. Tissue dust was immediately transferred into original cryovials on dry 
ice and stored at -80°C. 
2.7 Extraction of mRNA from Tissues 
Pancreas RNA was extracted using an adapted guanidine isothiocyanate 
method (Chang, et al., 1990; Han et al, 1987). In brief, pulverized tissue dust was 
added to pre-cooled RNA Extraction Buffer with guanidine thiocyanate (Sigma 
#50981), prepared on the day of extraction. Sodium acetate pH 4.0, saturated 
phenol, pH 4.5 (Amresco #0981), and chloroform was added sequentially for 
phase separation, and RNA was precipitated overnight in isopropanol at a 1:1 
volume ratio at -20°C. RNA pellets were dissolved in nuclease-free H2O (Fisher 
Scientific BP2819-1). 
2.8 Extraction of mRNA from Cell Lines 
mRNA was extracted from cell lines using 0.5 mL TRIzol (Invitrogen 
15596018) per six-well, in duplicate after washing cells two times in ice-cold 
RNAse free 1X phosphate-buffered saline (PBS). Chloroform extraction was used, 
followed by an overnight precipitation in 100% isopropanol at 4°C, then 75% 
ethanol before centrifugation and resuspension in nuclease-free H2O (Fisher 
Scientific BP2819-1). An Ultraviolet-visible (UV-Vis) spectrophotometer 
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(NanoDrop 2000, Thermo Fisher Scientific) was used to measure sample 
absorbances and determine final mRNA concentrations. 
2.9 Conversion of mRNA to cDNA  
For the synthesis of complementary DNA (cDNA), 1000 ng of mRNA was 
converted to cDNA using a High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems 4387406) and its protocol. For microRNA (miR) analysis, 10 
ng of mRNA was converted to cDNA using the Applied Biosystems TaqMan 
MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific 4366596) and its 
protocol.  
2.10 Quantitative Reverse Transcription-Polymerase Chain Reaction  
Complementary DNA (cDNA) was prepared for real-time quantitative 
reverse transcription-polymerase chain reaction (qRT-PCR) using 1X TaqMan 
Fast Advanced Master Mix (Applied Biosystems 4444557) and TaqMan Probes or 
a multiplex SYBR Green quantitative PCA assay with Power SYBR PCR Master 
Mix (Applied Biosystems 4367659). Applied Biosystems (AB) TaqMan probes 
(Thermo Fisher Scientific TaqMan Assays, Catalog No. 4331182) were common 
to: exon 2-3 of Htatip2, murine Tip30 (AB No. Mm00457476_m1); murine Rps6 
(AB No. Mm02342456); murine Egfr (AB No. Mm00433023_m1); or murine β-actin 
(AB No. MM0607939_s1). Human miR-10b was assessed using the hsa-miR-10b 
primer/probe set (Thermo Fisher Scientific Assay ID 002218) and the internal 
control RNU6B (Thermo Fisher Scientific Assay ID 001093). SYBR Green qPCR 
and SYBR Green Master Mix (Applied Biosystems 4444557) was used to confirm 
Tip30 mRNA expression levels using Tip30 exon 6. Forward (“Tip30 Exon 6-a”): 
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5’GTCCTACTGTGTGACAGGCAAG, Reverse (“Tip30 Exon 6-b”): 
5’ACTCAGCTACATGCAGCCCA. Rps6 was used as the internal gene expression 
control. SYBR Green qPCR was also used to detect c-Myc mRNA levels (Forward: 
GCCCAGTGAGGATATCTGGA, Reverse: ATCGCAGATGAAGCTCTGGT). c-
Myc levels were normalized to beta-actin (Forward: 
ATCATGTTTGAGACCTCCAACACC, Reverse: 
GGATCTTCATGAGGTAGTCTGCA). Real-time qRT-PCR was run on the Applied 
Biosystems ViiA7, and cycle threshold (CT) values were obtained after 40 cycles. 
All qRT-PCR experiments were run in duplicate per run, and pancreas tissues or 
cells lines from at least three different mice per group were analyzed. The relative 
quantity of gene expression values was calculated using the 2(-ΔΔ(C)T) method 
(Livak and Schmittgen, 2001). Fold increases were calculated relative to control or 
wild-type after normalization to an internal control. Statistical analysis was 
performed by using a Student’s two-tailed t-test when two groups were compared 
(in excel), or one-way analysis of variance (ANOVA) if comparing more than two 
groups, with a Tukey post-hoc test (SigmaPlot 12.5). For experiments using cell 
lines, at least two cell lines were from K30C mice, and at least one cell line was 
derived from K30Ctd mice, for Tip30-wild-type, and both Tip30-deficient groups 
(Tip30+/-, Tip30-/-).  
2.11 Histological Analysis and Immunohistochemistry-
Immunofluorescence  
Mice were sacrificed at the times indicated or were monitored until 
moribund. Tissues were fixed in 10% neutral buffered formalin (VWR International 
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BDH0502) overnight, before transfer to 70% ethanol. Tissues were embedded in 
paraffin on the KD BM II Tissue Embedding Station after processing using a 
Microm STP420 Tissue Processor (Thermo Fisher Scientific). Hydrated tissue 
blocks were faced, then tissues were sectioned at 4-5 µm thick using a Thermo 
Fisher Scientific HM 3555 microtome. Roughly 4-5 consecutive sections were 
obtained per mouse tissue to use for analysis. Slides with tissue sections were 
baked for 30 mins at 65°C, in a Robbins Scientific 310 Hybridization Incubator, 
before tissue deparaffinization and rehydration. Hematoxylin (Sigma GH5232) and 
eosin (Acros organics #20193000) were used to perform hematoxylin and eosin 
(H&E) staining. Antigen retrieval and unmasking were performed using a citrate-
based, pH 6 solution (Vector Laboratories H-3300) for immunohistochemistry 
(IHC), IHC immunofluorescence (IHC-IF), and Alcian Blue (Newcomer Supply 
1003A) staining. Tissues were passed through a series of dehydration steps, 
mounting (Fisher SP15-500), and cover-slipping (Fisherbrand 12-544G). Tissues 
were probed with CK-19 (Troma III, Developmental Studies Hybridoma Bank, 1:10) 
overnight at 4°C, in a humidified slide chamber after 3% hydrogen peroxidase 
(Fisher H325) exposure and wash. Slides were then incubated in Biotinylated 
Rabbit anti-Rat IgG (Vector Laboratories BA-4001) 1:400 in 5% normal goat serum 
in PBS (Vector Laboratories S1000). For IHC, the avidin-biotin complex (ABC) 
technique was performed using the Vectastain ABC HRP kit from Vector 
Laboratories. 3,3’-Diaminobenzidine (DAB) exposure was performed for the same 
duration of time for all samples. For IHC-IF detection of amylase, insulin, and 
glucagon, antigen-unmasked tissue sections were incubated in anti-Pancreatic 
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rabbit amylase antibody 1:400 (Abcam ab21156), rabbit anti-Insulin antibody 
(ab63820) 1:600, and mouse anti-Glucagon antibody (ab10988) 1:400 overnight 
at 4°C, in a humidified slide chamber. Normal goat serum was used as the diluent, 
except for in mouse on mouse detection in which case, the M.O.M. kit was used 
(Vector Laboratories BMK-2202). The M.O.M kit included protein concentrate, 
Mouse Ig Blocking Reagent, and Biotinylated anti-Mouse IgG. Alpha-SMA (mouse 
origin, Sigma A2547, 1:500) was detected by IHC with the M.O.M. kit. Goat anti-
Rabbit Alexa Fluor 488 (Thermo Fisher Scientific A11034) or Goat anti-Mouse 
Alexa Fluor 555 (Invitrogen A21429) were the secondary antibodies used in IHC-
IF primary detection. Slides were mounted (Invitrogen P36931 Prolong Gold 
mounting medium with DAPI), coverslipped, (Fisherbrand 12-544G), and allowed 
to dry overnight before imaging.  
Tissues were imaged using an Olympus BX60 Microscope with Lumen 200 
Fluorescence Illumination System (Prior Scientific) and Image Pro Plus 7.0 
software) at low (4X objective lens) and high (20X objective lens) power. For IHC-
amylase, glucagon, and insulin imaging of pancreas tissues, images were 
captured using “Mono”, and for CK-19 and α-SMA images were captured using 
“RGB” Olympus BX60 Microscope/Image Pro Plus 7.0 settings. For the scale bars 
provided in images of this report and taken using the Olympus BX60 microscope, 
a ruler in micrometers (μm) was imaged at low and higher power (“scale bar” image 
specific to each magnification). These images were opened alongside the images 
of tissues for each corresponding magnification. Both images were formatted to 
“lock aspect ratio” in Microsoft Publisher software (which was used to create 
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figures), then scaled down (using the same conditions for both images). A line was 
drawn on the imaged ruler in the “scale bar” image spanning 100 μm in Microsoft 
Publisher. For “scale bar” images and imaged tissue that were the same size only 
(both in power and in Microsoft Publisher) the 100 μm scale bar was transferred to 
the right, bottommost corner of the tissue image. This was done for both low and 
high power images provided in this report. This method was also used to create 
scale bars for images of visceral tissues and both in situ or ex vivo, but only if the 
image was taken with a ruler at the time of imaging. 
A Leica DM5000B microscope with Leica DFC 7000T camera and LASX 
software was used to image H&E sections of pulmonary tissues and liver in this 
report at low (2.5X objective lens) and high (20X objective lens) power. An image 
with an attached scale bar was taken for at least one field at each power. The scale 
bars provided by the LASX software for a 2.5X objective lens image was 750 μm 
in length, and for the 20X objective lens image was 100 μm in length; therefore for 
presentation of tissue at both low and high power, a scale bar that spanned 100 
μm was drawn and saved with the image for both images for consistency. Scale 
bars presented in this report are an accurate representation of the scale bars 
provided by the software. This microscope and camera was also used for the 
representative fields in Figure 15A-D and Figure 16. 
2.12 Lesion Scoring 
Pancreas and organ pathology was determined by the board certified 
pathologist, Dr. George Sandusky. We first assessed an H&E stained section of 
the entire tissue for the pancreata of 21 K30+/+C, 20 K30+/-C, 24 K30-/-C mice. In 
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addition, if additional sections were available, including CK-19 sections, all images 
available at higher power were compiled to determine the extent of PDAC (whether 
it was in the beginning stages or full blown) and for an overall scoring of PDAC 
precursor lesions. PDAC was assessed with the visualization of a glandular pattern 
in pancreas tissue, ductal architecture, and cellular and nuclear atypia (Hezel et 
al., 2006). The Hruban et al. (2006) consensus report for evaluating genetically 
engineered mouse models for PDAC was referenced, and statistically significant). 
An increase in pERK1/2 was also observed in miR-10b-overexpressing AsPC-1 
cells after 10-30 minutes of EGF treatment (Figure 41).of this report. An H&E 
section for seven to twelve lung, kidney, and spleen tissues was also examined by 
histopathological analysis.  
2.13 Isolation of Primary and Metastatic Pancreatic Cancer Cells from 
Tissues 
Fresh tissue biopsies were carefully minced (Exelint International, Size 10; 
29550), washed in five passes of 1% antibiotic-antimycotic (Life Technologies 
15240-62) and digested with 2 mg/mL Type IV Collagenase (Worthington 
LS004188) in plain HBSS, warmed to 37°C for 30-45 minutes. Cell suspensions 
were passed through a 70-micron mesh cell strainer (Corning 352350) and washed 
free of collagenase before plating. Pancreatic tumor, lung, and liver tissue biopsies 
were collected and processed in separate dishes; mincing scalpels were changed 
between tissues. 
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2.14 Cell Lines and Tissue Culture  
Single cell clones from three K30+/+C, three K30+/-C, and two K30-/-C murine 
pancreatic cancer cell lines (mPCCs) isolated for these studies (see Methods 2.13) 
were authenticated by IDEXX BioResearch (Columbia, MO, USA) and underwent 
MHV, MNV, MPV, MVM, Mycoplasma pulmonis, Mycoplasma sp., PVM and 
Sendai testing, genetic evaluation for an Interspecies Contamination Test and 
mouse nine-marker STR profiling. All testing came back negative, confirming that 
original cell lines established in the lab were mycoplasma and pathogen free, and 
were indeed mouse (Appendix B). AsPC-1 human pancreatic cancer cells 
(hPCCs) were obtained from the ATCC the American Type Culture Collection 
(Manassas, VA, USA). Samantha Deitz McElyea, a member of our lab, with 
expertise in establishing GFP-positive-microRNA (miR)-10b overexpressing-stably 
transfected human pancreatic cancer cell lines generated at least three stable 
AsPC-1-miR-10b-overexpressing (AsPC-1-miR-10b-OX-GFP) and three AsPC-1-
vector-control (AsPC-1-GFP-C) cell lines for the purposes of these studies. The 
materials and methods for miR-10b-overexpressing human PCCs has been 
reported (Ouyang et al., 2013). Briefly, 293T-based retroviral packaging Phoenix 
cells (Life Technologies) were transfected with either a MDH1-PGK-GFP 
microRNA-10b retroviral construct or an empty MDH1-PGK-GFP construct. 
Viruses were then harvested and AsPC-1 hPCCs were transduced. After 48 hours, 
GFP positive cells were isolated by flow cytometry.  
mPCCs and AsPC-1 cells were grown in complete RPMI (Hyclone 
SH30027.01) culture medium supplemented with 5% heat-inactivated and filtered 
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fetal bovine serum (FBS) (Tissue Culture Biologicals 101H1) and 1% Penicillin-
Streptomycin (P/S, Hyclone SV30010) in a HEPA filtered Thermo Scientific Forma 
Series II 3110 Water-Jacketed CO2 Incubator at 37°C and 5% CO2. Cell passage 
and plating for experiments were conducted in a biological safety cabinet with 
aseptic technique. Trypsin 0.05% (Hyclone SH30236) was used to dissociate cells 
in culture for passage. HBSS (Lonza 10-S43F) was used to wash cells before 
trypsinization and for experiments in culture. Trypan Blue Solution, 0.4% (Thermo 
Fisher Scientific 15250061) was used during cell counting to assess cell viability. 
Cell populations plated for experiment had greater than 80% viability. The majority 
of the experiments were performed using cell lines that were passaged less than 
20 passages. All tissue culture was performed under aseptic conditions. Cells were 
routinely checked for mycoplasma (Lonza LT07). Cells in these experiments were 
free from mycoplasma contamination. Cells were frozen in 10% DMSO (Fisher 
Scientific NC0945470)/FBS and stored in -80°C and/or liquid nitrogen. Cell lines 
were imaged using brightfield settings with DMI 3000B Microscope and Leica 
DFC310 FX camera with Las V4.5 software. GFP images were captured using a 
GFP D5, YFP filter and the same settings in figures depicted. For experiments 
using murine cell lines, at least two cell lines were from K30C mice, and at least 
one cell line was derived from K30Ctd mice, for each Tip30 wild-type, 
heterozygous, and homozygous-loss group. 
2.15 GFP/RFP Visualization and Fluorescent Imaging of K30Ctd GEMM 
Excitation of EGFP and Tomato were captured in a light box illuminated by 
fiber optic lighting (Illumatool BLS; Lightools Research, Encinitas, CA, USA). This 
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system allowed us to detect and visualize live recombined and nonrecombined 
cells and whole tissues expressing EGFP and Tomato. Whole-body images with 
the visceral abdominal cavity exposed (epidermal and dermal levels removed) 
were taken immediately after sacrifice, and allowed in situ GFP visualization of 
pancreas tissues as well as micrometastatic seeding of pancreatic cancer cells to 
distant organs. Pancreas, spleen, liver in part or full, and lungs were isolated and 
imaged ex vivo in a petri dish after being washed in 1X sterile PBS, to confirm 
detection of micrometastatic seeding visualized by whole body imaging. GFP and 
Tomato were illuminated with two Illumatool excitation lamps. GFP fluorescence 
was captured with a 470 nm +/- 40 nm emission filter. Tomato was illuminated with 
the same lamps and captured with a 572 nm +/- 35nm filter. Peak excitation for 
tdTomato is 554 nm (Muzumdar et al., 2007). High-resolution images were 
captured directly using an Olympus DP70 camera (DSP Technologies, Inc., Santa 
Barbara, CA, USA) secured to the top of the light box. Image-Pro Plus 7.0 software 
was used to preview and capture the images at camera’s normal resolution which 
is 0.003 inches/pixel. Adobe Photoshop was used to auto contrast the images. 
Adjustments to brightness and contrast are as indicated. 
2.16 Overexpression of microRNA-10b in a Human AsPC-1 Pancreatic 
Cancer Cell Line  
Materials and methods for creating microRNA (miR)-10b-overexpressing 
AsPC-1 cells were described previously in Methods 2.14 and reported in Ouyang 
et al. (2013). qRT-PCR was used to analyze both human miR-10b (Thermo Fisher 
Scientific Assay ID 002218) and the internal control RNU6B (Thermo Fisher 
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Scientific Assay ID 001093), in duplicate from three biological replicates of AsPC-
1-miR-10b-OX-GFP and AsPC-1-GFP-C stably transfected cell lines. CT values 
were obtained and normalized to RNU6B per experiment. AsPC-1-miR-10b-OX-
GFP miR-10b levels are represented as a fold change normalized to control 
(AsPC-1-GFP-C) or relative quantity (RQ). The mean ± SEM of three independent 
experiments is depicted in Figure 40. Student’s two-tailed t-test of RQ values was 
used to assess statistical significance. p<0.05 was considered statistically 
significant. 200,000 AsPC-1-miR-10b-OX-GFP or AsPC-1-GFP-C cells were 
serum starved (low-serum media: RPMI supplemented with 0.5% FBS, 0.1% 
Bovine Serum Albumin (BSA-Sigma A7906), 5 µg/mL apotransferrin, 5 ng/mL 
sodium selenite, and 1% P/S) for 24 hours (hrs) and then treated with 1 nM EGF 
(Millipore, Billerica, MA, USA) for 0, 10, 30 mins, or 24 hrs in low-serum media, as 
indicated. Densitometry was performed on at least three separate experiments 
using Image J. Protein levels from each experiment were normalized to a 
respective β-Actin or α-Tubulin loading control, and then to the 0 min time point for 
AsPC-1-GFP-C (Ctrl) cells (0 min-Ctrl), except for pAKT levels, which were only 
normalized to the loading control. This was because two pAKT experiments had 
“0 min-Ctrl” densitometry values of 0. For pEGFR Y1148 and EGFR, n=3; pAKT 
and AKT n=4. Data reported are the means ± SEM. 
2.17 Flow Cytometry and Fluorescence-Activated Cell Sorting (FACS) 
GFP-positive cell lines were established by sorting cells isolated from 
K30Ctd+/- mice after culture. GFP-positive cells were sorted using the BD FACS 
Aria II Cell Sorter or BD SORP Aria (IU Simon Cancer Center Flow Cytometry 
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Core). Cells were trypsinized and resuspended in 10 million cells/mL and passed 
through a 40-micron mesh cell strainer (Corning 352340). Similar settings 
(including gating to a GFP-negative cell line TP573) were applied for all cell sorting. 
GFP-positive and negative cells were collected and replated after sorting.  
2.18 Protein Extraction from Tissues and Cell Lines and Immunoblotting 
Pulverized pancreatic tissue dust was homogenized in cell lysis buffer (Cell 
Signaling Technology 9803) with 1X Protease Inhibitor Cocktail (cOmplete, Roche 
11697498001), 1 mM beta-glycerophosphate (Sigma G5422), 1 mM sodium 
orthovanadate (Sigma S6508), and 1 mM PMSF (Sigma 78830). Tissue dust 
lysates and lysates from cells were sonicated twice using Fisher Scientific Model 
120 Sonic Dismembrator and ultrasonic processor, with five second pulse-five 
second break intervals for one minute per sonication. Pierce BCA Assay (Thermo 
Scientific 23225) with a 562 nM wavelength was used to determine protein 
concentrations. 15 µg of protein was separated over 15% SDS-PAGE with 30% 
Acrylamide/Bis (Biorad 161-0158) and gel electrophoresis (Bio-Rad Criterion Cell 
135BR0033528) and transferred to PVDF membrane (0.45 μm, Millipore 
IPVH00010). Membranes were blocked with 5% BD Difco skim milk 
(232100)/TBST, and incubated in primary antibody overnight at 4°C per company 
recommendations. Secondary antibody HRP-conjugated antibodies (1:5,000) in 
5% milk/TBST were used to detect the primary antibody. Washes before and after 
secondary were in TBST at room temperature. Protein bands were visualized after 
adding Supersignal West Pico and Femto substrates (Thermo Scientific 34578, 
34095) to membranes, and exposure to autoradiography film (Ultra Cruz SC-
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201697) and a Konica Medical Film Processor (SRX-101A). More than three 
separate experiments were performed to confirm TIP30 protein levels in three-
month-old pancreas tissues from K30+/+C, K30+/-C, K30-/-C mice.  
For immunoblot analysis of cell lines mPCCs or hPCCs were washed twice 
with ice-cold 1X PBS, scraped in cell lysis buffer and 12 µg or 20 µg of protein, 
respectively, was separated over 10% SDS-PAGE and assessed as described 
above. The following antibodies were used: EGFR (CST 4267, 1:1000, 5% milk), 
N-cadherin (BD 610920, 1:2000, 5% milk), E-cadherin (BD 610181), CK-19 
(Troma III, Developmental Studies Hybridoma Bank, 1:500 5% milk), α-Tubulin 
(Sigma T9026, 1:2000, 5% milk), ɣ-Tubulin (Sigma T5326, 1:1000, 1% milk), β-
Actin (Sigma A1978, 1:100,000, 5% milk), HER2 (SC 284, 1:200, 5% milk, HER3 
(CST 4754, 1:1000, 5% BSA), TIP30 (Abcam ab177961, Lot GR163258-1, 1:5000, 
5% BSA). pEGFR Y1148 (CST 4404, 1:1000, 5% BSA), pAKT, AKT S473 (CST 
4060, 1:2000, 5% BSA), pERK1/2 (CST 4370, 1:2000, 5% BSA), and total ERK1/2 
(CST9102, 1:1000, 5% milk). A 250 kD protein ladder (BioRad 161-0375) was 
used for all immunoblotting experiments. The following secondary antibodies were 
used: Goat anti-Mouse (Biorad 170-6516), Goat anti-Rabbit (Biorad 170-6515), 
and Goat anti-Rat (EMD Millipore 401416). For tissues and cell lines at least three 
biological samples (from three different mice) were assessed. In addition, at least 
two (tissues) and three technical replicates (per cell line), in which protein was 
collected from a cell line on three different dates was assessed. Densitometric 
analysis of immunoblot data was performed using Image J software, to quantitate 
protein levels. Briefly, a rectangle with fixed dimensions per immunoblot (per 
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protein) was used to calculate background mean white pixel signal and mean white 
pixel signal per sample condition. The background mean white pixel was 
subtracted from the mean white pixel signal of each sample for the number of black 
pixels. The loading control was also quantitated in this manner. Normalization of 
data occurred in two steps 1) to the loading control and 2) to the K30+/+C, wild-type 
Tip30 control. For step 1, the black pixels of the samples were divided by the black 
pixels for the respective loading control for each sample. Then, for step 2, K30+/+C 
levels for three cell lines were averaged (n=3) and average values for K30+/-C or 
K30-/-C PCCs were divided by the average K30+/+C and depicted in bar graphs. 
For statistical analysis, values from step 1 were assessed.  
2.19 Two-Dimensional Clonogenic Growth Assay 
500 single cells were plated in duplicate in a six-well plate in complete 
media. After seven to eight days in culture, unless otherwise indicated, colonies 
were washed twice with ice-cold 1X PBS and fixed with 0.05% crystal violet (Sigma 
C6158) in 95% methanol solution for five minutes at room temperature. Crystal 
violet solution was removed and stained colonies were washed twice with 1X cold 
PBS and once with ddH2O to remove background dye. Dry plates were scanned 
and colony areas were assessed using the Image J Colony Area plugin software 
designed for six-well plates (Guzman et al., 2014). One representative experiment 
per cell line was used to determine mean two-dimensional growth.  
2.20 Three-Dimensional Colony Growth Forming Assay 
The three-dimensional (3D) culture system was described previously 
(Sempere et al., 2011). Briefly, for each experiment 5,000 mPCCs were plated in 
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duplicate (two wells) in a 48-well tissue culture plate. Cells were first resuspended 
in 200 µl of an ice-cold 3%-growth-factor-reduced matrigel (Corning 
356231)/complete media, before plating on top of 200 µl of solidified 1% soft 
agar/complete media. Autoclaved aliquots of 3% agar noble (BD Diagnostic 
Systems 214220) were stored at 4°C. Cells were fed every 4-5 days with 100 µl 
ice cold 3% matrigel/complete media. After 14-20 days in culture, colonies were 
imaged at 4X and 20X magnification using a DMI 3000B Microscope and Leica 
CFC310 FX camera and Las V4.5 software. Captured formats were 1392x1040 
units. Each well was then stained with a final concentration of 0.4 mg/mL MTT 
(Sigma M2128), for 3 hours at 37°C, before whole-plate imaging. Surface areas of 
3D colonies were scanned using an HP Scanjet G4050. Colony areas from 
scanned images were quantitated using Image J Colony Area plugin for custom 
plates (Guzman et al., 2014). Mean threshold intensities were used per plate to 
account for background, and percent areas occupied were divided by total well 
area percentages per well. Three biological replicates or three separate cell lines 
per group: Tip30+/+, Tip30+/-, and Tip30-/- in the KC background (K30+/+C-TP151-
GFP, TP711, TP715; K30+/-C-TP852-GFP, TP573, TP647; and K30-/-C-TP735-
GFP, TP592-1, TP889) were analyzed in this assay. Our cell line nomenclature 
uses the mouse ID number from which the cell line was derived. For each of the 
nine cell lines assessed, three separate experiments were first performed in 
duplicate on three different dates for each cell line, except for the cell line TP852-
GFP, for which only one experiment was performed in duplicate; and data was 
collected. For statistical analysis, one representative experiment of 3D growth for 
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each cell line after 17-18 days in culture was utilized, and K30+/+C, K30+/-C, and 
K30-/-C groups, with n=3, were compared by one-way analysis of variance 
(ANOVA) (SigmaPlot 12.5). Results did not reach statistical significance. 
2.21 Immunofluorescence Confocal Microscopy 
10,000 cells were plated in 8-well glass chamber slide in normal tissue 
culture media, 5% FBS, 1% P/S, grown to 60% confluence before being serum 
starved overnight after washing 2X with HBSS. Serum starving media consisted of 
0.5% FBS, 0.1% BSA, 5 µg/mL apotransferrin, 5 ng/mL sodium selenite, RPMI. 
Cells, 1% P/S were fixed with 4% paraformaldehyde at baseline (no EGF or 0 min 
time point) or following treatments with 1 nM EGF for 30 min or 120 min. Cell 
membranes were permeabilized during blocking with 1% BSA/0.15% TritonX/ 5% 
normal goat serum (Vector Laboratories S1000). PCCs were probed with anti-
EGFR (CST 4267 1:50) and 1:400 Goat anti-Rabbit Alexa Fluor 488 (Life 
Technologies A11034, Lot 1851447) antibodies to detect EGFR. Slides were 
mounted with Prolong Gold mounting medium with DAPI (Invitrogen P36931) and 
coverslipped (Fisherbrand 12-544G) and imaged using the Leica SP8 Confocal 
microscope with a 40X/1.3 oil immersion, Zoom of 2.3 and LASX software. 15-30 
cells were captured per field and two fields were imaged at a minimum after 
scanning the entire slide and processed using Fiji and Imaris 64 software for 
maximum intensity projection from a 3D volume. Background from a no primary 
antibody negative control image was removed from images shown during 
processing. Fiji software was used for image processing and to subtract 
background. The background was determined from a control image (obtained by 
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imaging a control field in the experiment that was incubated with the secondary 
antibody, but no primary antibody “no primary control”) and subtracted from all 
subsequent images. Antibodies detecting CK19 (rat origin, Troma III, 
Developmental Studies Hybridoma Bank) at a 1:200 dilution, and α-SMA (mouse 
origin, Sigma A2547) at a 1:100 dilution were used for representative staining in a 
cell line from each group. The following fluorophore-conjugated secondary 
antibodies were used for immunofluorescence detection: Goat anti-Mouse Alexa 
Fluor 555 (Invitrogen A21429) was used to detect α-SMA; Goat anti-Rat Alexa 
Fluor 647 (Invitrogen A21472) was used to detect CK19; Goat anti-Rabbit Alexa 
Fluor 488 (Thermo Fisher Scientific A11034) was used to detect EGFR.  
2.22 MIR10B and TIP30 Expression in hPDAC 
MIMAT0000254 (MIR10B) hPDAC RNAseq data was downloaded from 
UCSC Xena browser’s The Cancer Genome Atlas (TCGA) Pancreatic Cancer 
(PAAD) cohort (Goldman et al., 2019) and HTATIP2 (TIP30) from the TCGA 
provisional dataset (J. Gao et al., 2013; Cerami et al., 2012). Data was accessed 
on July 7, 2018. Patient-matched TIP30 and MIR10B expression values were used 
to create a scatterplot using SigmaPlot 13.0. An exponential decay curve was fit 
to the data, and the relationship between both values were assessed using the 
Spearman coefficient in SigmaPlot. 
2.23 K30C Survival Analysis 
K30+/+C, K30+/-C, and K30-/-C mice that were non-breeders were also 
monitored for survival in accordance with IACUC and LARC standards. Mice were 
monitored until moribund, which was determined by symptoms such as any and 
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first indication of difficulty breathing, short rapid breaths, irregular coat and 
grooming presentation (scruffiness), lack of eating and severe weight loss (as 
determined by LARC), and any other reasons determined by LARC to comply with 
humane treatment conditions. Mice monitored for survival were obtained from 
progeny with mouse ID numbers TP427 and higher (see Methods 2.1 for an 
explanation regarding the mouse identification system and Pdx1-Cre mouse strain 
background). This was to minimize any interference in differences in strain source 
on survival (see Methods 2.1). Mouse subjects used in the survival curve ranged 
from subject ID numbers TP431 to TP1217. Observations began with the first 
death occurrence on August 7, 2015. The survival study was terminated in July of 
2018. Mice that were taken at specific and pre-determined time points were not 
included in the survival analysis.  
Survival data were analyzed using the Kaplan-Meier estimator through 
GraphPad Prism 7.0 on July 20, 2018. Death was considered to be an event or 
occurrence (“1”). Mice were monitored for 12 months, however not all mice were 
able to be monitored for a total of 12 months due to rolling assignment to the study. 
If mice were alive at the conclusion of the study they were assigned a “0” or 
considered censored. Censored data and “0=censored” is reviewed by Rich et al. 
(2010) and Goel et al. (2010). For the purposes of these studies, these were mice 
that were alive before reaching the 12-month endpoint in the study (K30+/+C, n=4; 
K30+/-C, n=2; and K30-/-C, n=5). Since the study was concluded before 12 months 
for these particular mice we had no way to know nor predict their survival (in 
months). Therefore all “1” (experienced death or occurrence) and “0” (censored) 
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events were included in the statistical analysis so as not to skew the data in favor 
any one particular cohort. A logrank (Mantel-cox) test was performed on all survival 
data (both “1” and “0” events). The total number of mice per group including the 
censored subjects were as follows: K30+/+C, n=10; K30+/-C, n=14; and K30-/-C, 
n=13.  
2.24 Statistics 
A Student’s two-tailed t-test (Microsoft Excel) was performed, when two 
groups were compared. For more than two group comparisons, a one-way-
analysis of variance (ANOVA) with Tukey post-hoc was performed in Sigma Plot 
11.0. A power analysis was performed at the Biostatistics Walk-In Clinic to 
determine the number of animals needed for significance in tumor formation 
between groups, with a power of 0.80 and an alpha of 0.05. For statistical testing, 
p<0.05 was considered significant. Categorical data sets were analyzed with a Chi-
square test (SigmaPlot 13.0) or Chi-Square test for trend (GraphPad Prism 4.0) 
for three groups (K30+/+C, K30+/-C, and K30-/-C) using a 2x3 contingency table, 
followed by 2x2 contingency table and Fisher exact or Chi-square analyses 
between two groups with a Bonferroni Correction of 0.0167, to check for 
significance (SigmaPlot 13.0). Survival data were analyzed using a Kaplan Meir 
survival curve and Log-rank (GraphPad Prism 7.0), (see Methods 2.23). 
Continuous data (MIR10B and TIP30 expression in hPDAC, TCGA) was analyzed 
using a nonlinear fit (exponential decay) to the data derived from TCGA obtained 
from UCSC Xena browser using Sigmaplot 13.0, followed by statistical analysis 
using the Spearman’s rank correlation coefficient (Sigmaplot 13.0). Two separate 
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analyses were done, both with and without the outlier. For categorical and 
continuous data set statistical analyses we consulted with Dr. Susan Perkins, a 
Professor of Biostatistcs and member of both the Pancreatic Cancer Signature 
Center and the Biostatistics and Data Management Core of the Indiana Melvin and 
Bren Simon Cancer. Dr. Perkins is currently the Director of Design and Biostatistics 
Program of the Indiana Clinical and Translational Sciences Institute (CTSI). 
2.25  Composition of Buffers  
Laboratory grade double deionized water (ddH2O), from an EMD Millipore 
Milli-Q water purification system, was used in the composition of all buffers.  
 
Immunoblotting Gel Electrophoresis: 
Upper buffer (UB)-0.5 M Tris; 0.4% SDS; pH 6.8 
Lower buffer (LB)-1.5 M Tris; 0.4% SDS; pH 8.8 
 
SDS-PAGE Gels (per gel): 
10% separating gel-3.33 mL 30% acrylamide; 2.5 mL LB, 4.17 mL ddH2O 
12% separating gel-4.0 mL 30% acrylamide; 2.5 mL LB, 3.5 mL ddH2O 
15% separating gel-5.0 mL 30% acrylamide; 2.5 mL LB, 2.5 mL ddH2O 
Add 50 µL 10% APS, 10 µL TEMED per gel.  
 
Stacking gel: 0.67 mL 30% acrylamide; 1.25 mL UB, 3 mL ddH2O 
Add 25 µL 10% APS, 5 µL TEMED per gel.  
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6X Loading Dye: 1 g SDS; 7 mL UB; 3 mL Glycerol; 600 µL β-Mercaptoethanol 
(BME); 0.6% bromophenol blue 
 
5X Running Buffer (Diluted to 1X): 
0.96 M Glycine 
125 mM Tris 
For 4 L: 60.4 g Tris; 288 g Glycine; 20 g SDS 
 
Transfer Buffer: 
25 mM Tris; 192 nM Glycine; 20% Methanol 
For 8 L: 115.2 g Glycine; 24 g Tris; 1.6 L Methanol; 6.4 L ddH2O 
 
10X Tris-buffered saline (TBS) 
For 8 L: 192 g Tris; 704 g NaCl, pH 7.6 (55 mL 12 M HCl) 
 
Tris-buffered saline-Tween-20(TBST) 
1X TBS, add 8 mL Tween-20 (0.1%) 
 
50X Tris base, acetic acid and EDTA (TAE) 
121 g Tris 
28.55 mL Glacial Acetic Acid 
18.6 g EDTA 
Fill to 500 mL ddH2O, pH 8.5 
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2.26 Primers  
Primers are listed in 5’ to 3’, left to right.  
 
Kras 
K005 (mut Kras): AGCTAGCCACCATGGCTTGAGTAAGTCTGCA 
K006 (wt & mut Kras): CCTTTACAAGCGCACGCAGACTGTAGA 
 
PDX (Cre-Cre) 
Cre 1: TGATGAGGTTCGCAAGAACC 
Cre 2: CCATGAGTGAACGAACCTGG 
 
Pdx1-Cre (NCI) 
Pdx-F: CTGGACTACATCTTGAGTTGC 
Pdx-R: GGTGTACGGTCAGTAAATTTG 
 
Tip30 
MT (Reverse): GGC CTC TTC GCT ATT ACG C 
Common (Forward): TGA GTC TCT GCC CAA CA 
WTR (Reverse): TAA TGG ACA CCT TCC CCT CA 
 
tdTomato 
Wild-type Forward - CTC TGC TGC CTC CTG GCT TCT  
Wild-type Reverse - CGA GGC GGA TCA CAA GCA ATA  
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Mutant Reverse - TCA ATG GGC GGG GGT CGT T  
 
Kras G12D Conditional PCR 
LSL-1 GTCTTTCCCCAGCACAGTGC 
LSL-2 CTCTTGCCTACGCCACCAGCTC 
LSL-3 AGCTAGCCACCATGGCTTGAGTAAGTCTGCA 
 
2.27 PCR Reactions 
19 microliters of master mix was combined with one microliter of tail DNA 
for each PCR reaction as described below. In genotyping DNA isolated from 
pancreas tissues, other organs, or cell lines, 17 microliters of mastermix was 
combined with three microliters of ddH2O + 200 ng of DNA sample. Two separate 
PCR reactions were performed for TIP30 genotyping: one to detect the wild-type 
allele and another to detect the mutant (LacZ) allele.  
 
Kras/PDX  
Genotyping per reaction (µL) 
2 10x buffer 
1.2 MgCl2 
0.5 dNTPs 
0.1 Forward primer 
0.1 Reverse primer 
0.1 Taq 
15 H2O 
 
Tip30 
Genotyping per reaction (µL) 
2 10x buffer 
1 MgCl2 
0.5 dNTPs 
0.1 Common (Forward) primer 
0.1 Reverse primer (MT or WTR) 
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0.1 Taq 
15.2 H2O 
 
tdTom 
Genotyping per reaction (µL) 
1.8 10x buffer 
1 MgCl2 
0.5 dNTPs 
0.15 Forward primer (WTF) 
0.1 Reverse primer (WTR) 
0.2 Mutant primer (MT) 
0.1 Taq 
15 H2O 
 
Kras G12D Conditional PCR 
Genotyping per reaction (µL) 
1.8 10x buffer 
1 MgCl2 
0.5 dNTPs 
0.1 Forward primer (LSL-1) 
0.1 Reverse primer (LSL-2) 
0.1 Mutant primer (LSL-3) 
0.1 Taq 
13.3 H2O 
 
Pdx1-Cre (NCI) 
Genotyping per reaction (µL) 
2 10x buffer 
1.2 MgCl2 
0.5 dNTPs 
0.1 Forward primer 
0.1 Reverse primer 
0.1 Taq 
15 H2O 
 
2.28 PCR Cycling Conditions 
Thermocycler conditions plus predicted band sizes are indicated for each 
transgene used for these studies. Agarose percentages used to detect each 
transgene by gel electrophoresis is indicated for each transgene.  
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Kras  
Step #, Temperature 
1. 95°C, 15 min 
2. 95°C, 30 sec 
3. 60°C, 30 sec 
4. 72°C, 1 min 
5. Go to step 2, 35X 
6. 72°C, 5 min 
7. 10°C, hold  
Transgene = 600 bp, 2% gel 
 
PDX 
Step #, Temperature 
1. 95°C, 15 min 
2. 95°C, 30 sec 
3. 58°C, 1 min 
4. 72°C, 45 sec 
5. Go to step 2, 34X 
6. 72°C, 10 min 
7. 10°C, hold  
Transgene = 400 bp, 2% gel 
 
Pdx1-Cre (NCI) 
Step #, Temperature 
1. 95°C, 15 min 
2. 95°C, 30 sec 
3. 56°C, 30 sec 
4. 72°C, 30 sec 
5. Go to step 2, 35X 
6. 72°C, 10 min 
7. 10°C, hold  
Transgene = 650 bp,  
 
TIP30 Touchdown 
Step #, Temperature 
1. 95°C, 15 min 
2. 94°C, 20 sec 
3. 65°C, 15 sec (-0.5°C/cycle) 
4. 68°C, 10 sec 
5. Repeat steps 2-4 for 10 cycles 
6. 94°C, 15 sec 
7. 60°C, 15 sec 
8. 72°C, 10 sec 
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9. Repeat steps 6-8 for 28 cycles 
10. 72°C, 10 min 
11. 10°C, hold 
Mutant = 300 bp 
Heterozygote = 300 bp and 364 bp 
Wild-type = 364 bp, 2% gel 
 
tdTom 
Step #, Temperature 
1. 95°C, 15 min 
2. 95°C, 30 sec 
3. 61°C, 1 min 
4. 72°C, 1 min 
5. Repeat steps 2-4, 35X 
6. 72°C, 10 min 
7. 10°C, hold 
Mutant = 250 bp 
Heterozygote = 250 bp and 330 bp 
Wild-type = 330 bp, 1.5% gel 
 
Kras G12D Conditional PCR 
Step #, Temperature 
1 95°C, 15 min 
2 95°C, 30 sec 
3 61°C, 30 sec 
4 72°C, 45 sec 
5 Go to step 2, 34X 
6 72°C, 10 min 
7 10°C, hold 
Recombined (Mutant) = 650 bp 
LSL Cassette = 500 bp 
Wild-type = 622 bp, 3% gel 
 
2.29 TIP30 Antibodies 
The rabbit monoclonal anti-TIP30 antibody was purchased from Abcam 
(ab177961). It is raised against the C terminus and can detect isoforms 1 and 3 
(27,049 daltons and 30, 131 daltons respectively). Note that the oriGene 
TA590574 Rabbit Polyclonal TIP30 antibody was tested and gave non-specific 
bands. The GeneTex GTX100119, Lot 40709 Rabbit polyclonal antibody also gave 
non-specific bands.   
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CHAPTER 3. DEVELOPING AN IN VIVO MODEL SYSTEM TO STUDY THE 
ROLE OF TIP30 LOSS ON PDAC PROGRESSION 
3.1 Background and Rationale 
Tat-interacting protein (30 kD), TIP30, is encoded by the gene HTATIP2 
(CC3) (Xiao et al., 1998, Shtivelman, 1997). TIP30 shares some properties with 
short-chain dehydrogenase reductases (SDRs), thereby placing it in the SDR 
family of oxioreductases (Omari et al., 2005). Some of these properties include an 
SDR fold and high affinity for coenzymes NADH and NADPH; however, the dimer 
formation of TIP30 differs slightly from that of typical SDRs. In addition, a substrate 
has not yet been identified for TIP30, nor has its function as an oxioreductase been 
proven (Omari et al., 2005). Based on reports in the literature, TIP30 has been 
identified as a metastasis suppressor with proapoptotic functions (Shtivelman, 
1997; Xiao et al., 2000). Loss of TIP30 expression has been studied in the context 
of hepatocellular (Ito et al., 2003), lung (Li et al., 2013) and colorectal carcinoma 
(Chen et al., 2010). TGF-β-mediated silencing of TIP30 promotes metastasis in 
esophageal carcinoma (Bu et al., 2014). TIP30’s role as a metastasis suppressor 
is linked to its proapoptotic properties. Through mechanisms of nuclear import 
inhibition of proteins with a primary nuclear localization signal (NLS) or an M9 
transport signal, TIP30 can aid in exposing cells to cell-death signals (Xiao et al., 
2000; King and Shtivelman, 2004; Shi et al., 2008). TIP30 loss has been 
associated with lymph node metastasis and low E-cadherin protein levels in human 
pancreatic ductal adenocarcinoma (hPDAC). In a study comprised of 106 PDAC 
cases, Guo et al. (2014) found a significant correlation between E-cadherin and 
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TIP30 expression. Low TIP30 expression was associated with a significant 
decrease in PDAC patient survival (Guo et al., 2014). Our laboratory recently 
published that microRNA (miR)-10b, a frequently upregulated miR in PDAC, 
targets TIP30 for degradation and that miR-10b suppression of TIP30 in pancreatic 
cancer cells (PCCs) results in prolonged downstream EGFR signaling and EGF- 
and TGF-β- mediated enhanced invasion (Ouyang et al., 2013). Given the 
relationship between miR-10b overexpression and TIP30 loss, and the poor 
survival outcomes in PDAC patients with low TIP30 levels (Guo et al., 2014), we 
hypothesized that TIP30 loss contributes to the progression of PDAC and 
influences the metastatic potential of pancreatic cancer cells. 
3.2 Results 
3.2.1 TIP30 Genetic Alterations in Human PDAC 
To assess the role of TIP30 in human PDAC (hPDAC), we mined publically 
available databases and assessed The Cancer Genome Atlas (TCGA) whole 
exome sequencing data through cBioPortal (J. Gao et al., 2013; Cerami et al., 
2012). We found that HTATIP2 (gene for TIP30) was frequently altered in roughly 
49% of hPDAC cases (UTSW cohort n=53/109) (Witkiewicz et al., 2015). The 
UTSW dataset consists of micro-dissected PDAC samples. According to 
Witkiewicz et al. (2015), microdissection enriches for tumor cells and mutational 
calling. These factors contribute to increased sequencing quality, which is 
imperative for improved accuracy in analysis of patient samples. In the UTSW 
cohort, 92% of PDAC cases contained a KRAS mutation. This observation closely 
aligns with reports of KRAS mutations in 93-95% of hPDAC. KRASG12D is the most 
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frequent KRAS point mutation (Raphael et al., 2017; Almoguera et al., 1988; 
Rozenblum et al., 1997; Kern, 2000; Hruban et al., 2000). 
The cBioPortal database uses the Genome Identification of Significant 
Targets in Cancer (GISTIC) algorithm to determine putative copy-number levels 
per gene. A GISTIC score of -2 indicates a deep loss or homozygous deletion, -1 
is heterozygous loss (HETLOSS), 0 is diploid (WT), and anything greater than 2 is 
an amplification (GAIN/AMP); a score above 2 is considered a GAIN and a score 
above 3 is considered a high-level amplification (AMP) (J. Gao et al., 2013; Cerami 
et al., 2012). GISTIC scores allow for the identification of regions of significant 
amplification and deletion in chromosomal aberrations (reviewed in Beroukhim et 
al., 2007). Among 53 cases with TIP30 alterations, 53% were copy-number 
deletions (n=28/53) while 47% (n=25/53) were copy-number gains (Figure 6A). 
We observed an overall 26% occurrence of TIP30-heterozygous loss (HETLOSS) 
in this cohort of PDAC patient samples. We found that among the cases with TIP30 
loss, 86% (n=24/28) also had a KRAS mutation (Figure 6A).  
To evaluate the effects of TIP30 alteration on gene expression, we analyzed 
TIP30 gene expression in PDAC by copy number variation. We obtained gene 
expression data from the TCGA Provisional dataset accessed through cBioPortal 
(J. Gao et al., 2013; Cerami et al., 2012). Copy number gain of TIP30 led to a 
significant increase in TIP30 mRNA expression levels (p<0.001, n=149). There 
was a decreasing trend in TIP30 expression levels for hPDAC cases with TIP30-
copy-number loss, however this association was not significant (Figure 6B). In 
addition, expression levels in TIP30 wild-type (WT) or diploid PDAC patient 
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Figure 6. Alterations in TIP30 copy number are associated with TIP30 gene expression in 
human PDAC  
 
(A) University of Texas Southwestern database of copy number alterations in PDAC patient 
samples, n=109 (Witkiewicz et al., 2015) in cBioPortal (J. Gao et al., 2013; Cerami et al., 2012). 
Oncoprint was retrieved from http://www.cbioportal.org/ on November 29, 2017. KRAS point 
mutations are plotted against all HTATIP2 (TIP30) genetic alterations. High-level amplification 
(AMP), low level gains (GAIN), heterozygous loss (HETLOSS), and point mutation (MISSENSE), 
no alteration (gray). (B) HTATIP2 mRNA expression as compared to matched copy number gain 
or loss (Del for shallow deletion) in human PDAC (hPDAC). RNA-seq data from TCGA Provisional, 
n=149. Data was accessed in cBioPortal on November 29, 2017. RPKM, reads per kilobase per 
million mapped reads measure of gene expression. hPDAC, human PDAC cases.
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samples spanned a wide range: from 500 to 3,300 reads per kilobase per million 
(RPKM) mapped reads (Figure 6B). Lastly, hPDAC cases with TIP30 loss had 
limited TIP30 expression data. 
3.2.2 TIP30 Hypermethylation in Human PDAC  
TIP30 promoter region methylation has been reported in both colorectal 
(Chen et al., 2010) and esophageal carcinoma (Dong et al., 2014). Methylation is 
another form of epigenetic alteration that can regulate gene expression and 
contribute to pancreatic carcinogenesis (McCleary-Wheeler et al., 2013). To 
assess if TIP30 loss in human PDAC (hPDAC) cases occurred by means other 
than alteration of the genetic code itself, TIP30 DNA methylation data 
(Methylation450k) was obtained from the UCSC Xena browser database 
(Goldman et al., 2009) and accessed on November 11, 2018. TIP30 was highly 
methylated at the promoter and 3’UTR regions in hPDAC cases (TCGA, PAAD, 
n=195) (Figure 7A). These data suggest that hypermethylation could also account 
for TIP30 loss in human PDAC. The MethHC database (accessed on June 7, 2018) 
was used to further assess the relationship between the DNA methylation and 
TIP30 mRNA expression in hPDAC cases (Huang et al., 2015). In a PAAD cohort 
of 91 hPDAC cases, TIP30 expression inversely correlated with TIP30 promoter 
methylation in matched hPDAC (n=91, r=-0.594, p=5.995E-15) (Huang et al., 
2015) (Figure 7B), suggesting that high TIP30 methylation associated with 
decreased TIP30 expression. Three normal pancreas samples were present in the 
MethHC figure and had high TIP30 methylation and low TIP30 expression levels 
(Huang et al., 2015, Figure 7B, green).
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Figure 7. High TIP30 methylation is linked to decreased TIP30 expression in human PDAC  
 
(A) TIP30 is hypermethylated in human PDAC cases. HTATIP2 (TIP30) DNA methylation profile, 
by Methylation450K array in the TCGA pancreatic adenocarcinoma (PAAD) cohort, n=195. USCS 
Xena browser (Goldman et al., 2009) image was retrieved from https://xenabrowser.net on 
November 11, 2018. Beta values represent DNA methylation values. Methylation beta values of 0 
(least methylated) to 1 (most methylated) are shown as a gradient of blue to red, respectively. (B) 
HTATIP2 promoter methylation data in human PDAC (TIP30 Methylation) is plotted against 
matched HTATIP2 (TIP30) gene expression levels (Gene Expression), PAAD cohort, n=91 (r=-
0.594, p=5.995E-15). MethHC database (Huang et al., 2015) image was retrieved from 
methhc.mbc.nctu.edu.tw/php/index.php on June 7, 2018. Red, PDAC. Green, normal pancreas. 
TIP30 methylation is represented in methylation beta value units. TIP30 gene expression is 
represented by reads per kilobase per million mapped reads (RPKM). 
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3.2.3 TIP30 Antagonist MIR10B is Frequently Amplified in Human PDAC 
Studies in both pancreatic and esophageal cancer fields report that TIP30 
is a direct target of micro-RNA (miR)-10b (Ouyang et al., 2014; Dong et al., 2014).  
The miR-10b seed sequence has Watson-Crick complementarity to a region in 
TIP30’s 3’UTR; and miR-10b-overexpressing pancreatic and esophageal cancer 
cells have decreased TIP30 mRNA levels (Ouyang, H., 2014; Dong et al., 2014). 
The non-coding gene MIR10 is found in two variants in mammals and on two 
different chromosomes: 2q31.1 (MIR10B), and 17q21 (MIR10A). Both share 
similar seed sequences, differing by only one nucleotide in the mature strand, and 
have both similar and distinct targets (reviewed by Tehler et al., 2011). Since miR-
10b is also one of the most frequently upregulated miRs in PDAC (Preis et al., 
2011) and overexpression of miR-10a was also found to decrease TIP30 protein 
levels in pancreatic cancer cells (Ouyang et al., 2014), we hypothesized that both 
MIR10B and MIR10A are genetically altered in human PDAC (hPDAC). To assess 
the presence of MIR10B and MIR10A genetic alterations in hPDAC we mined 
TCGA data and found that both miRs are frequently altered in PDAC cases (Figure 
8A). 43 of 109 PDAC cases without a TIP30 alteration or with TIP30 amplification 
or copy number gain alterations also have amplification or copy number gain of 
MIR10B, family member MIR10A, or both (n=10/109) (TCGA PDAC, UTSW). 
These findings suggest that hPDAC cases without TIP30 HETLOSS could attain 
decreased TIP30 expression levels despite TIP30 wild-type status or positivity for 
TIP30 copy-number amplifications or gain. Thus, microRNA-dependent 
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Figure 8. TCGA analysis of MIR10B alterations in hPDAC and correlation with TIP30 
expression 
(A) Oncoprint of TCGA HTATIP2 (TIP30) copy number alterations (CNA), and MIR10B, and 
MIR10A copy number amplifications (AMP) and gains (GAIN) (UTSW, n=109, Witkiewicz et al., 
2015). Image adapted from cBioPortal (J. Gao et al., 2013; Cerami et al., 2012) and retrieved from 
http://www.cbioportal.org/ on November 29, 2017. MIR10B and MIR10A copy number AMP and 
GAIN occur in hPDAC cases that are HTATIP2 (TIP30)-wild-type or have TIP30 copy number AMP, 
GAIN, or heterozygous loss (HETLOSS). PDAC cases with MIR10B and MIR10A HETLOSS are 
not depicted here. (B) Correlation between HTATIP2 (TIP30) expression and MIMAT0000254 
(MIR10B) expression in hPDAC (TCGA provisional, n=182). Data was downloaded from the UCSC 
Xena browser database (Goldman et al., 2009) on July 7, 2018 (https://xenabrowser.net/). 
Exponential decay curve was best fit for the data, upon consultation with a biostatistician. 
Spearman coefficient: r=-0.231, p=0.00172. Gene expression values are represented by reads per 
kilobase per million mapped reads (RPKM).
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mechanisms play an important role in epigenetic silencing of gene expression in 
pancreatic cancer (McCleary-Wheeler et al., 2013).  
3.2.4 Co-occurrence of TIP30 Copy Number Alterations with MIR10B and 
MIR10A Amplifications 
In the UTSW dataset, the 87 hPDAC cases that were either diploid or 
amplified/gained for TIP30 also had an amplification in either MIR10A or MIR10B 
(UTSW, n=109, Figure 8A). Since TIP30 is a direct target of MIR10B, we assessed 
the relationship between TIP30 copy number alterations (CNAs) and MIR10B 
amplification. We mined TCGA Provisional data and found that TIP30 CNAs co-
occur with amplification and gain of both MIR10B (TCGA Provisional, p=0.007), 
and MIR10A (p=0.015). To confirm the validity of the copy number alteration data, 
we assessed the MIR10A (MIMAT0000253) and MIR10B (MIMAT0000254) 
RNAseq data from Xena browser (Goldman et al., 2019, accessed on July 7, 
2018). We compared gene expression values of MIR10A or B to matched TIP30 
gene expression values in human PDAC (hPDAC) cases. MIR10B expression was 
negatively correlated with TIP30 expression, in hPDAC (r=-0.231, p=0.00172 by 
Spearman’s rank correlation coefficient; TCGA PAAD, n=182; Figure 8B). One 
hPDAC case was an extreme outlier with respect to MIR10B levels, as the RPKM 
was near 200,000; and the average RPKM for this dataset was closer to 15,000 
(Figure 8B). This, however, did not affect the relationship between TIP30 and 
MIR10B expression (Figure 9). We conducted a Spearman Correlation on the data 
without the outlier, and a similar relationship between TIP30 and MIR10B 
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Figure 9. Relationship between MIR10B and TIP30 expression in human PDAC 
Correlation between TIP30 (HTATIP2) expression and MIMAT0000254 (MIR10B) in human PDAC 
(hPDAC), as shown in Figure 8B, but without the outlier (TCGA provisional, n=181). Data was 
accessed on July 7, 2018 in UCSC Xena browser (Goldman et al., 2009), https://xenabrowser.net. 
Exponential decay curve was best fit for the data, upon consultation with a biostatistician. 
Spearman coefficient: r = -0.221, p=0.00287. Gene expression values are represented by reads 
per kilobase per million mapped reads (RPKM). 
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expression was observed (r=-0.221, p=0.00287, TCGA PAAD, n=181). The 
relationship between TIP30 and MIR10B expression levels was nonlinear; 
therefore an exponential decay curve was fit to the data (Figure 8B, Figure 9). 
Surprisingly, MIR10A and TIP30 expression data did not share a similar 
relationship. Human PDACs with high MIR10A expression levels also had high 
TIP30 expression levels (r=0.1468, p=0.048; TCGA PAAD, n=182).  
3.2.5 Generation and Characterization of K30+/-C and K30-/-C Mice 
To monitor and characterize Tip30 loss in PDAC, we generated a novel 
K30C mouse which employs autochthonous, oncogenic Kras-driven murine PDAC 
(mPDAC) development. We crossed the well-established LoxP-STOP-LoxP (LSL)-
KrasG12D (K);Pancreatic duodenal homeobox 1 (Pdx1)-Cre (C), genetically 
engineered mouse model (GEMM) (“KC”, Hingorani et al., 2003) to full-body Tip30-
deficient mice (Ito et al., 2003; Li et al., 2013) to generate KC mice with Tip30-
deficiency (K30+/-, -/-C). The KC mouse model of mPDAC closely resembles that of 
human PDAC (hPDAC) and has been well-characterized (Hingorani et al., 2003). 
In our studies, “KC” refers to the LSL-KrasG12D; Pdx1-Cre mouse and not the LSL-
KrasG12D; P48-Cre mouse (Hingorani et al., 2003). KC pancreas ductal lesions 
progress through the full spectrum of pancreatic intraepithelial neoplasia as seen 
in hPDAC with a six months to one year latency of PDAC formation, and low 
frequency of metastases (Hingorani et al., 2003; reviewed in Hezel et al., 2006; 
Guerra and Barbacid, 2013). In their original study, Hingorani and colleagues 
(2003) reported that one LSL-KrasG12D; Pdx1-Cre mouse presented with both liver 
and lung parenchyma and pleural metastasis at 6.25 months of age. LSL-KrasG12D 
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mice harbor a point mutation in exon 2, the first Kras coding exon, at codon 12. 
This results in the amino acid substitution of glycine to an aspartic acid residue 
(G12D) in the endogenous Kras locus (Johnson et al., 2001; Jackson et al., 2001).  
Pancreatic duodenal homeobox 1, Pdx1, previously known as IPF1, is a 
transcription factor necessary for the development of early pancreatic buds from 
the ventral foregut endoderm and is known to give rise to the alpha and beta cells 
of adult mouse islets (Offield et al., 1996). The Pdx1 protein coding region is 
replaced by a Cre recombinase coding sequence (Pdx1-Cre, Gu et al., 2003). 
Pdx1-Cre directs a mosaic pattern of Cre-mediated recombination and excision of 
the LoxP-flanked transcription termination site (STOP sequence) in the pancreas 
tissue (Hingorani et al., 2003). The STOP sequence is upstream of the oncogenic 
Kras point mutation in the LSL-KrasG12D cassette; this prevents the expression of 
oncogenic Kras in LSL-KrasG12D mice without Cre. This system results in spatially 
controlled expression of mutant KrasG12D in the pancreas epithelium (Jackson et 
al., 2001; Sauer, 1993; Sauer and Henderson, 1988; Hingorani et al., 2003) 
(Figure 10A).  
    The Tip30-deficient knock-out GEMM, first reported in 2003, is composed 
of a germline, insertion mutation for complete ablation of Tip30 expression in the 
entire mouse (Ito et al., 2003). A targeting vector consisting of a 2.7-kb, HindIII-
SacI flanked LacZ-neomycin cassette replaces exons 2-3 of the Tip30 genomic 
sequence, in-frame (Ito et al., 2003, Figure 10B). We detected this insertion just 
after the 25th nucleotide of exon 2, or 17 amino acids (aa) after the initiation start
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Figure 10. Schematic for generation of K30+/+, +/-, -/-C and K30+/+, +/-, -/-Ctd+/- or -/- mice 
(A) KC mouse model (Hingorani et al., 2003). Cre recombinase (“CRE” pink hexagon), driven by 
the Pancreatic duodenal homeobox 1 (Pdx1) promotor mediates excision of the STOP cassette 
flanked by LoxP sites. STOP cassette excision results in expression of oncogenic Kras (KrasG12D). 
Red asterisk represents one copy of KrasG12D in the pancreas. (B) Tip30-deficient mouse model 
(Ito et al., 2003, Li et al., 2013). Blue asterisk represents a full-body Tip30-deletion, including in the 
pancreas. A LacZ-neomycin resistant (neoR) cassette ablates exons 2-3 of Tip30. One wild-type 
allele and one mutant copy is depicted. (C) LoxP-tdTomato-LoxP-EGFP (Muzumdar et al., 2007) 
is dual-fluorescent reporter mouse. A tdTomato (td+/- or td-/-) mouse and pancreas is red until Pdx1-
Cre-mediated excision of the tdTomato cassette, at which point the pancreas tissue will fluoresce 
green. GEMMs in A-B were crossed to generate K30+/+, +/-, and -/-C mice. GEMMs in A-C were 
crossed to generate K30+/+, +/-, -/-Ctd+/- or -/- mice. pCA, chicken β-actin core promoter with a CMV 
enhancer.
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site, and not at 10th amino acid as reported in Ito et al. (2003). Tip30 is not 
essential for development in mice and Tip30 loss alone did not result in primary 
tumors of the pancreas (Ito et al., 2003; Li et al., 2013). In 2003, Ito et al. reported 
that Tip30-deficient mice developed a high incidence of hepatocellular carcinoma 
at 18-20 months (Ito et al., 2003). In a 2013 study, the same group reported that 
78-week-old Tip30-deficient mice had increased lung adenocarcinoma in a BALB/c 
background, as compared to wild-type controls (Li et al., 2013). The BALB/c mouse 
strain develops lung tumors at a high incidence and is sensitive to lung tumor 
formation (Li et al., 2013; Begley et al., 2012).  
For our studies, we employed one copy of Pdx1-Cre (Gu et al., 2003) in our 
mouse model to mediate stochastic Cre recombinase expression. Pdx1-Cre drives 
LoxP-STOP-LoxP excision, and constitutive expression of one mutant Kras copy, 
KrasG12D/+ (herein referred to as KrasG12D) in the pancreas epithelium of KC mice 
(Hingorani et al., 2003). We generated mouse cohorts with Tip30-heterozygous 
(K30+/-C), Tip30-null (K30-/-C), and Tip30-wild-type (K30+/+C) genotypes on a 
mixed BALB/c/B6/129SvJae noncongenic background. Littermate controls (30+/-, 
or 30-/-, or wild-type) were generated internally or from within the same mouse 
colony as the experimental groups per The Jackson Laboratory recommendations. 
We also generated the following double mutant littermate controls: K30+/-, 30+/-C, 
K30-/-, and 30-/-C mice (Appendix C1). Detection of successful recombination 
induced by Pdx1-driven Cre activity was achieved using a PCR method that 
differentiates between the wild-type Kras allele, the LSL cassette, and the 
recombined mutant allele that harbors the remaining LoxP site plus the Kras point 
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mutation. This method is known as the “Kras G12D Conditional PCR” method 
(Jacks, 2017) and is described further in section 2.4.1 of the Materials and 
Methods. We confirmed Cre-mediated excision-recombination of the conditional 
LSL-KrasG12D allele, thus the presence of KrasG12D in pancreata collected from an 
age-matched cohort of three-month-old K30C mice. 88% of the K30+/+C, K30+/-C, 
and K30-/-C pancreata, assessed for recombination, tested positive for partial 
recombination (n=15/17). Only two out of the 17 samples tested for very low or 
undetectable recombination levels. DNA from the tail does not test positive for 
recombination (Hingorani et al., 2003). In addition to the pancreas, Hingorani et al. 
(2003, Supplemental) detected LSL-KrasG12D recombination and Cre activity in 
genomic DNA from the stomach, duodenum, and mucocutaneous papillomas; 
however, the heart, lung, liver, spleen kidney, colon tissues, which were also 
assessed for recombination, tested negative (Hingorani et al., 2003, 
Supplemental). In our studies, we confirmed that DNA from K30C muscle biopsies 
were negative for recombination compared to pancreas tissues (Figure 24).  
    K30+/+C, K30+/-C, K30-/-C, and control mice were born with near expected 
Mendelian genetic ratios (see section 2.1). We first determined Tip30 status using 
tail genomic DNA from K30C mice. We collected a tail snip from each mouse in 
the cohort (TP30 mouse colony) and performed genotyping PCR for LSL-KrasG12D 
(Kras), Pdx1-Cre (“PDX” or “Cre-Cre” primers see section 2.26), and Tip30 mutant 
transgenes according to The Jackson Laboratory (see section 2.4, 2.26-2.28). The 
Tip30 mutant PCR product was detected in one reaction, using primers that anneal 
to the LacZ sequence and an intronic region preceding Exon 2 of Tip30 (“common” 
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primer), and produced a 300 base pair (bp) product. To detect a wild-type Tip30 
allele, the common primer plus a primer that anneals to the intronic region directly 
after Exon 2 of Tip30 (“mutant’ primer), was used in a separate reaction and 
produced a 364-bp product. The Tip30 wild-type sequence was separated across 
the same agarose gel as the Tip30 mutant DNA fragment. K30+/+C and Tip30 wild-
type mice tested positive for only one 364-bp product. K30+/-C and Tip30-
heterozygous mice tested positive for both a wild-type and a mutant 300-bp 
product, and K30-/-C and Tip30-null mice tested positive for only the 300-bp mutant 
product. Tail snip DNA from 55 mice in the colony was also genotyped for both 
Pdx1 and Cre sequences simultaneously (Pdx1-Cre NCI, see section 2.26 for 
primer sequences) to validate that the Cre-positivity was coming from a Pdx1-Cre 
transgene, and not any other Cre. We confirmed that there were no other Cre 
transgenes in our mouse colony (other than Pdx1-Cre). Combined, these 
genotyping methods allowed us to group mice into three categories: K30+/+C, 
K30+/-C or K30-/-C. K30C tail snip DNA tested positive for mutant KrasG12D and Cre 
transgenes.  
To further validate Tip30 status, we subjected DNA extracted from an age-
matched cohort K30+/+C, K30+/-C, and K30-/-C mouse pancreas tissues to Tip30 
genotyping PCR as well as Kras G12D Conditional PCR (Jacks, 2017) to confirm 
successful LSL-KrasG12D recombination and the presence of oncogenic Kras 
(Appendix C2.A, B2.C). DNA from K30+/+C mouse pancreata tested positive for 
one wild-type Tip30 PCR product, while DNA from K30+/-C and K30-/-C mouse 
pancreata tested positive for both the wild-type and the mutant Tip30 product, or 
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just the mutant product, respectively (Appendix C2.A). The cohort of mice with 
confirmed Tip30 genotyping also exhibited partial LSL-KrasG12D recombination in 
the pancreas (Appendix C2.C). We evaluated a total of pancreas tissues from six 
different mice from each group and confirmed tail-genotyping results.  
Two K30+/-C mice in the study (TP576 and TP630) did not test positive for 
the Tip30 mutant transgene by standard genotyping PCR and were initially placed 
in the K30+/+C category. However, at five weeks, and three and a half months, 
respectively, these mice fell sick and exhibited a phenotype that was not observed 
by any other K30+/+C mice in our colony. TP576 and TP630 pancreas tissues had 
decreased Tip30 mRNA levels compared to K30+/+C mice (not shown). Upon more 
thorough investigation and sequencing, we confirmed that TP576 and TP627 had 
a copy of the mutant allele. Insertion and deletion mutations were identified by 
sequencing using specific primers that annealed and amplified the mutated region. 
We confirmed the presence of the LacZ sequence in these two mice (not shown); 
therefore, we reassigned them to the K30+/-C group.  
To evaluate if the genetic alteration of Tip30 copy number loss altered Tip30 
gene expression in K30C mice, we isolated mRNA from pancreas tissues of age-
matched K30C mice with validated KrasG12D status. We assessed Tip30 mRNA 
levels using real-time quantitative reverse transcription (RT)-PCR and found that 
K30+/-C pancreata exhibited a significant decrease in mean Tip30 expression 
levels when compared to K30+/+C pancreata at exons 2-3 (n=6, p=0.007 by 
Student’s t-test) (Figure 11A). Tip30 mRNA was not detectable (ND) in K30-/-C 
pancreata (Figure 11A). We further confirmed the decrease in Tip30 pancreas 
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Figure 11. TIP30 levels are decreased in K30+/-C and K30-/-C pancreata 
(A) Relative quantity of Tip30 exon 2-3 mRNA levels by qRT-PCR in murine pancreas tissues from 
an age-matched three-month-old K30+/+C-TP578, TP579, TP580, TP197, TP228, TP581, K30+/-C-
TP431, TP452, TP468, TP470, TP473, TP684, and K30-/-C -TP526, TP543, TP555, TP336, TP400, 
TP404, TP364 mice (n=6). Relative expression levels were calculated after normalization to internal 
loading control Rps6. Data is represented relative to K30+/+C controls. RQ, Relative quantity. ND, 
not detected. (B) TIP30 protein levels in three-month-old pancreas tissues (Panc) from K30+/+C-
TP578, TP579, TP580, TP58, K30+/-C-TP452, TP468, TP470, TP473, and K30-/-C-TP364, TP526, 
TP543, TP555 mice (n=4). The TIP30 antibody used detects the two major isoforms of TIP30 (30 
kD, and 27 kD). γ-Tubulin is the loading control. 
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tissue gene expression by analyzing Tip30 exon 6 mRNA levels (Appendix C2.B). 
Tip30 exon 6 mRNA levels were significantly decreased in pancreas tissues from 
K30+/-C mice (ages 2-3 months), when compared to K30+/+C controls (n=4, 
p=0.006, by one-way ANOVA and Tukey post-hoc test).Tip30 mRNA levels were 
negligible in K30-/-C mouse pancreata when compared to K30+/+C (n=4, p<0.001, 
Appendix C2.B). When compared to K30+/-C pancreata, K30-/-C mice also 
exhibited significantly decreased Tip30 exon 6 mRNA levels in pancreas tissues 
(n=4, p=0.025) (Appendix C2.B). In addition to mRNA analysis, we verified that 
TIP30 protein levels were also decreased in Tip30-deficient K30C mice. Western 
blotting analysis confirmed that pancreata from K30+/-C had decreased TIP30 
protein levels, and that K30-/-C mice had undetectable levels of TIP30 (Figure 11B) 
suggesting that K30-/-C mice were Tip30-null. The decrease of TIP30 protein levels 
in the pancreas tissue of K30+/-C mice appeared to be more than half (Figure 11B). 
To ensure that Tip30 loss did not affect islet architecture, we compared 
immunohistochemistry immunofluorescent (IHC-IF) staining of amylase, glucagon, 
and insulin in pancreas tissues from three-month-old K30+/+C mice (n=4) to that of 
K30+/-C (n=4) and K30-/-C (n=2) mice (Figure 12). We examined five high-power 
fields per animal and observed expected distributions of amylase, glucagon, and 
insulin in the pancreas parenchyma in the analyzed mice from all three groups. 
We did not detect any notable alterations in the pancreas architecture of the 
endocrine and exocrine compartments. Tip30-deficient/KC groups had a few 
enlarged islets. We quantitated islet areas with Image J using 20X (high-power) 
images from five separate fields per mouse for four K30+/+C mice, four K30+/-C 
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Figure 12. Loss of Tip30 in the KC background did not alter the architecture of the endocrine 
and exocrine compartments  
IHC-Immunofluorescence (IF) staining for amylase (green, top row), insulin (green, lower panel) 
and glucagon (red, lower panel), with DAPI nuclear stain (blue) in three-month-old pancreas tissue 
from K30+/+C (n=4), K30+/-C (n=4), K30-/-C (n=2) mice did not reveal any significant differences in 
insulin, glucagon, or amylase distribution between groups. A representative field from a stained 
section for K30+/+C (mouse ID TP579), K30+/-C (mouse ID TP431), and K30-/-C (mouse ID TP526) 
mice is shown. Scale bar: 100 μm. These images were evaluated with a pathologist. 
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mice, and two K30-/-C mice. There was an increased trend in mean islet size from 
0.375 (K30+/+C) to 0.72 (K30+/-C), and 0.72 (K30-/-C), respectively. However, these 
quantitated differences were not significant; this could be due to small sample size. 
3.2.6 Heterozygous-Tip30 Loss Accelerated PDAC-Associated Death in 
K30C Mice 
    A series of experiments were initiated to evaluate Tip30 genetic dose on 
PDAC formation in the KC background. We hypothesized that Tip30 loss 
accelerates murine PDAC (mPDAC) progression, and leads to poor survival 
outcomes in Tip30-deficient, K30C mice. To assess the impact of Tip30 loss on 
pancreas lesion progression, we first compared pancreas sections from three-
month-old KC mice that were Tip30-heterozygous (K30+/-C), Tip30-null (K30-/-C), 
or Tip30-wild-type (K30+/+C). Prior to necropsy, total body mass was recorded for 
each mouse. We observed no difference in mean total body mass between 
K30+/+C and K30+/-C mice. However, K30-/-C mice weighed roughly five grams less 
than the other two groups of mice (n=7-10 mice per group), but this result was not 
statistically significant (Appendix C3). Mouse pancreas tissues were visually 
inspected at the time of necropsy and mice that were three months of age did not 
show any indication of tumor formation, other than an occasional large pancreata 
(Appendix C3).  
Although pancreatic tumor formation was not detectable by gross 
observation at three months, we observed a decline in health in some of the Tip30-
deficient K30C mice compared to controls and three-month-old K30+/+C mice. 
Tip30 copy-number loss was associated with an increase in morbidity-related 
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symptoms in K30C mice. Specifically, two of seven K30+/-C mice and four of ten 
K30-/-C mice presented with a hunched, scruffy coat, and difficulty breathing or 
“sick” status compared to one of the seven three-month-old K30+/+C mice, and 
were required to be euthanized at three months of age. We therefore hypothesized 
that the overall decline in health for Tip30-deficient K30C mice was a result of 
PDAC-associated neoplasia, undetectable by methods of gross observation. 
We next utilized immunohistochemistry and light microscopy to further 
evaluate the pancreata of K30C mice. To assess the role of Tip30 loss on mPDAC 
initiation and precursor lesion progression in K30C mice, we examined the 
histological sections from at least six mice per three-month-old K30+/+C, K30+/-C, 
and K30-/-C cohorts. To better visualize pancreatic cancer precursor lesion 
formation and PDAC we used an antibody specific to the pancreatic cancer cell 
epithelial marker cytokeratin 19 (CK-19). This staining was followed by a 
hematoxylin counterstain to discern pancreatic intraepithelial neoplasia (PanIN) 
lesion formation and PDAC from normal parenchyma. CK-19 marks the presence 
of pancreatic cancer cells in PDAC tissues (Jain et al., 2010; Preis et al., 2011).  
We examined low-power and at least five high-power fields for each mouse 
and noted the abundance of CK-19 stain per field as well as any changes in 
pancreatic ductal architecture that were distinct from a normal duct. Since the KC 
mouse model utilizes both the genetic and histopathological progression of human 
PDAC we used the progression model illustrated in Figure 2 of Bardeesy and 
DePinho (2002) and Hezel et al. (2006) as a reference to identify normal pancreatic 
ducts from pancreatic precursor lesions such as PanIN and PDAC. We observed 
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an increase in CK-19-positve pancreatic precursor lesion formation in compound 
mutant Tip30-heterozygous KC mice (K30+/-C), compared to both K30+/+C and 
K30-/-C mice in our three-month-old validated cohorts (Figure 13A). A total of six 
mice were evaluated per group and a representative field per mouse for four mice 
per group is included in Figure 13A.  
Our initial hypothesis would suggest that K30-/-C mice will have similar or 
more advanced pathology than mice with monoallelic loss of Tip30 (K30+/-C). To 
our surprise, three-month-old K30-/-C mice presented with little to no lesion 
formation, by CK-19 staining. Our assessment of additional serial sections for the 
three-month-old cohorts did not appear to provide any evidence for additional 
lesions in K30-/-C mouse tissues that may have not been captured in the first 
section of tissue examined. Serial sectioning of 24 additional sections was 
performed by Rachael Topolski, a member of our laboratory. We stained section 
No. 11, 12 and 23, 24 for CK-19/hematoxylin stain, but found no major differences 
from our initial observations.  
To assess PDAC formation due to KC background alone, we evaluated 
hematoxylin and eosin (H&E)-stained sections from K30+/+C mice at different time 
points with a pathologist. We used histopathological analysis of one section of 
pancreata collected at necropsy from K30+/+C mice aged two to six months to 
assess pancreas pathology. PanIN lesions and PDAC initiation were variable 
within age groups; however, we observed an increased grade of PanIN lesions as 
a function of age as well as complete penetrance of PDAC in K30+/+C mice by six 
months of age (n=2/2). One mouse out of 3 two-month-old K30+/+C mice presented 
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Figure 13. Survival analysis of CK-19-positive PDAC precursor lesions in the K30C mouse 
model 
(A) CK-19 staining of pancreas specimen from three-month-old KrasG12D;Pdx1-Cre;Tip30+/+, +/-, or -
/- (K30C) mice. A representative field of pancreas tissue is shown per mouse (P1-4), and pancreas 
lesions from four mice per genotype are shown, with low and high magnification (n=6). Five high-
power fields were imaged per mouse: K30+/+C (TP228, TP578, TP579, TP581), K30+/-C (TP431, 
TP452, TP468, TP470, and K30-/-C mice. Scale bars: 100 µm. (B) Survival curve (Kaplan-Meier) 
of the KrasG12D;Pdx1-Cre;Tip30+/+ (K30+/+C), KrasG12D;Pdx1-Cre;Tip30+/- (K30+/-C), and 
KrasG12D;Pdx1-Cre;Tip30-/- (K30-/-C) cohorts. Mice that were still alive at the conclusion of the study 
are represented as tick marks that appear on the Kaplan-Meier curves as “censored” (see Rich et 
al., 2010; Goel et al., 2010) observations. The total sample size in these Kaplan-Meir curves 
(including censored mice) are as follows: K30+/+C: n=10, K30+/-C: n=14, K30-/-C: n=13. Log-rank, 
p=0.1149. 
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with the beginnings of PDAC, while the remaining two-month-old mice (n=2/3) 
presented with early PanIN lesions (PanIN-1B). At three months of age, 4 out of 7 
K30+/+C mice examined had either a detectable PanIN-3 precursor lesion, the 
beginning of PDAC, or both. The PDAC histology for one of these mice took up the 
vast majority of the pancreas parenchyma (n=1/7). At four months, all K30+/+C mice 
presented with PanIN-3 (n=3/3), with cancer localized in the pancreatic duct 
detected in 1 of the 3 mice. In the five-month cohort, 3 out of 4 five-month-old 
K30+/+C mice presented with PanIN-2 and -3 lesions. Moreover, 2 out of 2 six-
month-old K30+/+C mice presented with full-blown PDAC, with a focal area of lymph 
node metastasis in one of these two mice (TP177). Even though PDAC metastasis 
has been reported in a 6.25-month-old KrasG12D;Pdx1-Cre (KC) mouse by 
Hingorani et al. (2003), overall progression to PDAC in the KC mouse model is 
slow (Westphalen and Olive, 2003). Both six-month-old K30+/+C mice either had 
visible evidence of tumor formation (TP177) or a cystic appearing pancreatic tumor 
that was 15-20 mm in diameter (TP182). Because we did not expect to see PDAC 
cases in K30+/+C mice at six months, we genotyped for a panel of transgenes to 
exclude the possibility of additional GEMMs accidentally crossed into our model 
(Appendix A). We also submitted DNA samples, isolated from cell lines 
established from two different mouse pancreata per genotype (K30+/+, +/-, and -/-C), 
for whole genome sequencing. We did not detect any transgene contamination or 
spontaneous mutations in our mouse model.  
In Hingorani et al. (2003), PanIN-2 and PanIN-3 presentation was not 
abundant until KrasG12D;Pdx1-Cre (KC) mice reached nine months of age 
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(Hingorani et al., 2003); therefore, the PDAC progression observed in our K30+/+C 
mice occurred at a more advanced rate. Using the K30+/+C mice as our point of 
comparison, we next proceeded to further evaluate the increase in CK-19-positive 
lesions observed in K30+/-C mice and depicted in Figure 13. Following pathological 
analysis, we compiled a summary of the histological landscape and spectrum of 
PDAC precursor lesions in each group of K30C mice (Table 2). We visually 
scanned and examined entire mouse pancreas sections for each mouse in our 
three-month-old cohorts (K30+/+C, K30+/-C, K30-/-C) at low and high power with a 
pathologist. At least seven mice per cohort were examined for microscopic 
evidence of preinvasive and invasive ductal PDAC. To determine the distribution 
of PDAC precursor lesions and PDAC between groups of K30C mice we evaluated 
high power images of CK-19 and H&E stains for at least five distinct focal areas 
per section. Areas of ductal atypia, hyperplasia, acinar to ductal metaplasia, focal 
areas of pancreatic intraepithelial neoplasia (PanIN), PDAC, and additional PDAC-
associated disease were evaluated and noted in the report by our pathologist. For 
mice diagnosed with PanIN, further analysis of high powered fields were used to 
determine the highest grade of PanIN lesion per focal area. Table 2 summarizes 
the pathology detected in the pancreas of each mouse, with the grade of PanIN 
lesion (from PanIN-1 to PanIN-3) indicated. If tissues appeared normal they were 
marked as such; and if PanIN lesion or PDAC was detected the occurrence 
(intensity level or density) was noted. For example, a distinction was made 
between PDAC that the pathologist noted was just beginning but was in too early 
stages to be diagnosed as such (half X in Table 2 or level 0.5 intensity), moderate  
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Table 2. Histopathological detection and distribution of PDAC precursor lesions and PDAC-
associated disease in three-month-old K30C mice 
 
 
 
PDAC progression and PDAC-associated disease including lymph node spread in three-month-old 
K30C mice after consultation with a pathologist. Each X represents a focal area of lesion/s 
detected. One intact “X” represents incidence or one focal area for the entire tissue section (and 
=1) and indicates that the event occurred. Half of an X indicates that PDAC was reported to be 
beginning, but a definitive PDAC diagnosis could not be made. Half of an X (intensity level=0.5) is 
the lowest level of PDAC intensity observed in K30C mice. The number of X’s represents the 
intensity or occurrence for the indicated lesion/pathology per mouse (and pancreas tissue section). 
An intensity level 4 (four “X”’s) represents the highest incidence of focal areas with lesions and the 
highest lesion intensity per mouse. PanIN, pancreatic intraepithelial neoplasia. Note the detection 
of affected organs (lungs) in K30+/-C mice compared to K30+/+C and K30-/-C mice (n=7-10). Lymph, 
lymph node. Lymph Met, lymph node metastasis.  
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PDAC, or full-blown PDAC (four X’s in Table 2 or level 4 intensity). For PanIN 
occurrence, if a mouse had three different focal areas of PanIN it was assigned 
three X’s or a level 3 intensity value; two focal areas were assigned two X’s or a 
level 2 intensity value, etc. For pancreas sections with less than five focal areas, 
the areas with highest grade lesions in the entire tissue section were assessed. A 
visual representation of average lesion and PDAC density and distribution, noted 
in Table 2, is presented in heat map form in Figure 14. Average lesion intensity in 
the heat map does not include individual mice that did not present with a focal 
lesion per indicated lesion category (ductal atypia, PanIN-1, PanIN-2, PanIN-3, 
PDAC, Inflammation, Lymph node involvement), except for the level 0 depiction. 
Level 0 or dark blue shading indicates that there were zero mice that had said 
lesion or pathology type (Figure 14). The majority of the pancreas sections used 
for Table 2 were CK-19-stained (n=6), however hematoxylin and eosin (H&E) 
stained sections were also examined (Table 2). If a mouse had both an H&E 
section and a CK-19 section and a lesion was only detected in one of the two 
sections, then the mouse was observed to have had incidence of the reported 
lesion and the data was added to the summary in Table 2. 
Based on our compiled observations, 71.4% of K30+/-C mice (n=6/7) had 
either a detectable PanIN-2, an abundance of PanIN-3 lesions or PDAC (n=2/7, 
Table 2). Comparatively, K30+/+C mice also presented with PanIN-2 to PDAC in at 
least one focal area at a rate of 71.4% incidence (n=5/7). However, in contrast to 
K30+/-C mice, K30+/+C (n=4/7) and K30-/-C (n=2/10) mice presented with a modest 
distribution of PanIN-2 and PanIN-3 lesions per mouse. The lesion density and
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Figure 14. Representation of lesions identified per histopathological grade across the K30C 
mouse models at three months 
K30+/-C mouse pancreatic tissue sections with at least one focal area of pathology exhibited the 
highest average occurrence of PanIN-3, PDAC, and invasive or metastatic PDAC to the lymph 
node (Lymph node involvement) as compared to K30+/+C and K30-/-C groups. Data represented in 
this heat map are a graphical representation of the average occurrence in pathology-positive K30+/+, 
+/-, and -/-C mice (mice in which an incidence was detected). Only mice with an occurrence were 
used to calculate average occurrence and lesion distribution/density (also referred to as intensity). 
An average occurrence of 0 (dark blue) indicates that there were no mice in that group with the 
indicated pathology. Average occurrence was calculated using the data in Table 2, where a 
pathologist noted focal area incidence as well as the level of lesion occurrence per mouse in three-
month-old K30+/+, +/-, and -/-C groups (n=7-10). For this heat map, the scale of average occurrence 
ranges from lowest (0 or dark blue shading) to highest (2 or dark red shading). Mice with a noted 
intensity level of at least 0.5 (half an X in Table 2) were included in the averages represented in 
this heat map. The average values represented in the scale from lowest to highest are as follows: 
0, 0.5, 1, 1.33, 1.67, and 2. 
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distribution is represented as an average in the heat map in Figure 14. The 
average occurrence of intensity of lesion per type is represented as lowest (dark 
blue or an average value of 0) to highest (dark red or an average value of 2) 
(Figure 14). Briefly, to calculate average intensity, mice with lesions per category 
in Table 2 received a numerical value for each “X” or occurrence. Half of an “X” 
represents the lowest level of intensity observed and was assigned a value of 0.5. 
One “X” was assigned a value of 1, two “X”’s were assigned a value of 2, etc. 
These values were then averaged to represent the average lesion intensity for 
mice with at least one detectable lesion per indicated category. Lastly, a color scale 
was distributed across all of the averaged data for the three groups (K30+/+, +/-, and 
-/-C).  
While the percent incidence (development of a focal area) of PanIN-3 or 
PDAC did not differ between K30+/+, +/-, and -/-C groups (Table 2), there was a 
striking difference in K30+/-C lesion intensity for PanIN-3, PDAC, and lymph node 
involvement compared to K30+/+C and K30-/-C mice (Table 2, Figure 14). For 
K30C mice that presented with lesions, Tip30-heterozygous K30C mice had the 
highest level of PanIN-3 and PDAC (Figure 14). PanIN-3 lesions were more 
commonly found in patients diagnosed with PDAC (Konstantinidis et al., 2013). 
Tip30-heterozygous K30C mice also exhibited the most advanced PDAC-
associated disease. Specifically, four K30+/-C mice had moderate to high 
distribution of PanIN-2 to PDAC (n=4/7, Table 2); and two of those K30+/-C mice 
(n=2/7) had either PDAC-associated lymph node invasion or metastasis when 
compared to K30+/+C (n=0/7) and K30-/-C (n=0/10) mice (Figure 15-16). Mice with 
 118 
 
Figure 15. PDAC-associated lymph node metastasis was detected in a three-month-old 
K30+/-C mouse  
(A) Hematoxylin and eosin (H&E) staining of a pancreas section from a K30+/-C mouse with more 
than 50% PDAC and lymph node metastasis at three months of age. Mouse ID is TP470. (B) Higher 
magnification of lymph node metastasis detected in A. Yellow arrow heads point to pancreatic 
cancer cell invasion in lymph node and black arrows point to a duct-like PDAC phenotype. (C) 
Representative image of cytokeratin-19 (CK-19) with hematoxylin counter-stain of TP470 
pancreatic lesions and PDAC and CK-19-positive pancreatic cancer cells (PCCs) in pancreas and 
lymph node. (D) Higher magnification of lymph node region in C. Red arrow heads point to CK-19-
positive PCCs. Lymph node is marked with asterisk. (E) Alpha-SMA stain with gland-gland 
presentation (black arrow) and PCC invasion (yellow arrow heads). (F) CK-19 stain of pancreas 
section with a noted pancreatic intraepithelial neoplasia (PanIN)-3 lesion and haphazard growth 
pattern (desmoplasia). Necrotic glandular debris (gray arrow), loss of nuclear polarity (red arrows), 
and nuclear irregularities (yellow arrow heads) were also observed. These images were evaluated 
with a pathologist and Hruban et al., 2006 was used as a reference. Mouse ID for this figure is 
TP470. Scale bars: 100 µm 
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Figure 16. Early PDAC and lymph node invasion in a K30+/-C mouse  
(A) Representative low-power image of a CK-19 with hematoxylin counter-stained section of 
pancreas tissue from a three-month-old mouse with PDAC and lymph node invasion. Mouse ID is 
TP223. Lymph node is marked with asterisk. (B) Higher magnification of subcapsular lymph node 
invasion in A. Yellow arrow heads point to stained macrophages. (C) Higher magnification of PDAC 
focal area in A. Black arrow points to ductal differentiation. These images were evaluated with a 
pathologist. Scale bars: 100 μm. 
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detected inflammation in pancreas tissues had equal levels of inflammation across 
K30+/+, +/-, and -/-C groups. There was a third K30+/-C mouse in the three-month 
study for which a reactive lymph node was noted (Table 2-Mouse ID TP431). 
Although, examination of the pancreas section from mouse TP431 revealed only 
one focal area with a PanIN-2 lesion (Table 2, see Figure 13-K30+/-C-P1), TP431 
and another K30+/-C mouse with detectable PanIN-3 (TP452) displayed strong 
mucin immunoreactivity in focal areas of high-grade PanIN formation by alcian blue 
stain (Appendix C4.C-D), as compared to K30+/+C mice. Mucins are glycoproteins 
that are reported to enhance PDAC tumorigenesis and metastasis (Kaur et al., 
2013). Whether the strong mucin staining observed in the precursor lesions of the 
two K30+/-C mice was linked to lymph node involvement and metastatic disease 
cannot be stated with certainty. Additional staining of mouse pancreas sections 
from each group with quantitation, as well as assessing the mRNA and protein 
levels from these tissues would help determine the differences in mucin expression 
profiles between K30+/+,+/-, and-/-C mice, and the role of mucin in accelerating 
Tip30-heterozygous disease progression and metastasis in the K30C model.  
We also examined additional K30C mice from as young as five weeks old 
to 11 months old but were limited by sample size to draw any definitive conclusions 
for PDAC progression or compare lesions between groups of K30C mice at 
additional timepoints. The pathologist did however detected an enlarged lymph 
node in the section of pancreas tissue from a five-month-old K30+/-C mouse 
(TP573) in the examination. The pathologist noted that this particular lymph node 
was 20 times (20X) the size of a normal lymph node. This mouse had a detectable 
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PanIN-3 lesion and had focal areas that were approaching PDAC pathology. 
Further staining is required to accurately assess any metastatic disease in the 
lymph node by histological analysis for this mouse. A pancreatic cancer cell line 
was established from the pancreas of this TP573 mouse and used for further 
studies documented in this report (Table 4). More mouse pancreata will need to 
be examined and rigorously scored for a true quantitative assessment of 
differences in PDAC progression between K30+/+C and K30+/-C mice and 
substantiate a role for Tip30-heterozygous loss in accelerating the molecular 
landscape of PDAC in the K30C PDAC model. In summary, the advanced CK-19 
positive lesions, abundance in PDAC precursor lesion in K30+/-C mice compared 
to other groups, and evidence of lymph node invasion and metastasis led us to 
interpret that monoallelic loss of Tip30 accelerated pancreatic neoplasia in our 
K30C mouse model. Lesion density (the amount of lesions or focal areas of lesions 
reported per lesion or pathology type-“average occurrence” in Figure 14) and 
advanced PDAC-associated disease (detection of lymph node invasion or 
metastasis in a pancreas tissue section, Table 2, Figure 14) suggested that K30+/-
C mice had advanced PDAC-associated disease progression when compared to 
K30+/+C and K30-/-C mice.  
Surprisingly, according to the histopathological analysis and average 
occurrence, K30-/-C displayed the lowest level of PDAC intensity (Figure 14); this 
combined with the results from the survival analysis (Figure 13B) suggested that 
K30-/-C mice were protected at earlier timepoints (Figure 14). K30-/-C mice 
exhibited the highest overall median survival of the three K30C groups of mice: 
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eight months (n=10-14) as compared to five months (K30+/+C) and four months 
(K30+/-C). In addition, K30-/-C mice also exhibited the highest five-month survival 
(77%, n=13) compared to 40% in the K30+/+C group (n=10) and 21% in the K30+/-
C group (n=14) of mice (Figure 13B). Therefore, predictably, the K30-/-C group of 
mice had the highest presentation of normal parenchyma or very low grade ductal 
atypia or hyperplasia in focal areas (n=7/10) compared to K30+/-C (n=3/7) and 
K30+/+C (n=3/7) at three months (by histopathological analysis). Based on the 
pathology analysis, the majority of K30-/-C mice also only presented with the 
beginning stages of PDAC and no further disease, suggesting a latency to PDAC 
formation in this group compared to the other K30C groups. We hypothesize that 
complete loss of Tip30 protected K30C mice from PDAC disease progression at 
earlier timepoints. On the other hand, because 50% of K30-/-C mice exhibited 
PanIN-2-PDAC incidence (n=5/10), albeit at low levels of average occurrence, 
PDAC may have been initiated but the progression to clinical manifestation may 
have been delayed for reasons we could not explain in the scope of these studies. 
In summary, the histopathological analysis reported in Table 2 and average 
occurrence (Figure 14) in our K30C mouse models suggested that one copy loss 
of Tip30 accelerated PDAC and PDAC-associated disease in a three-month-old 
cohort of K30C mice. Because phenotypic differences existed between K30C with 
monoallelic loss of Tip30 and K30C mice that were Tip30-null we hypothesized 
that Tip30 copy number or dose mediates disease progression in the K30C mouse 
model. Additional mice with a quantitative comparison of lesions between groups 
are needed to determine if the differences we observed between groups are 
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statistically significant. We could not explain the advanced progression to PDAC 
observed in K30+/+C mice, however we predict that this advanced progression may 
have contributed to our inability to observe significant differences in PDAC 
incidence between our groups of mice. To address these concerns we need to 
compare equal numbers of mice at earlier time points (one to two months), in a 
pure, congenic background to minimize variability.  
In our characterization of the Tip30-deficient K30C mouse models, we also 
assessed the role of Tip30 loss in PDAC-associated survival. Decreased Tip30 
expression was linked to lymph node metastasis and poorer overall survival in a 
cohort of 106 chemotherapy and radiation therapy-naïve PDAC patients (Guo et 
al., 2014). We used the Kaplan-Meier estimate of survival to analyze non-breeder 
Tip30-deficient K30C mice (K30+/-C and K30-/-C), compared to K30+/+C mice that 
were generated internally. 30-/- and 30+/- internal, littermate controls were also 
observed. Mice were monitored up to 12 months, except as indicated in section 
2.23. Towards the end of data collection for the survival analysis, mice that could 
not be monitored for 12 full months, and were still alive at the end of the study were 
categorized by the statistical software as “censored” observations. We included in 
these subjects in our statistical analyses, and as tick marks on the survival curves 
in Figure 13B (see section 2.23 for more details). Time of death was noted when 
mice became moribund, were requested to be euthanized by veterinary staff, or 
were found dead.  
Our survival analysis revealed that Tip30-heterozygous-KC mice (K30+/-C) 
fell sick more rapidly, and early compared to other K30C groups. K30+/-C mice 
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predominately fell sick between 5-16 weeks of age (Figure 13B) and exhibited a 
median overall survival of four months (n=14), as compared to eight months in 
K30-/-C mice (n=13, p=0.0788, Log-rank) (Figure 13B). In comparison to K30+/+C 
and K30+/-C groups, K30-/-C mice had the highest median survival, suggesting that 
the K30-/-C genotype was protective, before eight months of age. While Tip30-
heterozygous-KC mice exhibited a trend for poor survival outcome (n=14), when 
compared to K30+/+C (n=10) who had a median survival of five months (n=10), and 
K30-/-C (n=13) mice, the differences in survival between all three groups did not 
reach statistical significance when assessed by Log-rank test (Figure 13B).  
Pancreatic tumor development was not visible through gross observation 
and necropsy in both K30+/-C and K30-/-C mice until five and six months (Figure 
17B-C, Table 3). Although there was a trend for an increase in tumor formation in 
K30+/-C and K30-/-C mice compared to K30+/+C mice at 5-6 months, the sample 
size was too small to reach any statistical significance. Interestingly, however, 
tumors varied in phenotype between both groups (Figure 17-19). By gross 
evaluation, K30+/-C mice presented with mostly pancreatic nodules (Figure 17), 
even at later time points of up to twelve months (Figure 18A-B). Later time points 
consist of our observation of three available mice: a K30+/-C mouse evaluated at 
twelve months (Figure 18A-B), ten months (Figure 19), and eight months (Figure 
19). These data are limited due to an insufficient number of mice evaluated. In a 
six-month cohort, K30+/-C mice presented with increased detectable pancreatic 
nodules (n=4/7) as compared to K30+/+C (n=1/6) and K30-/-C (n=2/4) mice (Table 
3). Overall, K30+/-C mice had firmer pancreatic tissue at younger ages compared
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Figure 17. Pancreata from four- to five-month-old K30+/-C mice and pancreatic nodule 
formation 
(A) Pancreas and spleen from a four-month old female, TP622, imaged ex vivo. (B) Pancreas from 
a five-month old female, TP573, imaged ex vivo. Pancreatic nodule outlined with a black dashed 
circle, not shown to scale. (C) Pancreatic tumor formation in a five-month old female, TP544 with 
spleen still attached. Ruler in mm. 
 
 
 
Table 3. Tumor presentation at necropsy in five to six-month-old K30C mice 
  Tumor Cyst* % Tumor 
5 MO K30+/+C 0/5 1/5 0% 
 K30+/-C 4/9 0 44% 
 K30-/-C 2/3 1/3 67% 
6 MO K30+/+C 1/6 2/6 17% 
 K30+/-C 4/7 0 57% 
 K30-/-C 2/4 0 50% 
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Figure 18. Frank tumor formation in Tip30-null K30C and K30Ctd+/- mice 
(A) Pancreas in situ of 12-month-old K30+/-C mouse, TP164. Black arrows point to nodule 
formation. Yellow arrows point to cystic region. (B) Pancreas from A, imaged ex vivo. (C) Pancreatic 
tumor (dotted line) in nine-month-old K30-/-C mouse, TP889, in situ. (D) Pancreatic tumor from C, 
attached to spleen and imaged ex vivo. (E) Pancreatic tumor (dotted line) in ten-month-old K30-/-C 
with tdTom-EGFP construct (K30-/-Ctd+/-, TP881). (F) Pancreatic tumor from E, attached to spleen 
and imaged ex vivo. (G) Normal pancreas tissue (dotted line) in 12-month-old K30-/- mouse, TP832. 
(H) Pancreas tissue from G, attached to spleen and imaged ex vivo. Scale bars: 5 mm. Ruler in 
mm.
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Figure 19. Complete deletion of Tip30 results in increased incidence of gross pancreatic 
tumor formation with late presentation  
 
Top Row: 8-9-month (mo.)-old pancreas tissue with spleen attached. Mouse ID, from left to right: 
E1908, TP890, TP942†, TP1004, TP889. Bottom Row: 11*-12-month (mo.)-old pancreas tissue 
with spleen attached, mouse ID from left to right: TP858, TP841, TP995, TP851, TP746. Scale 
bars: 5 mm. *TP851 is 10 months. †Cyst formation observed in some K30+/+Ctd mice. 
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to K30+/+C mice (n=1/5) and K30-/-C (n=2/3) mice (Figure 17, Table 3). Although 
nodular-like in appearance, nodular areas were difficult to cut through at necropsy. 
These nodules may or may not be small tumors (approximately three mm in 
diameter). Focally nodular parenchyma has been reported in older KC mice (five 
months) by Hingorani et al. (in Figure 1D 2003). Of all mice observed in these 
studies including controls, only K30C with full Tip30-loss developed frank tumors 
that encompassed the entire pancreas tissue, albeit at later time points (Figure 
18-19). We did not observe large, frank tumor formation in K30+/-C mice. There 
was also a low penetrance of small pancreatic cysts or a cystic pancreas across 
the K30C mouse models as is indicated in Table 3.  
3.2.7 K30+/-C Mice Developed a High Incidence of Gross Pulmonary Lesions 
One of our most striking observations from these studies was the 
presentation of pulmonary lesions in K30+/-C mice (Figure 20). Seven of these 
mice were reported sick with difficulty breathing (n=7), and thus were included in 
the survival analysis. We examined the lungs of 31 K30+/-C, 20 K30-/-C and 17 
K30+/+C mice ranging between the ages of 5 and 44 weeks old for tumor incidence 
(Appendix C5). Not only did K30+/-C mice have decreased overall median survival 
when compared to K30+/+C and K30-/-C mice, 42% of K30+/-C mice (n=13/31) 
exhibited an incidence of pulmonary lesions and abnormalities as early as five 
weeks and as late as eight months compared to 0% K30+/+C mice (n=0/17, 
p=0.002) and 10% K30-/-C mice (n=2/20) (Figure 20, Appendix C5-C6). Chi-
square analysis was performed on all three groups of K30C mice and a significant 
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Figure 20. Tip30-heterozyous K30C mice developed increased incidence of gross 
pulmonary abnormalities 
 
(A) Pulmonary lesions in lung tissues from five-week-old to thirty-two-week-old K30+/-C mice. 
Dashed region outlines the observed lesion formation. The apex of the lung is oriented to the bottom 
in these images, with the heart still attached to lung tissues. Scale bars: 5 mm. Lung images shown 
are from: K30+/+Ctd+/--TP995 healthy lung control, and K30+/+C-TP576, -TP448, -TP452, -TP622, 
and -TP1004 mice. Seven additional mice with pulmonary lesions were imaged. (B) Percent 
incidence of pulmonary lesion formation in K30C mouse model. Number of mice with gross 
pulmonary lesions observed over total number of mice assessed per group. +/+, K30+/+C; +/-, K30+/-
C; -/-, K30-/-C mice. Chi-square p=0.001. Followed by Fisher exact test with Bonferroni correction. 
p=0.002 for +/+ vs. +/-. Other two-group comparisons had no significant difference.
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difference in lesion incidence was determined (p=0.001, n=17-31) (Figure 20). 
This was followed by a Fisher exact test and Bonferroni correction which confirmed 
that the incidence of pulmonary lesions observed in K30+/-C mice was significant 
as compared to K30+/+C controls (p=0.002, n=17-31).  
Tip30 deficiency has been reported to accelerate spontaneous lung tumor 
development in 78-week-old BALB/c mice (Li et al., 2013) and the BALB/c genetic 
background is prone to lung tumors at high frequency (Begley et al., 2012; Li et 
al., 2013). However, in contrast to Li et al. (2003), 92% of the K30+/-C mice that 
presented with this phenotype were 24 weeks old or less (n=12/13 mice). Also, 9 
of 13 K30+/-C mice with pulmonary lesions were only 8-16 weeks-old. Therefore, 
to exclude the possibility that Tip30-deficiency alone caused pulmonary lesion 
formation, and to confirm that the phenomenon we observed appeared only Tip30-
deficient K30C mice, a total of 6 Tip30-heterozygous (30+/-) and 22 Tip30-null (30-
/-) littermate controls with and without LSL-KrasG12D or Pdx1-Cre transgenes, but 
not both, were evaluated. In addition, 6 wild-type controls ranging from five weeks 
to six months in age were also examined. These animals did not present with 
pulmonary lesions or visible signs of disease at necropsy (see list of genotypes in 
Appendix C1). 
These data combined suggested that Tip30-heterozygous loss and 
KrasG12D driven to the pancreas epithelium resulted in preferential pulmonary 
involvement. Pulmonary lesions were at least five millimeters in diameter, with 
some that encompassed an entire lobe or both lobes of the lung tissue (Figure 20, 
Appendix C6). Mice that presented with a pulmonary lesion were mostly affected 
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in the right lobe. In K30+/-C mice that developed pulmonary lesions, there were 
almost equal numbers of males and females (n=7 M; n=6 F), suggesting that 
pulmonary lesion development was not sex-dependent. Based on the increased 
pancreas pathology in the K30+/-C group detected in the three month cohort we 
hypothesized that our unique observation of increased pulmonary lesions in K30+/-
C mice were linked to PDAC-associated disease, and metastatic disease. 
The high incidence of visible pulmonary pathology in K30+/-C mice led us to 
re-examine the pancreas tissues in these mice as only one of these mice 
presented with a visibly detectable pancreatic tumor (five-month-old TP647, within 
the head of the pancreas). We performed a histological assessment of an H&E 
stained pancreas section from nine Tip30-heterozygous-KC mice that 
demonstrated visible lung lesions. We hypothesized that the pulmonary lesions 
were associated with pancreatic lesions that could only be detected by histological 
examination. Our analyses with the aid of our pathologist revealed a range of 
pancreatic lesions and pathology ranging from ductal atypia, chronic inflammation, 
to PanIN-3 precursor lesions, in eight out of nine pulmonary lesion-positive K30+/-
C mice (Figure 21). These observations support the hypothesis that the pancreas 
pathology induced by the KC background, and observed in K30+/+C mice alone at 
slightly longer latency may have cooperated with full-body Tip30-heterozygous 
loss to accelerate disease progression in K30+/-C mice.  
Pancreatic cancer cell (PCC) dissemination has been reported to precede 
pancreatic tumor formation and detection of PDAC by rigorous histological analysis 
(Rhim et al., 2012). We, therefore, hypothesized that pulmonary lesions in K30+/-
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Figure 21. K30+/-C mice with pulmonary lesions presented with microscopic pancreatic 
ductal atypia and PDAC precursor lesions 
(A) Hematoxylin and Eosin (H&E) staining of five-week-old mouse ID TP576. Ductal atypia. (B) 
CK-19 stain of TP576. (C) H&E stain of eight-week-old mouse ID TP448. Beginning of a pancreatic 
intraepithelial neoplasia (PanIN)-3 lesion. (D) H&E stain of 12-week-old mouse ID TP452. Marked 
hyperplasia. (E-F) Loss of polarity and nuclear atypia in low (E) and high (F) power images of H&E 
stained section of 16-week-old mouse ID TP627. Scale bars: 100 µm. Squares indicate focal areas 
with lesions. Asterisk indicates lymph node.
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C mice were a result of PCC metastasis. To detect PCC metastasis to the lung we 
examined one H&E-stained lung tissue section each from 11 of the 13 K30+/-C 
mice which presented with visible pulmonary lesions for evidence of PCC 
metastatic lesions. Surprisingly, we were not able to detect PDAC metastasis in 
these lung sections. Instead, pulmonary-lesion-positive K30+/-C mice had a 45% 
incidence of lung adenocarcinoma (n=5/11) (Figure 22C-D). H&E sections from 
pulmonary tissues of both K30-/-C and K30+/+C mice were also examined, and 16% 
of K30-/-C mice (n=1/9) exhibited pulmonary histology similar to lung 
adenocarcinoma that was identified in the K30+/-C group. This mouse also 
happened to have a pulmonary lesion by gross observation (Appendix C6.E). 
Lung adenocarcinoma was not detected by histological analysis in K30+/+C mice 
aged two-three months (n=7) (Figure 22). Pulmonary tissues from two 30-/- control 
mice were also assessed by pathology and were histologically negative for lung 
adenocarcinoma. Histopathological analysis revealed a higher incidence of thymic, 
follicular, or mantle zone lymphoma when assessing the spleen, and kidney, in 
addition to detectable lymphoma in the lungs of some subjects (Figure 22D). This 
included early lymphoma and lymphoma in n=3/7 K30+/+C mice, in all 12 K30+/-C 
mice with gross pulmonary lesions, and n=2/7 K30-/-C mice. Lymphoma 
assessment was based on H&E sections of spleen, kidney, and pulmonary tissues. 
Incidences of lymphoma were also detected in 30-/-C control mice. The 
histopathological analysis of six lungs from two- to three-month-old K30-/-C mice 
came back normal. Amongst three-month-old mice, we observed three with 
extramedullary hematopoiesis (EMH), myelodysplastic syndrome 
 134 
 
 
Figure 22.Tip30-heterozygosity increases lung adenocarcinoma incidence in pulmonary 
lesion-positive K30+/-C mice  
 
(A) Representative normal mouse lung tissue section stained for H&E from a Tip30-wild-type 
K30+/+C mouse. Areas of trachea and alveolar ducts (higher magnification) are visible. (B) 
Representative lung tissue section of 30-/- control mice (n=2) in the K30C cohort. (C-D) H&E staining 
of lung adenocarcinoma with some darker areas of lymphoma detected in representative images 
of two 2-3-month-old K30+/-C mice. (C) Low and high power of lung adenocarcinoma with high 
inflammation detected in a two-month-old K30+/-C-TP448 mouse. (D) Lung adenocarcinoma and 
lymphoma presentation in a three-month-old K30+/-C-TP431 mouse with inset magnifying abundant 
macrophage infiltration. (E-F) Representative fields of two-month old K30-/-C mouse pulmonary 
tissue sections, and lung tissues from the K30-/-C cohort that were negative for pulmonary lesion 
formation by gross observation. Scale bars: 100 µm. Low power image (2.5X) on the left, and high 
power insert (20X) on the right is presented for each subject.
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(MDS), with small germinal centers in the spleen. Follicular lymphoma was 
detected in some spleen as well. Additional staining to distinguish lung 
adenocarcinoma from PDAC metastasis would help strengthen these studies. 
3.2.8 Pancreatic Cancer Cell Dissemination to Lung Tissues in K30+/-C mice 
The observation of early pulmonary lesions in K30+/-C mice with detectable 
lung adenocarcinoma without PDAC metastasis by histological analysis was 
surprising. Because KrasG12D;Pdx1-Cre (KC) mice do not test positive for LSL-
KrasG12D recombination in the lungs or liver (Hingorani et al., 2003, Supplemental), 
Pdx1-Cre leakage to the lung tissues was unlikely. Added to this, 17 K30+/+C (aged 
of 2-6 months) did not present with the pulmonary lesion phenotype (Appendix 
C5). In particular, pulmonary lesion incidence was significantly increased in K30C 
mice that had one copy loss of Tip30. (K30+/-C) with p=0.001 by chi square statistic 
(Figure 20B). In a separate article, Li et al. (2013) reported an increased incidence 
of lung tumors and lung adenocarcinoma in 78-week-old Tip30-deficient mice on 
the BALB/c background, a mouse strain that is more susceptible to lung tumor 
formation (Li et al., 2013; Begley et al., 2012). A total of Tip30-deficient mice (aged 
1-12 months) with either a LSL-KrasG12D, a Pdx1-Cre, neither, or both transgenes 
were examined by gross observation (Appendix C1). However, we did not 
observe the pulmonary lesion phenotype in Tip30-deficient mice alone (30+/- or 30-
/-) in our studies (Appendix C1); and not only did we observe a significant 
preferential incidence in pulmonary lesions based on Tip30 copy number (Figure 
20B), the time to pulmonary lesion incidence occurred early compared to the Li et 
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al. (2003) report, at an average of three months (when examined up to 12 months, 
see Appendix C5).  
Due to the high abundance of PDAC-associated lesions and PDAC-
associated lymph node invasion and metastases detected in the cohort of K30+/-C 
mice compared to the other two groups of K30C mice and the occurrence of an 
affected lung phenotype as early as 5 weeks, we hypothesized that the pulmonary 
lesions had resulted from a PDAC metastatic seeding event. In a recent study, 
Rhim et al. (2012) reported that pancreatic cancer cell dissemination precedes 
histopathological detection of PDAC (Rhim et al., 2012). Rhim et al. (2012) found 
that mutant PDAC cells entered the circulation before PDAC detection by rigorous 
histopathological analysis (analysis of multiple sections throughout the entire 
tissue). We therefore hypothesized that one copy loss of Tip30 accelerated 
pancreatic cancer cells seeding to the lungs in our K30+/-C mouse model, and that 
metastasis had evaded detection by histopathological analysis.  
We sought to evaluate the pulmonary tissues of K30+/-C mice with lesions 
for KrasG12D-positive pancreatic cancer cells. We used the Kras G12D Conditional  
PCR method from The Jacks Lab (Jacks, 2007) to examine the DNA from the 
pancreas, pulmonary lesion, and adjacent normal, healthy lung tissue of K30+/-C 
mice. Here, we hypothesized that lung lesion formation was a secondary event 
that occurred in response to pancreatic cancer cell seeding of the lung tissues of 
K30+/-C mice. We hypothesized that the lung lesions were PDAC-associated and 
would be positive for a population of KrasG12D-positive PCCs that could then be 
identified by the recombined allele and insertion of one LoxP site (650 bp). To test  
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this hypothesis, we biopsied the pulmonary tissue lesions as well as neighboring, 
observably healthy (“adjacent-normal”). Gross examination was used to determine 
whether the tissue region was abnormal or normal. This matched sampling method 
allowed us to compare affected areas versus adjacent-normal lung tissues within 
K30+/-C mice. We used Kras G12D Conditional PCR (Jacks, 2017) to assess the 
presence of mutant Kras in DNA extracted from the biopsied tissues, as well as 
snap-frozen pancreas and muscle tissues, as available. Genomic DNA from 
K30+/+C, K30+/-C, and K30-/-C mouse pancreata tested positive for recombination 
and therefore, they were considered to be KrasG12D-positive. Presence of KrasG12D 
in the pancreas gave rise to KrasG12D-positive pancreatic cancer cells isolated from 
the pancreas epithelium, confirmed by fluorescence-activated cell sorting (FACS) 
of GFP-positive cells (Appendix C7). Pancreatic cancer cells were labeled with 
GFP, germline, after the incorporation of the dual fluorescent reporter mouse 
tdTomato-EGFP (Muzumdar et al., 2007, Figure 10) into the K30C mouse model, 
and pure GFP populations as well as PCCs derived from the pancreas tissues of 
K30C mice were fully recombined for KrasG12D (Figure 23B).  
In addition to 1-LoxP-KrasG12D-positive pancreas tissue and PCC DNA 
(Figure 24, Figure 23B), DNA from the pulmonary lesions of K30+/-C pulmonary 
lesion-positive mice was positive for oncogenic Kras (by recombined 1-LoxP- 
KrasG12D, n=3/3, Figure 24). Two out of three K30+/-C mice with a pulmonary lesion 
visible by gross examination had undetectable KrasG12D in biopsied, healthy-
appearing lung tissue using the same method. Adjacent normal lung tissue DNA 
in 5-week-old TP576 and 2-month old TP448 was negative for the 1-LoxP-KrasG12D 
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Figure 23. Characterization of PCCs from K30C and K30Ctd+/- models of murine PDAC 
(A) Genotyping PCR for Tip30 wild-type allele (top band, WT) and Tip30 mutant allele (bottom 
band, MUT) in separate PCR reactions, using genomic DNA extracted from the following mPCCs: 
TP711 (1), TP715 (2), TP573 (3), TP647 (4), TP592-1 (5), and TP889 (6). First three lanes 
represent Tip30 -/-, +/-, and +/+ tail DNA genotyping controls. Ladder, 10 kB. (B) Recombination 
efficiency of mPCCs and presence of oncogenic Kras, as assessed by Kras G12D Conditional PCR 
(Jacks, 2017) for cell line DNA and controls from pancreas tissues. Pdx1-Cre, DNA from a control 
mouse pancreata positive for wild-type Kras allele only at 622 bp. 2-LoxP, DNA from a control 
mouse pancreata positive for both a 622-bp product and an unrecombined LSL-KrasG12D allele at 
500-bp. 1-LoxP, DNA from a mouse pancreata positive for the 622 bp, 500 bp, and recombined 1-
LoxP-KrasG12D (650 bp) products. Samples #1-6 are as described in A. TP151-GFP (7), and TP912-
Lu-GFP (8). Ladder, 10 kB. (C) Relative Tip30 mRNA levels from murine PCCs (mPCCs) with wild-
type (TP151-GFP, TP711, TP715: +/+), heterozygous loss (TP573, TP647, TP852-GFP: +/-), or 
complete loss (TP592-1, TP735-GFP, TP892-GFP: -/-) of Tip30. Three cell lines per group were 
normalized to an internal Rps6 loading control and to the mean of three Tip30 WT mPCC lines 
(+/+). Data represent the means ± SEM of three cell lines per group. Student’s t-test for +/+ vs. +/-
, p=0.1889. Cell line IDs correspond to mouse ID’s from which cell lines were derived. “-GFP” 
indicates the cell line was isolated from a K30Ctd+/- mouse and was sorted by GFP using flow 
cytometry. (D) Two to three mPCCs each from different K30C and K30Ctd+/- mice were assessed 
for TIP30 protein levels. TP151-GFP, TP711, TP715 (+/+); TP573, TP647, TP852-GFP (+/-), and 
TP592, and TP735-GFP (-/-). 20 µg of protein was separated over 15% SDS-PAGE. This 
experiment was repeated three different times (technically) with two different aliquots of the same 
antibody. The TIP30 antibody ab177961 from Abcam detects two major isoforms (27 and 30 kD) 
of TIP30. α-Tubulin is the loading control.  
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Figure 24. Pancreas tissues and abnormal pulmonary lesions, but not adjacent normal lung 
tissue*, from K30+/-C mice tested positive for KrasG12D-recombined PCC DNA 
Kras G12D PCR of DNA from the pancreas and muscle tissues of K30+/+; +/-; or -/- C mice, and both 
abnormal lung and healthy (normal) lung tissue biopsies from K30+/-C mice with pulmonary lesion 
presentation was used to detect the presence of 1-LoxP-KrasG12D-positive PCC DNA using the Kras 
G12D Conditional PCR method (Jacks, 2017). The first control is a negative control, from pancreas 
tissue of a mouse negative for both the LSL-KrasG12D and the Pdx1-Cre transgenes (TP418, Kras-
/Cre-), and the second a positive control from a mouse with one copy of the LSL-KrasG12D transgene 
(Kras+), and as expected, no recombination event. The Kras+/Cre+ control (TP228) appears not 
to be positive for LSL-KrasG12D recombination, although originally genotyped as a K30+/+C mouse 
at weaning. Recombined 1-LoxP allele, 650 bp (red dot); wild-type Kras, 622 bp (yellow dot); 
unrecombined 2-LoxP, 500 bp (blue dot). Ladder, 10 kB. *3.5-month-old TP630 mouse tested 
positive for recombined 1-LoxP DNA in the biopsy of adjacent normal lung tissue. Muscle tissue 
served as negative internal controls and tested negative for recombination or PCC DNA. Normal 
lung tissue appeared healthy and were free of lesions by gross observation.  
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PCR product (Figure 24). A third 500-bp PCR product in this analysis confirmed 
the presence of unrecombined LoxP-STOP-LoxP construct, which we interpreted 
as DNA from lung cells of the pulmonary tissues. All three groups (K30+/+C, K30+/-
C, and K30-/-C) tested negative for recombination in muscle tissues, while K30-/-C 
and K30+/+C groups tested positive for partial recombination in the pancreas 
(Figure 24).  
The third K30+/-C mouse (mouse ID TP630) exhibited a phenomenon known 
as loss of heterozygosity (LOH) of the wild-type Kras allele. Mouse ID TP630 had 
a larger pulmonary lesion than the other two mice in this analysis, possibly 
because it was older: 14 weeks of age compared to 8 weeks (TP448) and 5 weeks 
(TP576) of age. This may or may not have contributed to a more advanced diseae 
state in this region of affected tissue. We were not able to detect wild-type Kras by 
PCR in this mouse’s pulmonary lesion, but both the adjacent normal lung and 
pancreas tissue biopsies in this mouse retained detectable levels of the wild-type 
Kras allele by this PCR method (Figure 24, see Appendix C8). Copy number loss 
of one KRAS allele with a mutation in the second allele is seen in 35% of hPDAC 
cases according to TCGA data (n=100/109, UTSW), accessed through cBioPortal 
on November 14, 2018 (J. Gao et al., 2013; Cerami et al., 2012). In addition, we 
were able to detect 1-LoxP-KrasG12D in the adjacent normal lung tissue biopsy of 
TP630. Note that DNA from the muscle tissue did not test positive for 
recombination. In addition, DNA sampled from mouse pancreata of control mice 
that lacked the Pdx1-Cre transgene but were positive for the LSL-KrasG12D allele. 
Ductal atypia was detected in a pancreas section of this mouse by 
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histopathological analysis. These findings suggested that, for this mouse, although 
the adjacent-normal tissue was visibly lesion-free, the tissue still maintained some 
pancreatic cancer cells that were undetectable by gross examination. In total, two 
out of three of mice with pulmonary lesions and 1-LoxP-KrasG12D positive DNA 
were confirmed to have detectable lung adenocarcinoma by pathological 
evaluation (two-month-old TP448 in Figure 22C, and four-month-old TP630). 
Combined the advanced histopathology observed in the pancreas tissues of K30+/-
C mice, and the similarity in KrasG12D-recombined DNA from the PCCs and 
pancreas tissues in our mouse models (Figure 23B and Figure 24, Appendix 
C2.C) with the DNA from the pulmonary lesions but not adjacent normal lung 
tissues (n=2, Figure 24), these additional findings supported that PCC had seeded 
the lungs of K30+/-C mice. However, we understand that more substantiation is 
needed to confidently state that a recombination event did not occur during 
embryogenesis in the pulmonary tissues of K30+/-C mice and contributed to the 
results obtained from our observations.  
To further evaluate if Tip30-heterozygosity enhanced metastatic pulmonary 
seeding in KC mice, we crossed the dual-fluorescent membranous 
tomato/membranous enhanced GFP (mT/mG) Cre reporter mouse (Muzumdar et 
al., 2007) into our model (K30Ctd+/-). EGFP-labeling of the pancreas epithelium 
was driven Pdx1-Cre excision of the LoxP-tdTomato-LoxP cassette. This resulted 
in GFP-positive pancreas tissues (Figure 25) and allowed us to sort PCCs for 
GFP-positivity by flow cytometry (Appendix C7(A)-(B)). One allele of LoxP-
tdTomato-LoxP-EGFP (herein “td”) is sufficient for adequate GFP fluorescence 
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(Muzumdar et al., 2007). When using the same imaging settings, td+/- and td-/- mice 
did not exhibit any distinguishable differences in phenotype or fluorescence. PCCs 
derived from GFP-fluorescent pancreata and distant organ seeding (disseminated 
or metastatic PCCs) were confirmed to have the KrasG12D mutation by the “Kras 
G12D Conditional PCR” method (Jacks, 2017) (see Figure 24B, Lane No. 7). 
To confirm Pdx1-Cre-specific GFP-targeting, we imaged the internal organs, both 
in situ and ex vivo, of Tip30-deficient; td+/- mice with and without Pdx1-Cre using 
the same light box fluorescent imaging settings. Compound mutant Tip30-
deficient;Pdx1-Cre-negative;td+/- mice were always RFP-positive (Figure 25A-B). 
While Tip30+/- and Tip30-/-;td+/- mice that were positive for the Pdx1-Cre transgene 
exhibited green-fluorescent pancreas tissues (Figure 25C-D). The pulmonary 
lesion that developed in a three-month-old K30+/-Ctd+/- mouse did not fluoresce 
(green) as an entire mass, and we were unable to detect GFP-positive PCCs in 
the lesion by fluorescence light box imaging (n=1/5). We interpreted these data as 
support for no off-target Pdx1-Cre recombination in the lung tissues of both K30+/+, 
+/-, or -/-C mice and K30+/-C-mouse pulmonary lesions.  
One two-month-old K30+/-C mouse (mouse ID TP852) in our study was 
reported as sick but did not present with a pulmonary lesion. Although the lungs 
appeared healthy by gross observation (similar to that of K30+/+C control mouse 
ID TP995 in Figure 20A), we were able to visibly detect micrometastatic seeding, 
clustered predominately in the superior and middle lobes of the right lung near the 
trachea (Appendix C9) by GFP imaging. The pathologist diagnosed K30+/-Ctd+/--
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Figure 25. Pdx1-Cre-driven EGFP labeling using the dual LoxP-tdTomato-LoxP-EGFP 
reporter mouse 
(A-B) Tip30-deficient control mice without the Pdx1-Cre transgene present negative for EGFP 
labeling of pancreas tissue by in situ GFP/RFP imaging. (A) Five-month-old, Tip30-heterozygous 
(30+/-td+/-) mouse (TP666). (B) Representative image (TP693) of three, three-month-old 30-/-td+/- 
Tip30-/- mice imaged. (C-D) Pdx1-Cre drives EGFP labeling to the pancreas epithelium in Tip30-
deficient mice. (C) Representative image (TP690) of two, three-month-old, Tip30-
heterozygous;Pdx1-Cre (30+/-Ctd+/-) mice imaged in situ. (D) Representative image (TP704) of two, 
three-month old 30-/-Ctd+/- mice. (E-H) Lung (Lu), liver (Liv) and pancreas (P) tissues imaged ex 
vivo. 
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TP852 with chronic ductal inflammation of the pancreas, after examining a 
histological section of pancreas tissue from this mouse. 
GFP-positive pancreatic cancer cells (PCCs) from both pancreas and lung 
tissues were cultured and successfully expanded from K30+/-Ctd+/--TP852 (Figure 
26). By day four, in culture, metastatic PCCs appeared disorganized in morphology 
(with elongated projections) and exhibited a disproportionate cytoplasmic to 
nuclear ratio and a strong GFP signal that lined the nuclear membrane (Figure 
26D). By Day 11, GFP-positivity was uniform throughout GFP-positive metastatic 
PCCs. The presence of supporting cells, that were GFP-negative, could also be 
visualized in culture by Day 11 (Figure 26E). Without GFP-labeling (Figure 26E, 
bottom panel) these disseminated PCCs would have been indistinguishable from 
the surrounding cells in culture (Figure 26E, brightfield). DNA and cellular analysis 
suggested the presence of two different populations of cells in the lung tissues: 
those that were recombined and KrasG12D positive, as well as cells that were not 
recombined and Kras wild-type only. TP852-pancreatic and -lung-metastatic (lung 
met) PCCs were sorted for GFP-positivity using fluorescence-activated cell sorting 
(FACS) (Appendix C7(B)). GFP-negative cells were sorted into a separate pool, 
however the cell sorting may have not resulted in a pure population as is indicated 
in Figure 26F. In culture, the GFP-negative pool of cells presented with GFP cells 
over time, suggesting that there may have been limitations in sorting a pure 
negative population.  
Genomic DNA was extracted from the GFP-positive lung met PCCs 
(TP852-Lu-GFP) and assessed for recombined 1-LoxP-KrasG12D. Similar to our 
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Figure 26. GFP-positive PCCs isolated from the pulmonary tissue of a two-month-old K30+/-
C mouse are fully recombined for KrasG12D 
(A) Negative control for GFP imaging using PCCs negative for LoxP-tdTomato-LoxP-EGFP 
transgene. (B) Cells cultured from pancreas of two-month-old K30+/-Ctd+/- mouse (TP852), Day 11 
in culture. (C-E) Cells cultured from lung of mouse TP852, shown at Day 0 (C), Day 4 (D), and Day 
11 (E) in culture, respectively. Red arrows indicate GFP positive metastatic PCCs. Scale bars: 100 
µm in A-E. Fields were imaged in both brightfield (top) and GFP (below). (F) Fluorescence-
activated cell sorting of mixed cell population shown in E, followed by Kras G12D Conditional PCR 
(Jacks, 2017) of GFP-positive sorted cells (+) and GFP-negative sorted cells (-). GFP-positive 
sorted cell population was fully recombined (red dot, recombined 1-LoxP-KrasG12D allele at 650 bp). 
Yellow dot, wild-type Kras allele at 622 bp; blue dot, Unrecombined 2-LoxP at 500 bp. 10 kB ladder.   
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observations in primary PCCs isolated from pancreas tissues (Figure 23B), K30+/-
Ctd+/--TP852-Lu-GFP-positive sorted cells had fully recombined 1-LoxP-KrasG12D 
transgene DNA (Figure 26F). TP852-Lu-GFP [GFP positive] metastatic PCCs 
therefore tested positive (fully recombined) for oncogenic Kras suggesting that 
they indeed had originated from the pancreas tissue (Figure 26F). These data 
support that oncogenic Kras PCCs with Tip30 heterozygous are capable of 
seeding the lungs of Tip30-heterozygous KC mice. These seeding event may 
contribute to the early lung adenocarcinoma observed in our model system. We 
recognize that more mice will need to be analyzed to substantiate these 
interpretations. 
Cells were also isolated from the pancreas and lung tissues of a three-
month-old K30+/+Ctd+/- mouse (TP912) (Appendix C7(A)). TP912 was not 
expected to have GFP positive cells in the lungs as the mouse was not sick, nor 
did it have any GFP-positive cells visible by fluorescent imaging. We hoped to use 
these cells as a negative control for mechanistic studies of metastatic PCCs that 
had seeded the lungs in K30+/-C mice. However, in culture of cells isolated from 
the lung tissue, a population of GFP-positive cells were visualized and subjected 
to fluorescence-activated cell sorting. Gating these cells to a GFP-negative 
pancreatic cancer cell line (Appendix C7(A), Neg Ctrl) revealed that the cells 
indeed were GFP-positive (Appendix C7(A), Neg Ctrl vs. TP912-Lung). The 
mixed population of cells from TP912-Lung tested positive for both recombined 1-
LoxP-KrasG12D and unrecombined LSL DNA. This suggested that PCCs that had 
seeded the lung yet were not detectable by gross observation or visualization with 
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light box GFP imaging co-existed with a population of lung cells in K30+/+C mouse 
ID TP912 lung tissue. The GFP-positive cell line from the lung of TP912 was called 
TP912-Lu-GFP. An H&E-stained pancreas section of the TP912 mouse was 
evaluated by our pathologist, and a PanIN-3 lesion with microinvasion and 
carcinoma in situ was detected. Kras G12D Conditional PCR (Jacks, 2017) to 
detect oncogenic Kras revealed that the sorted TP912-Lu-GFP cells were 
comprised of fully recombined 1-LoxP-KrasG12D DNA (Figure 23B, lane 8). In 
addition, DNA from TP912-Lu-GFP cell was also sent for whole genome 
sequencing (the average read depth was 31X). Our analysis of the TP912-Lu-GFP 
sequence confirmed that these cells were negative for the Tip30 Exon 2-3 deletion. 
Our sequencing analysis also confirmed that the Rb1, Tp53, and Smad4 gene 
sequences were wild-type in these cells; therefore we considered this mouse to be 
a true K30+/+C mouse.  
3.2.9 Complete Loss of Tip30 Enhanced Hepatic Seeding, Frank Tumor 
Formation, and Late Onset of Metastatic Burden in K30-/-C Mice 
In contrast to the phenotype observed in K30+/-C mice, K30-/-C mice 
developed classical, dense PDAC tumors (Figure 18, Figure 19). K30-/-Ctd+/--
TP735 (mouse ID TP735) presented with this phenotype at three months. 
However, the other K30-/-C mice did not present with this phenotype until at least 
nine months (K30-/-C, n=1; and K30-/-Ctd+/-, n=2). Not only could the pancreatic 
tumors be unmistakably identified, histological assessment with a pathologist 
confirmed the following pathology: cystic adenocarcinoma of the pancreas, 
moderately differentiated PDAC, PDAC with detection of a broken membrane, and 
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moderately differentiated PDAC plus fibrosarcoma (spindeloid tumor) for the H&E 
sections from K30-/-C tumors aged six to eleven months old. Sarcomatoid histology 
is reported to be a less common subtype of PDAC (Hezel et al., 2006). Since the 
heterozygous loss of Tip30 resulted in increased pulmonary metastatic seeding 
and increased secondary pulmonary lesion formation, we hypothesized that total 
loss of Tip30 also enhances early PDAC metastasis that may bypass detection by 
gross assessment. We assessed H&E stains of liver and lung tissues from three-
month-old K30-/-C mice but did not detect any indication of liver or lung metastatic 
lesions by histology. Therefore we proceeded to evaluate a cohort of K30C mice 
that were also positive the dual fluorescent tdTomato-EGFP reporter (Muzumdar 
et al., 2007). The addition of this transgene (LoxP-tdTomato-LoxP-EGFP) results 
in enhanced green fluorescent expression in the pancreas epithelium only in the 
presence of Pdx1-mediated Cre recombinase (Figure 25). Mice that are positive 
for this transgene (td+/- or td-/-) but negative for Pdx1-Cre express tomato, a red 
fluorescence, in their pancreas tissues (Figure 25A-B).  
In an attempt to detect the presence or absence of any micrometastatic 
seeding organs from three-month-old K30+/+Ctd+/- (n=3), K30+/-Ctd+/- (n=5) and 
K30-/-Ctd+/- (n=4) mice were examined and imaged using a GFP/RFP light box 
imaging system, both in situ and ex vivo (Figure 27). This is described in more 
detail in section 2.15. Micrometastatic seeding was identified by groups of dotted 
clusters that ranged in size (Figure 27B, white arrow). Micrometastatic seeding to 
the liver was observed in 75% of three-month-old K30-/-Ctd+/- mice compared to 0 
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Figure 27. Complete loss of Tip30 enhances micrometastatic seeding to the liver in a novel 
mPDAC model (K30-/-Ctd+/-)  
(A) Whole body dual GFP/RFP light box imaging of a K30-/-Ctd+/- mouse (TP703). 60% Brightness 
and 50% contrast was used in this image for better visualization. White dashed box and inset 
represents one area of micrometastatic seeding detected. Dotted oval outlines the spleen (S), 
which is attached to the GFP-positive pancreas (P). Both the gallbladder (G) and bladder (B) 
autofluoresce. The stomach (red asterisk) and the small intestine (red arrowheads) are GFP-
positive. (B) GFP/RFP light box imaging of pancreas, liver, and lungs from mouse in A, ex vivo. 
White arrow points to example of micrometastatic seeding. Blue arrowheads point to examples of 
autofluorescence from imaging. (C) Quantitation of mice observed with liver micrometastatic 
seeding: K30+/+Ctd+/- (+/+), K30+/-Ctd+/--TP733 (+/-), and K30-/-Ctd+/--TP703, TP735, TP771 (-/-). 
Chi-square test for trend, p=0.0315. n=3-5, as indicated. K30+/+Ctd+/- vs. K30-/-Ctd+/- p=0.0472. 
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out of 3 K30+/+Ctd+/- (p=0.0472 by Chi-square test for trend, n=3/4), after an overall 
significance was detected between the three groups. The incidence of 
micrometastatic seeding detected in the liver of 1 out of 5 K30+/-Ctd+/- mice was 
not significant when compared to micrometastatic seeding to the liver of K30-/-Ctd+/- 
mice (Figure 27C). Due to the small sample size, the Chi-square result may not 
be valid. There were limitations in GFP-imaging and autofluorescence at image-
capture; i.e., the gallbladder was found to autofluoresce under this imaging 
modality. Autofluoresence is distinguished by jagged streaks of light (Figure 27B, 
blue arrows). The duodenum and stomach were GFP-positive, as were other areas 
of the small intestine (Figure 27A vs. Appendix C10); we also observed this to be 
the case in K30+/+Ctd+/- or -/- mice (Figure 25 vs. Appendix C10). We isolated cell 
lines from the liver and the pancreas tissues of a three-month-old K30-/-C td+/- 
mouse (mouse ID TP735) with micrometastatic seeding in the liver (detected by 
GFP imaging). We then sorted both the primary and metastatic PCCs (TP735-LM-
GFP PCCs) using FACS to confirm the presence of GFP-positive PCCs in the liver 
of K30-/-C mice with micrometastatic seeding (Appendix C7(B)). We also froze 
sections from these tissues that appeared to contain GFP-positive 
micrometastases, as well as pancreas, lung, and liver from control mice that were 
GFP-negative, in optimal cutting temperature (OCT) compound for future studies. 
One K30-/-Ctd+/- mouse presented with GFP positivity past the caecum and in the 
colon or large intestine (mouse ID TP746, see Appendix C11). The Pdx1-
Cre;LSL-KrasG12D model has been reported to result in lesions of the 
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gastrointestinal epithelium including the stomach and small bowel, but not in the 
lung, heart, liver, spleen, or kidney (Hingorani et al., 2003). 
Macrometastases usually develop soon after dissemination (Nguyen et al., 
2009). For this reason, we followed K30-/-C mice to later time points and observed 
mice for grossly visible metastases. Three to five-month-old K30-/-Ctd+/- mice did 
not show any signs of metastasis by histological analysis, not even those that were 
positive for micrometastases by light box GFP/RFP imaging or positive for GFP-
sorted-KrasG12D PCCs isolated from the liver. In contrast, the three K30-/-C mice 
that developed frank tumor presentation by nine to eleven months of age also 
presented with liver nodules (Figure 28A) and lesions or full-blown lymph node 
metastases visible by gross observation (Figure 29). A total of five mice between 
the ages of 9-11 months, from both K30C and K30Ctd cohorts, were available for 
these analyses. 
We confirmed that Tip30 loss led to PCC liver metastases in two cases. The 
pancreatic tumors in these mice measured as big as ~45 mm in diameter. Nine-
month-old K30-/-C-TP889 (mouse ID TP889) (Figure 18C-D, Figure 19) presented 
with gross hepatic nodule formation (Figure 28A).Age-matched and littermate 
K30+/+C and Tip30-deficient control mice did not exhibit this phenotype (Figure 
28B-C). Severe, gross lymph node metastasis and metastatic burden to the liver 
was also observed in ten-month-old K30-/-Ctd+/--TP881 (Mouse ID #881) (Figure 
29). Histopathological analysis confirmed that the gross liver nodules observed in 
TP889 were sites of PDAC metastases (Figure 28A, D-Fields 1-3), with evidence 
of necrosis (Figure 28D-Field 4). A third mouse, in this late-aged group, only 
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Figure 28. PDAC hepatic metastasis in a Tip30-null K30C mouse 
(A) Gross liver nodule formation observed in a nine-month-old K30-/-Ctd+/+ mouse (TP889), imaged 
ex vivo compared to disease-free livers from age and sex-matched (B) K30+/+Ctd+/- (TP942) and 
(C) 30-/-td+/- (TP890) mice. TP890 was also a littermate control. Ruler in mm. Images in the second 
column of A-C were taken with a flash setting. (D) Three different fields from an H&E stain of K30-
/-Ctd+/+-TP889 liver tissue. Field 3 represents a necrotic lesion. Histopathological analysis and 
PDAC-associated macrometastatic lesions were confirmed with our pathologist. Scale bars: 100 
µm.  
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Figure 29. Representative image of PDAC tumor and subsequent metastatic burden in liver 
and lymph nodes of a K30-/-Ctd+/- mouse 
(A) GFP positivity in pancreatic tumor (PT) is surrounded by larger tdTomato-positive stromal 
reaction. GFP-positive mass and nodules were detected on the liver. Lungs were free of GFP-
positivity. (B) Lymph node metastasis lines inner cavity (black arrows). Mouse ID is TP881. Lymph 
nodes (LN Met), and PDAC tumor (PT) attached to the spleen (S). These images were examined 
by our pathologist. 
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developed micrometastatic seeding to the liver but did not present with observable 
gross nodule formation or liver metastasis (Appendix C11). Histopathological 
analysis of a section of liver tissue instead identified lymphoma, even though this 
mouse had a ~10 mm in diameter pancreatic tumor (Figure 19-TP746 pancreatic 
tumor); and PDAC with necrosis was identified by histology (not shown). These 
preliminary observations in our PDAC mouse model suggested that total loss of 
Tip30 resulted in pancreatic cancer cell liver metastasis. Consistent with our 
observations of the K30-/-Ctd+/- model, pulmonary tissue from TP881 was negative 
for full-GFP positivity, metastatic nodules, or pulmonary lesion formation by gross 
observation (Figure 29). 
We also observed an abnormal large cyst formation (measuring 10-22 mm 
in diameter) in four K30+/+Ctd+/- mice (see Figure 19, TP942), while 30-/-Ctd+/- or 
30+/-Ctd+/- and wild-type controls (30+/+Ctd+/-) did not exhibit this phenotype. In 
addition, GFP positivity and visual representation of potential KrasG12D 
recombination in Pdx1-Cre;LSL-KrasG12D;LoxP-tdTomato-LoxP-EGFP mice 
extended further into the small intestines than was visible in Pdx1-Cre;LoxP-
tdTomato-LoxP-EGFP mice (Appendix C10, Figure 25). The pathology of the 
pancreatic lesions and tumors observed in the K30+/-C and K30-/-C, respectively, 
were different from the pancreatic cysts observed in K30+/+Ctd+/- mice. K30+/+Ctd+/- 
pancreata seemed normal otherwise and mesh-like, without the presence of a 
tumor (Figure 19). These fluid-filled cysts may resemble more closely the part of 
a mucinous cystic neoplastic (MCN) lesion containing nonhemorrhagic fluid, as 
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reported by de Wilde et al. (2012). However, additional analyses are needed to 
confirm their identity.  
3.3 Summary 
In this study, we generated and characterized a mouse model of PDAC with 
Tip30-heterozygous (K30+/-C) and -homozygous loss (K30-/-C) to investigate if 
Tip30 loss accelerates pancreatic cancer in a murine model of PDAC (mPDAC). 
Tip30-heterozygous loss enhanced PDAC-associated disease and lesion 
progression in a cohort of three-month-old mice K30C, compared to Tip30-wild-
type and Tip30-null K30C mice. K30+/-C mice presented with a gross pancreatic 
tumor pathology mostly in the form of pancreatic nodules, even at later ages, 
compared to classical pancreatic tumor presentation in older K30-/-C mice (9-11 
months). A preponderance of CK-19-positive pancreas lesions, advanced disease 
stage diagnosed by lymph node invasion and metastasis, and poorer survival 
outcome across a cohort of age-matched mice led to the observation that 
heterozygous-loss of Tip30 contributed to the increased distribution of PDAC 
precursor lesions and advanced disease. Analysis of TCGA data of human PDAC 
cases revealed that HTATIP2 heterozygous loss occurred in 26% of hPDAC cases 
(UTSW, n=109) and that decreased TIP30 expression also results from TIP30 
promoter methylation or increased expression of MIR10B in hPDAC.  
The findings from our first hypothesis on Tip30 loss in PDAC tumor 
formation and progression then led us to investigate the role of Tip30 loss in 
enhancing metastatic burden in this murine K30C PDAC model (Figure 30). 
Indeed, we found evidence of pancreatic cancer cell seeding in the lungs of K30+/-
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Figure 30. Summary and schematic of Tip30-copy-loss-mediated, organ-specific 
dissemination and metastasis in a murine model of PDAC 
(A) In KC mice described in Hingorani et al. (2003), Pdx1-Cre drives a conditional KrasG12D mutation 
to the pancreas epithelium (red *), with no trace in the pulmonary or hepatic tissues as detected by 
Kras G12D Conditional PCR in Hingorani et al. (2003). In this study, K30+/+C mice were generated 
in the same background (BALB/c/B6/129SvJae mixed background) as the Tip30-deficient K30C 
mice under investigation. We observed shorter latency to PDAC than was reported by Hingorani et 
al. (2003). (B) In a three-month cohort, K30+/-C mice exhibited more pronounced pancreas 
precursor lesions and PDAC by histology with evidence of lymph node invasion and metastasis 
(n=2/7). Additionally, 42% of K30+/-C mice developed early pulmonary lesions (3a), and had poor 
survival outcome. Biopsies from the pulmonary lesions tested positive for the presence of PCCs 
via a PCR assay to detect the recombined mutant Kras allele and remaining LoxP site that was 
introduced in the pancreas epithelium, (dotted line and “2”). Matched adjacent normal pulmonary 
tissue (3b) tested negative for recombination and greatly positive for the unrecombined PCR 
product (n=2). Evaluation of H&E sections by a pathologist confirmed lung adenocarcinoma in 5 
out 12 lung sections from mice with pulmonary lesions. These preliminary results suggested that 
pancreatic cancer cells seeded the lung in Tip30-heterozygous KC mice, and a Tip30-heterozygous 
pulmonary/immune environment may have contributed to early progression of lung 
adenocarcinoma and other abnormalities in the lung. (C) Tip30-null mice developed 
micrometastatic seeding to the liver when crossed with KC mice (K30-/-Ctd) at a higher frequency 
compared to K30+/-Ctd mice, at three months (n=3/4). Hepatic metastatic nodule formation was 
visualized grossly in two 9-10-month-old K30-/-C mice. PDAC metastatic lesions by H&E stain 
shown in circle. K30-/-C mice developed frank pancreatic tumors that were dense and encompassed 
the entire pancreas tissue. 
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C mice and in the liver of K30-/-C mice by utilizing a tdTomato-EGFP reporter 
mouse in our studies that allowed for GFP labeling, and further identification, a 
sorting of 1-LoxP-KrasG12D pancreatic cancer cells. We also used the method of 
“Kras G12D Conditional PCR” method developed by The Jacks Lab (Jacks, 2017) 
to identify PCCs in the affected lung tissues of K30C mice with heterozygous but 
not in the adjacent normal lung tissue (n=2). K30C mice with one copy loss and 
homozygous loss of Tip30 had increased disease burden in affected secondary 
tissues, the lungs, and the liver, respectively, which presented in the form of either 
gross pulmonary lesions and lung adenocarcinoma (in K30+/-C) or liver metastases 
(in K30-/-C) (Figure 30). Pancreas tissues, primary PCCs, metastatic sites, and 
corresponding metastatic PCCs isolated from the observed metastatic sites were 
confirmed to be positive for 1-LoxP-KrasG12D DNA and were therefore confirmed 
to be pancreatic cancer cells. Lastly, the massive pancreatic tumor formation in 
nine to eleven-month-old K30-/-C mice that had not been previously observed in 
the KC mouse model (Hingorani et al., 2003), support our hypothesis that Tip30 
copy loss accelerates PDAC and metastatic organotropism in the K30C model. 
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CHAPTER 4. CHARACTERIZATION OF TIP30-DEFICIENT MURINE 
PANCREATIC CANCER CELLS FROM K30C AND K30Ctd MICE 
4.1 Background and Rationale 
Investigating the role of Tip30 loss in an autochthonous PDAC model 
(K30C) revealed differences in the phenotype and time to tumor formation, as well 
as preferential differences in organ-specific-pancreatic-cancer cell (PCC) 
dissemination and metastasis between Tip30-heterozygous K30C mice (K30+/-C) 
and Tip30-null K30C mice (K30-/-C). K30+/-C mice presented with PCC seeding of 
pulmonary tissues and K30-/-C mice presented with PCC hepatic metastases. We 
next sought to understand underlying mechanistic differences in Tip30 copy 
number loss on pancreatic cancer cell activity and their contribution to PDAC 
tumorigenicity. We isolated cell lines from the pancreas tissues of K30C mice as 
well as from organs observed to be burdened with metastatic disease or seeding 
to test the hypothesis that loss of TIP30 in pancreatic cancer cells alters PCC 
growth kinetics, the expression of cell growth and survival proteins in PCCs, and 
epithelial-mesenchymal transition (EMT). Reports of Tip30 loss resulting in a 
growth advantage in mouse embryonic fibroblasts (MEFs) (Ito et al., 2003) led us 
to predict that any cell, especially a cancerous cell, with a loss in Tip30 would have 
a growth advantage.  
To begin investigating the role of Tip30 copy number loss in PCC growth 
kinetics, we first performed in vitro assays to assess two-dimensional and three-
dimensional growth in Tip30-heterozygous and Tip30-null PCCs, compared to 
Tip30-wild-type PCCs. In addition, we performed biochemical assays to 
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investigate the role of Tip30 loss on EGFR levels in murine PCCs. siRNA 
knockdown of Tip30 prevented the fusion of a Rab5/ACSL4/endophillinB/TIP30 
complex, slowing EGFR trafficking; and in internalization studies deleting Tip30 in 
primary hepatocytes (Tip30-/-) led increased EGF-EGFR complex colocalization 
(Zhang et al., 2011). To add to this, TIP30-knockdown delayed EGFR degradation 
in a human hepatocellular cell line (Zhang et al., 2011). Few studies have focused 
on the role of Tip30 loss in pancreatic cancer. In 2003, Ouyang et al. reported that 
overexpression of TIP30 antagonist, miR-10b, in human pancreatic cancer cells, 
increased the levels of EMT-associated gene expression and EGF-stimulated 
invasion. The authors also reported that silencing Tip30 by siRNA resulted in 
sustained EGFR signaling (Ouyang et al., 2013). How Tip30 gene dose mediates 
pancreatic cancer cell function and activity have not yet been reported. 
4.2 Results 
4.2.1 Generation of Primary and Metastatic Pancreatic Cancer Cell Lines 
from K30C and K30CtdTom-EGFP (K30Ctd) Mouse Models 
To evaluate mechanistic changes in Tip30-heterozygous and -null 
pancreatic cancer cells (PCCs), we established cell lines from both K30C and 
K30Ctd+/- mouse pancreata and metastatic lesions. PCCs and metastatic PCCs 
from K30Ctd+/- mice were labeled (-GFP PCCs) after flow sorting for GFP positivity 
(Appendix C7(A)-(B)). Cell lines were isolated from mice with visible pancreatic 
or metastatic pathology at sacrifice (Table 4). In the case of K30+/+C controls, 
where a detectable tumor or seeding was not visible by gross examination, cell
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Table 4. Tissues used to establish pancreatic cancer cell lines (PCCs) 
 
Genotype Mouse 
ID 
Age 
(mo) 
Pancreas Description Pathology 
Report 
(Pancreas) 
K30+/+Ctd+/- TP151 3 Tumor & Cystic Cyst, PanIN-3, 
Reactive lymph 
node 
K30+/+C TP711 4 Small Cyst PanIN-3 
K30+/+C TP715 4 - PanIN-3 
K30+/-Ctd+/- TP852 
 
2 - Chronic ductal 
inflammation 
K30+/-C TP573 5 Meshy, pancreatic 
nodules 
 
PanIN-3, 
Enlarged lymph 
node (20X), 
approaching 
adenocarcinoma  
K30+/-C TP647 5 Meshy, with pancreatic 
nodule, small tumor in 
head of pancreas. 
 
PanIN, 
inflammation 
K30-/-Ctd+/- TP735 
 
3 Dense tumor Adenocarcinoma 
K30-/-C TP592 6 Cystic pancreas, large 
tumor 
 
Broken 
basement 
membrane 
K30-/-C td+/+ TP889 9 Dense, firm, gross  Cystic 
adenocarcinoma 
 
Age in months (mo). 20X, twenty times greater than normal. 
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lines were established from tissues, as available, for a basis of comparison 
between Tip30-wild-type and -deficient PCCs or metastatic (met) PCCs. Two 
Tip30 wild-type PCC lines were established from four-month-old K30+/+C mice, 
with PanIN-3 pancreatic histopathology. The third cell line was established from a 
three-month- old K30+/+Ctd+/- mouse in which a tumor was grossly visible, and 
PanIN-3 and a reactive lymph node detectable by histopathological evaluation 
(Table 4). Differences between the K30C and K30Ctd tomato mouse models in 
regards to PDAC tumor development have not yet been investigated. We validated 
Tip30 genotyping, presence of the engineered oncogenic Kras mutation (Jacks, 
2017), and TIP30 protein levels in K30C and K30Ctd (GFP) PCCs (Figure 23). 
We observed nearly 100% LSL-KrasG12D recombination in primary pancreatic 
cancer cells established from these models, including sorted GFP PCCs (n=3 per 
group, K30+/+C, K30+/-C, or K30-/-C with or without tdTomato-EGFP) (a 
representative analysis is shown Figure 23B), thereby suggesting that the cells 
isolated from pancreas tissues were indeed PCCs and positive for mutant Kras. 
These interpretations stemmed from visualizing complete loss of the 500-bp PCR 
product that detects the unrecombined LSL cassette, by methods of gel 
electrophoresis. After successful GFP sorting, metastatic PCCs also followed the 
pattern of 100% recombination efficiency observed in primary PCCs (Figure 23B, 
Figure 26F).  
Additionally, whole genome sequencing was performed on mPCCs. With 
assistance from Dr. Francis Enane (IU School of Medicine), Tip30 was confirmed 
to be intact at exons 2-3 by sequencing analysis. Rb1, Tp53, and Smad4 were 
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also confirmed to be wild-type in K30+/+C PCCs, including the TP912-Lung-GFP 
sample. The K30+/+Ctd+/- cell line TP151-GFP exhibited lower TIP30 protein levels 
compared to the other two cell lines from K30+/+C mice without the tdTomato 
construct. Similar variability was observed in the K30+/-C group; however, overall 
TIP30 protein levels of K30+/-C PCCs were still less than that of K30+/+C PCCs by 
an average of 50% (Figure 23D). Similar variability was observed in PCC Tip30 
mRNA levels. Tip30 mRNA levels in a GFP cell line from each K30C group 
followed the same trend as Tip30 mRNA levels in pancreas tissues and in cell lines 
from K30C mice. However, compared to cell lines isolated from K30C mice without 
the tdTomato construct, cell lines established from K30Ctd mice had the lowest 
Tip30 mRNA levels of all three cell lines for both the K30+/+Ctd and the K30+/-Ctd 
group (see TIP30 protein level differences in K30+/+Ctd PCCs in Figure 23D). It is 
conceivable that the heterogeneity observed from mouse-to-mouse in our studies 
could also be observed on a cellular level. Additional cell lines from both groups of 
mice, and preferably at least three from each model could help account for the 
variability coming from the EGFP construct. Cell lines were CK-19 positive but 
were also positive for smooth muscle actin (α-SMA), a mesenchymal cell marker 
(Figure 31-32).  
K30+/-C mice with visible pulmonary lesions or lung seeding by GFP 
(TP852) were used to establish pulmonary metastatic PCCs (-Lung PCCs). K30-/-
C mice with visible liver nodules or visible hepatic micrometastatic seeding 
detected by fluorescence light box imaging were used in establishing metastatic 
liver PCCs (-LM PCCs) from the hepatic tissues of TP889 and TP735 mice. TP735- 
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Figure 31. Primary K30C PCCs did not show marked differences in CK-19 protein levels 
(A) Representative immunoblot of basal CK-19 levels in mPCCs from K30C and K30Ctd+/- GEMMs 
with wild-type (+/+, TP711. TP715), heterozygous (+/-, TP673, TP647), and homozygous (-/-. 
TP592-1, TP889) loss of Tip30 (n=2 shown, repeated three different times per cell line except for 
GFP cell lines, performed once). CK-19 protein levels were assessed for a total of three 
independent PCCs per group (Tip30+/+-TP151-GFP, -TP711, -TP715 PCCs; Tip30+/--TP573, -
TP647, -TP852-GFP PCCs; and Tip30-/--TP592-1, -TP889, -TP735-GFP PCCs). (B) Data 
represent the densitometry means ± SEM of three cell lines per group: Tip30+/+-TP151-GFP, -
TP711, -TP715 PCCs; Tip30+/--TP573, -TP647, -TP852-GFP PCCs; and Tip30-/--TP592-1, -TP889, 
-TP735-GFP PCCs. Protein levels were normalized to loading control (α-Tubulin) and K30+/+C PCC 
levels (+/+). One-way ANOVA followed by Tukey post-hoc test performed on n=3; no significant 
difference found between groups.  
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Figure 32. Detection of epithelial and mesenchymal marker levels in K30C PCCs by immunofluorescence 
+/+, Tip30-wild-type. +/-, Tip30-heterozygous. -/-, Tip30-null. 
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LM-GFP PCCs were assessed for KrasG12D recombination after flow sorting 
(Appendix C7(B)) and were found to have similar, fully recombined DNA (not 
shown) as both primary PCCs and as is shown for the lung metastatic PCCs in 
Figure 26F. These observation further strengthened the hypothesis that loss in 
Tip30 copy number mediated pancreatic cancer cell dissemination and seeding of 
pulmonary tissues on our model. The resemblance in genetic characterization 
between primary PCCs, liver- and lung metastatic PCCs supported the hypothesis 
that the cells and DNA isolated from the pulmonary tissue and positive for 
oncogenic Kras were PCCs that originated from the pancreas. 
4.2.2 Tip30-Deficienct mPCCs have increased Two- and Three-Dimensional 
Growth Properties 
Puck et al. (1956) first described the clonogenic assay to assess the ability 
of cancer cells to form colonies after seeding. We performed two-dimensional (2D) 
clonogenic and three-dimensional (3D) growth assays to assess differences in 
growth of K30+/-C or K30-/-C PCCs compared to K30+/+C PCCs (Figures 33-34). 
Murine PCCs (mPCCs) exhibited an average trend for increased growth, that 
correlated with copy number loss of Tip30 (Figure 34A). While TIP30 protein and 
mRNA (individual mRNA levels not shown) levels were markedly lower in TP151-
GFP PCCs than in that of TP711, and TP715 K30+/+C PCCs (Figure 23D), this 
difference did not translate to a growth advantage in 2D or 3D (Figure 33A, Figure 
34A).  
Metastatic PCCs from the liver of K30-/-C mice exhibited increased two-
dimensional colony growth forming areas when compared to metastatic PCCs 
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Figure 33. Complete loss of Tip30 enhances colony formation for murine pancreatic cancer 
cells in vitro 
(A) Two-dimensional growth of murine pancreatic cancer cells (mPCCs) with two Tip30-wild-type 
alleles (+/+), Tip30-heterozygous loss (+/-), and Tip30-homozygous loss (-/-) was assessed using 
a clonogenic growth assay (n=3, per group). Colony formation was monitored for 7-8 days. mPCCs 
were derived from K30C and K30Ctd+/- GEMMs. One representative image per cell line is shown. 
Experiments were repeated three separate times except for TP735-GFP and TP852-GFP cell lines 
(performed two separate times), and in duplicate. (B) PCCs established from metastatic lesions of 
the liver (-LM) or metastatic seeding or gross lesions of the lung (-Lu) for TP852-GFP and TP627 
respectively. Growth was assessed after 7-8 days, except for TP627-Lu, which was allowed to grow 
for 20 days to monitor if K30+/-C lung metastatic PCCs were capable of colony formation. 
Experiments were repeated three separate times except for TP852-GFP-Lu (twice), and TP627-
Lu-20 days (once). Brightness of scanned images were adjusted to 70% with a contrast (50%). 
(C)TP912-GFP-Lu is from a K30+/+Ctd+/- mouse, and serves as a metastatic PCC control. Colony 
formation was assessed after 7-8 days.
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Figure 34. Tip30-deficiency accelerates 3D anchorage-independent growth in pancreatic 
cancer cells  
(A) In a three-dimensional growth assay that utilizes 3% matrigel (Sempere et al., 2011), murine 
pancreatic cancer cells (mPCCs) exhibited a trend of increasing 3D colony formation and growth 
with decreasing Tip30 copy number. 3D growth was assessed after 17-18 days in culture, and total 
colony areas were quantitated after MTT incorporation in ImageJ. Data represent the means ± SEM 
of three cell lines per group (K30+/+C-TP151-GFP, -TP711, -TP715 PCCs; K30+/-C-TP573, -TP647, 
-TP852-GFP PCCs; and K30-/-C-TP592-1, -TP889, -TP735-GFP PCCs). (B) A representative 
brightfield image of mPCCs with either wild-type Tip30 (+/+), hetloss of Tip30 (+/-), or Tip30-null (-
/-) genotype status at low and high power. The following cell lines are represented: TP711 (+/+), 
TP573 (+/-), and TP889 (-/-) PCCs (in 3D). Scale bars: 100 µm.  
 168 
isolated from the lungs of K30+/-C mice (Figure 33B). Tip30-heterozygous lung 
metastatic (met) PCCs eventually formed colonies in 2D when the growth period 
reached 20 days in culture. Finally, while GFP-positive PCCs, isolated from the 
lungs of a three-month-old K30+/+C mouse (TP912)-intended for use as a control-
expanded in culture, these cells did not form 2D colonies (Figure 33B).  
Anchorage-independent growth is a well-established hallmark of 
carcinogenesis and one of the three tests used to establish tumorigenicity 
(Borowicz et al., 2014; Shin et al., 1975; Mori et al., 2009). With regards to 
physiological relevance, there are limitations for growing cells in 2D and on plastic. 
Growth in 3D culture systems is considered to provide more biologically relevant 
information (Edmondson et al., 2014). We performed three-dimensional growth 
assays using primary pancreatic cancer cells (n=3) to confirm our 2D observations. 
Tip30 loss gave murine PCCs (mPCCs) a growth advantage in our 3D culture 
system. This assay consisted of a 3% matrigel (a gelatinous collagen IV/laminin-
rich medium) suspension where 3D colonies would develop, that rested over a 
layer of 1% soft-agar solution (Sempere et al., 2011). Growth kinetics varied 
between cell lines within both Tip30-heterozygous and Tip30-null mPCC groups. 
We observed a trend for increased 3D colony formation in Tip30-deficient and -null 
mPCCs after 17-18 days. Tip30-null mPCCs formed double the 3D colony areas 
of Tip30-deficient (Tip30+/-) mPCCs. The colony areas of Tip30-null PCCs doubled 
that of Tip30-heterozygous PCCs. A similar trend in Tip30 copy number loss and 
growth has been reported in immortalized mouse embryonic fibroblast cells (Ito et 
al., 2003). In addition, while Tip30-null mPCC 3D colonies were larger or more 
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abundant when compared to Tip30-wild-type PCCs, both of these groups shared 
a similar phenotype. 3D colonies that formed from either Tip30-wild-type or -null 
mPCCs formed very smooth spheres that were sometimes hollow. In contrast, 
mPCCs with heterozygous loss of Tip30 had a striking phenotypical difference in 
colony formation when compared to both Tip30-null and -wild-type PCCs. In 3D 
growth conditions, these K30+/-C PCCs had an invasive-like phenotype (Figure 
34A, B). Tip30-heterozygous PCCs formed disorganized and aggressive-looking 
3D colonies, with multiple budding events, or protrusions, extending from a primary 
colony (Figure 34B). mPCCs from K30+/-C genotype, with one copy loss of Tip30, 
may therefore have enhanced invasive properties, but additional assays would 
need to be conducted to confirm this hypothesis.  
Tip30-null TP735-GFP PCCs exhibited a seven-fold increase in growth in 
3D (p=0.0008) when compared to Tip30-wild-type-TP151-GFP (K30+/+Ctd+/-) 
PCCs (Figure 35A-B) suggesting that complete Tip30 loss led to increased growth 
capacity of mPCCs. TP735-GFP PCCs formed colonies that were composed of 
elongated and spindle-like cells compared to K30+/+Ctd+/- PCC line TP151-GFP 
(Figure 35C). This difference between the two cell lines was only visible in 3D 
culture, and both cell lines shared a similar phenotypic morphology in 2D culture 
(Figure 35C). These studies highlight the importance of assessing growth in 3D 
when evaluating PCC growth potential and the impact of tumor and metastasis 
suppressor loss in PCCs. Although PCC growth in vivo is the ultimate evaluation 
of tumorigenicity and would confirm the metastatic potential of Tip30-null 
compared to Tip30-heterozygous mPCCs. 
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Figure 35. Tip30-/--GFP-positive mPCC growth in 3D culture as compared to Tip30+/+-GFP 
PCCs 
(A) A representative image of 3D Growth of K30-/-Ctd+/- mPCCs (TP735-GFP) compared to 
K30+/+Ctd+/- (TP151-GFP) PCCs at low and high power. Visualization by GFP imaging in right panel. 
Scale bars: 25 µm. (B) Quantitation (by ImageJ) of MTT incorporation and total colony areas for 
three independent experiments represented in A. Colonies formed over 16-17 days in a three-
dimensional growth assay. Data represent the means ± SEM of three independent experiments, 
normalized to Tip30+/+ control PCCs. Student’s two-tailed t-test was performed, p=0.0008. (C) 
GFP+ PCCs exhibit similarities in cell morphology in two-dimensional growth culture conditions. 
Brightness was set to 60% and Contrast to 70% in the TP735-GFP 2D GFP image (-/-, GFP) to 
allow for better visualization of morphology. Both DIC images were adjusted to a Brightness of 60% 
and 70%, for +/+, and -/- respectively with a contrast change from 50% to 70% of the original image 
in Microsoft Publisher. Scale bars: 50 µm. 
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The increase in 2D and 3D growth forming areas of Tip30-deficient PCCs 
led us to hypothesize that Tip30 copy number loss influenced PCC proliferation. 
Tip30 has been reported to regulate c-Myc, a transcription factor encoded by the 
c-MYC oncogene that regulates cell proliferation (Miller et al., 2012), expression in 
mammary glands by interacting with the estrogen receptor α-interacting 
coactivator CIA (Jiang et al., 2004). Tip30-deficiency was found to enhance c-Myc 
transcription, while overexpression of Tip30 was found to repress it (Jiang et al., 
2004). To understand if differences in c-Myc transcript levels played a role in 
Tip30-deficient PCC proliferation, c-Myc transcript levels were assessed in murine 
pancreatic cancer cell lines isolated from the pancreas tissues of K30+/+, +/-, and -/-
C mice (n=3 per group). Interestingly, Tip30-heterozygous PCCs (Tip30+/-) 
exhibited a 50% trend of decrease in c-Myc levels when compared to Tip30-wild-
type (Tip30+/+) and Tip30-null (Tip30-/-) PCCs, suggesting that the enhanced 
growth kinetics observed inTip30-deficient PCC may have occurred independent 
of c-Myc. However, this interpretation cannot be substantiated without further 
analyses; since, these results did not reach statistical significance (n=3, Figure 
36). This could be due to the heterogeneity between cell lines and a need for 
increased sampling of c-Myc levels in more than three cell lines.  
4.2.3 Increased EGFR Protein and mRNA Levels in PCCs with Tip30-
Heterozygous Loss  
EGFR overexpression is reported characteristic of hPDAC (Korc et al., 
1992). Additionally, EGFR pathway upregulation has been shown to precede 
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Figure 36. c-Myc mRNA expression levels in K30C murine PCCs 
Relative quantity of c-Myc in K30C PCCs, after qRT-PCR is shown. c-Myc levels were normalized 
to β-actin, and Tip30-wild-type (+/+) pancreatic cancer cells (PCCs). Data represent the means ± 
SEM of three cell lines per group (K30+/+C-TP151-GFP, -TP711, -TP715 PCCs; K30+/-C-TP573, -
TP647, -TP852-GFP PCCs; and K30-/-C-TP592-1, -TP889, -TP735-GFP PCCs). A one-way 
ANOVA followed by Tukey post-hoc test for n=3 was performed. Data did not reach statistical 
significance. +/+, Tip30-wild-type; +/-, Tip30-heterozygous; -/-, Tip30-null.  
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tumorigenesis in Kras-mutant mice (Ardito et al., 2012). TIP30 loss was reported 
to increase EGF-EGFR complex formation in the early endosome in hepatocellular 
carcinoma cells (Zhang, 2011). TIP30 loss has also led to alveolar epithelial type 
II (AT2) cell expansion, increased EGFR in lung tissues and tumors, and the 
increased expression of downstream signaling proteins pERK1/2 and pAKT in 
TIP30-deficient human lung adenocarcinoma cells (Li et al., 2013). We therefore 
decided to interrogate the presence of EGFR in pancreatic cancer cells (PCCs) 
with genetic loss of Tip30. We hypothesized that Tip30-loss would alter EGFR 
protein levels, and expected to see an inverse relationship between EGFR protein 
levels and Tip30 copy number loss. Three validated murine pancreatic cancer cell 
lines isolated from K30C pancreatic tumors, with either a Tip30-wild-type, Tip30-
heterozygous, or Tip30-null genetic background (Table 4), were utilized to 
examine EGFR protein levels. 
Interestingly, only the Tip30-heterozygous PCCs exhibited increased EGFR 
protein levels (Figure 37A-B). Tip30-heterozygous PCCs had a seven-fold 
increase in EGFR compared to Tip30-wild-type PCCs; and EGFR levels in Tip30-
null PCCs compared to Tip30-heterozygous PCCs were decreased significantly 
(p=0.046). Tip30-heterozygosity also resulted in a 70% increase in Egfr transcript 
levels (did not reach statistical significance) while PCCs with complete loss of 
Tip30 exhibited a 50% decrease in Egfr mRNA levels (n=3, p=0.01 by one-way 
ANOVA) when compared to Tip30+/- PCCs (Figure 37C). We also used confocal 
microscopy imaging to assess the localization of EGFR in K30+/-C PCCs and to 
confirm our biochemical observations of EGFR protein levels. Compared to
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Figure 37. Tip30-heterozygous PCCs have increased EGFR protein and transcript levels  
(A) Representative immunoblot of basal EGFR and N-cadherin levels in mPCCs from K30C and 
K30Ctd+/- GEMMs with wild-type (+/+), heterozygous (+/-), and homozygous (+/-) loss of Tip30 (n=2 
shown). Experiment was repeated three different times per cell line except for GFP cell lines, 
(performed once). (B) Densitometry quantitation of EGFR levels in A. Data represent the 
densitometry means ± SEM of three independent cell lines per group: K30+/+C-TP151-GFP, -
TP711, -TP715 PCCs; K30+/-C-TP573, -TP647, -TP852-GFP PCCs; and K30-/-C-TP592-1, -TP889, 
-TP735-GFP PCCs. Protein levels were normalized to loading control (α-Tubulin, and K30+/+C PCC 
levels (+/+). One-way ANOVA followed by Tukey post-hoc test performed on three biological 
replicates per group (three different cell lines per group). p<0.05 was considered statistically 
significant. (C) Relative Egfr transcript levels in K30C PCCs. Egfr mRNA levels were normalized to 
β-actin. Data represent the means ± SEM of three cell lines per group. One-way ANOVA followed 
by Tukey post-hoc test for n=3 cell lines per group (see list in B). p<0.05 was considered statistically 
significant. +/+, Tip30 wild-type; +/-, Tip30-heterozygous; -/-, Tip30-null.  
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K30+/+C and K30-/-C PCCs, EGFR levels were highest in K30+/-C PCCs (n=2). 
Thirty minutes of 1 nM EGF treatment resulted in a change of EGFR distribution 
from cytosolic to perinuclear in K30+/-C PCC line TP573 (from mouse ID TP573) 
(Figure 38). The cell line with the lowest EGFR protein level in the K30+/-C group 
(TP852-GFP) had an increase in HER2 and HER3 levels. Other than this 
observation in that single cell line, genetic loss of Tip30 did not seem to significantly 
alter HER2 and HER3 levels (data not shown).  
4.2.4 N-Cadherin and E-Cadherin Protein Levels in Tip30-Deficient mPCCs 
Rely on Tip30 Gene Dose  
Epithelial cell migration is known to require the loss of cell polarity and cell-
cell adhesion properties, as well as an acquisition of mesenchymal properties 
including upregulation of mesenchymal-cell like markers (Padua and Massagué, 
2009; Voon et al., 2017). The process whereby cells shift towards a more migratory 
and invasive state and express marker levels associated with their altered state is 
known as epithelial-mesenchymal transition or EMT (Nieto et al., 2016). Circulating 
pancreatic cancer cells that are N-cadherin-positive harbor a mesenchymal and 
invasive phenotype and show low E-cadherin levels (Rhim et al., 2012). Although 
both E-cadherin-positive and -negative cells from mice with pancreatic 
intraepithelial neoplasia (PanIN) were capable of forming pancreatic tumors in 
mice in a study by Rhim et al., E-cadherin-low PanIN cells that had undergone 
EMT displayed an advantage in tumor-initiation (Rhim et al., 2012). We sought to 
investigate if loss in Tip30 gene copy number resulted in pancreatic cancer cells 
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Figure 38. Perinuclear EGFR accumulation as a consequence of EGF treatment in a cell line 
isolated from the Tip30-heterozygous K30C mouse 
K30+/-C-TP573 PCCs were treated with 1 nM EGF after serum starvation overnight for the indicated 
time points (0-120 minutes of EGF treatment). EGFR distribution (green) is shown with DAPI 
nuclear stain (blue). White arrows point to perinuclear localization. Scale bars: 20 μm.
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that were more EMT-like, characterized by increased N-cadherin and decreased 
E-cadherin levels. 
Interestingly, similar to the EGFR observations, we found that N-cadherin 
levels were increased in K30+/-C PCCs (n=2, Figure 37A). The N-cadherin levels 
in the third K30+/-C cell line, TP852-GFP, were undetectable precluding 
quantitative presentation of the data. However, in the Tip30-null mPCC lines 
analyzed (n=3), N-cadherin protein levels were lower when compared to K30+/-C 
PCCs (Figure 37A). We note that these latter observations are from just two K30+/-
C cell lines. Additionally, two liver-met PCC lines from K30-/-C mice exhibited lower 
N-cadherin levels compared to metastatic PCCs from the lung (not shown). In 
addition to low N-cadherin levels, Tip30-null PCCs exhibited a six-fold decrease in 
E-cadherin protein levels when compared to Tip30-heterozygous PCCs (p=0.054, 
Figure 39) and Tip30-wild-type PCCs (p=0.058). There was no significant 
difference in CK-19 levels in mPCCs between each group (Figure 31).  
4.2.5 Overexpression of microRNA-10b Increased Basal EGFR and AKT 
Levels in Human AsPC-1 Pancreatic Cancer Cells 
MicroRNA (miR)-10b is an antagonist of TIP30 in pancreatic and 
esophageal cancer cells (Ouyang et al., 2014; Dong et al., 2014). Furthermore, 
miR-10b overexpression in human pancreatic cancer cells (hPCCs) lowers Tip30 
mRNA levels by half when compared to control (Ouyang et al., 2013) similar to the 
levels seen in the pancreas tissues and PCCs from K30+/-C mice (Figure 11A, 
Figure 23C). To confirm the finding that Tip30-heterozygosity was the cause of   
 178 
 
 
 
 
 
 
Figure 39. Tip30-null PCCs have decreased E-cadherin protein levels 
(A) Representative immunoblot of basal E-cadherin levels from two different mPCC lines obtained 
from two K30+/+, +/-, and -/- C mice. (B) Representative immunoblot of basal E-cadherin levels for 
three technical replicates of one GFP cell line from a K30+/+, +/-, and -/- Ctd+/- mouse. (C) 
Densitometries of protein levels in A-B were normalized to respective loading controls and to mean 
K30+/+C PCC E-cadherin protein levels (Ctrl). Data represent the densitometry means ± SEM of 
three independent cell lines per group: K30+/+C-TP151-GFP, -TP711, -TP715 PCCs; K30+/-C-
TP573, -TP647, -TP852-GFP PCCs; and K30-/-C-TP592-1, -TP889, -TP735-GFP PCCs. One-way 
ANOVA followed by Tukey post-hoc test was performed. p<0.05 was considered significant for n=3 
(three separate PCC lines from each group of K30+/+, +/-, and -/-C or td+/- mice). Wild-type (+/+), 
heterozygous (+/-), and homozygous (+/-) loss of Tip30.  
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increased basal EGFR levels, we evaluated basal EGFR protein levels and 
downstream effectors, in a human PDAC cell line (AsPC-1) engineered to 
overexpress miR-10b (AsPC-1-miR-10b-OX-GFP). This cell line was established 
in the Korc laboratory (Methods 2.16). AsPC-1-miR-10b-OX-GFP human PCCs 
(hPCCs) were confirmed to exhibit an eight-fold increase in miR-10b microRNA 
levels (p=0.012, n=3), when compared to control (AsPC-1-GFP-C), (Figure 40). 
Three independent experiments were performed, and miR-10b levels were 
normalized to the internal loading control RNU6B. 
MicroRNA (miR)-10b-overexpressing AsPC-1 cells were probed for 
phosphorylated and total EGFR and AKT, using an antibody specific for EGFR and 
with no cross-reactivity with other ErbB family members and a pan AKT antibody 
after 0, 10, 30 minutes (min) or 24 hours (hr) EGF treatment (Figure 41). AKT (or 
protein kinase B) is a serine/threonine protein kinase involved in regulating cell 
survival (Pap and Cooper, 1998). A subset of PDAC tumors are reported to have 
high levels of AKT2 (Yamamoto et al., 2004). At basal conditions, miR-10b 
overexpression increased both total and phosphorylated EGFR and AKT levels 
(Figure 41). Total AKT levels remained relatively consistent between untreated 
and 10-min to 24-hr, EGF-treated conditions in AsPC-1-miR-10b-OX-GFP 
compared to control hPCCs (Figure 41). A similar trend of increasing 
phosphorylated-EGFR (pEGFR) and phosphorylated-AKT (pAKT) levels was 
observed in both AsPC-1-miR-10b-OX-GFP and control AsPC-1-GFP-C hPCCs 
treated with EGF (Figure 41). However, increase in the phosphorylated protein 
levels were slightly more pronounced in AsPC-1-miR-10b-OX-GFP cells (n=3, not   
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Figure 40. miR-10b levels in human AsPC-1 PCCs with miR-10b-overexpression  
qRT-PCR was used to assess the microRNA (miR)-10b levels in miR-10b-overexpressing human 
AsPC-1 cells (AsPC-1-miR-10b-OX-GFP) as compared to control (AsPC-1-GFP-C). CT values 
were obtained and normalized to RNU6B per experiment, and the fold increase is depicted. Data 
represent the mean ± SEM of three independent experiments. Student’s two-tailed t-test was used 
for statistical significance. p<0.05 was considered statistically significant.  
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Figure 41. Basal EGFR and AKT protein levels are increased in AsPC-1 pancreatic cancer 
cells overexpressing miR-10b 
(A) AsPC-1-miR-10b-OX-GFP (10b-OX) or AsPC-1-GFP-C (Ctrl) PCCs were treated with 0, 10, 30 
minutes (min), or 24 hours (hr) 1 nM EGF after 24 hr serum-starvation (low-serum conditions) and 
were examined for phosphorylated (p) and total EGFR, AKT, and pERK1/2 protein levels and β-
actin loading control. A representative immunoblot (of at least three independent experiments) is 
shown. (B) Data represent the densitometry means ± SEM of three to four experiments shown in 
A. pAKT and AKT densitometries are from four independent experiments. Protein levels were 
normalized to loading controls and then to the 0 min-Ctrl for pEGFR, EGFR, and AKT. pAKT levels 
were normalized to loading control only. 
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statistically significant). An increase in pERK1/2 was also observed in miR-10b-
overexpressing AsPC-1 cells after 10-30 minutes of EGF treatment (Figure 41). 
4.3 Summary 
Tip30-deficient immortalized mouse embryonic fibroblasts were reported to 
increase in cell number with each copy number loss of Tip30 in a 2D growth assay 
(Xiao et al., 2003); therefore, we investigated whether the loss of TIP30 could lead 
to accelerated 2D and 3D murine PCC (mPCC) growth kinetics. Due to the role of 
TIP30 in EMT and metastasis (Zhu et al., 2015; Zhao et al., 2007; Shtivelman, 
1997), we also predicted that in addition to enhancing proliferation, loss of Tip30 
could lead to alterations in expression of EMT markers and an invasive phenotype 
in PCCs. To this end, we observed that Tip30 loss accelerated the colony growth 
formation both in vitro and in a three-dimensional culture system of primary 
oncogenic-Kras PCCs isolated from K30C pancreas tissues. Differences in Tip30 
copy number resulted in differences in mPCC-accelerated growth and colony 
morphology in 3D. In addition, metastatic Tip30-null PCCs isolated from the liver 
had a growth advantage in 2D (Figure 33B, n=2) and 3D when compared to Tip30-
heterozygous PCCs isolated from pulmonary tissues of K30+/-C mice (not shown). 
K30+/-C metastatic PCCs took longer to form visible colonies in 2D when compared 
to K30-/-C metastatic PCCs (Figure 33B). Interestingly, EGFR levels were 
increased seven-fold in Tip30-heterozygous PCCs compared to Tip30-wild-type 
PCCs (Figure 37B, n=3). Tip30-null PCCs had low levels of basal EGFR protein 
compared to both Tip30-heterozygous and wild-type PCCs; however the decrease 
in EGFR was only significant when compared to Tip30-heterozygous PCCs 
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(p=0.046 by one-way ANOVA, n=3, Figure 37B). This trend for increased EGFR 
was also observed at the mRNA level, and by assessing localization by confocal 
microscopy.  
Lastly, we found that both basal EGFR and AKT levels were increased in a 
human pancreatic cancer cell line, AsPC-1, overexpressing miR-10b. These 
findings further support our observation that Tip30-heterozygosity (or partial loss) 
increased basal EGFR levels in pancreatic cancer cells. Immunofluorescence 
studies confirmed that Tip30 status did not result in a striking difference in CK-19 
levels between mPCCs. Immunofluorescence studies did reveal, however, the 
presence of alpha-SMA in these PCCs, especially those with heterozygous-Tip30 
loss. However further quantitation and western analyses would need to be done, 
as not all mesenchymal-like markers were observed to be increased in this study 
(data not shown). While N-cadherin was found to be increased in Tip30-
heterozygous mPCCs, Vimentin levels were not consistently increased when 
compared to Tip30-wild-type mPCCs. There were also no significant differences 
detected in p53 protein levels (data not shown). Tip30+/- mPCCs exhibited 
increased N-cadherin (n=2) with no change in E-cadherin when compared to 
Tip30-wild-type PCCs. In contrast Tip30-/- mPCCs exhibited low N-cadherin and 
E-cadherin levels (Figure 37A vs Figure 39C). These results suggest copy loss 
of Tip30 results in an epithelial-mesenchymal hybrid phenotype, which recently 
has been described in cancer (Pastushenko et al., 2018).   
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CHAPTER 5. DISCUSSION 
Pancreatic Ductal Adenocarcinoma (PDAC) makes up the majority of 
pancreatic cancers and has a poor prognosis. This outcome is due in large part to 
its highly metastatic nature. Metastatic disease accounts for 90% of all cancer 
deaths (Chaffer and Weinberg, 2011). The current standard of care for PDAC is 
FOLFIRINOX or gemcitabine plus nab-paclitaxel. However, these therapeutic 
regimens have not made a significant impact in the overall five-year survival of 
PDAC over the past 40 years. 91-92% of patients diagnosed with PDAC die from 
this disease (Siegel et al., 2018). Factors influencing this poor outcome include 
late presentation at advanced stages of the disease, and therapeutic resistance.  
Tip30, also known as Htatip2, was originally identified as a metastasis 
suppressor in non-small cell lung cancer (NSCLC) and a proapoptotic factor 
(Shtivelman, 1997). We found TIP30 to be genetically altered in human PDAC in 
our analysis of TCGA data in cBioPortal (Witkiewicz et al., 2015; J. Gao et al., 
2013; Cerami et al., 2012). In our studies, we have generated a unique mouse 
model to study pancreatic cancer progression, and have found that the genetic 
dose of Tip30 mediates organ-specific PDAC metastasis. This study is the first 
report of the characterization of a Tip30-deficient mouse model with autochthonous 
PDAC, driven by conditional expression of oncogenic Kras to the pancreas 
epithelium (K30C). Other than a recent paper describing epithelial plasticity in 
metastatic organotropism in pancreatic cancer (Reichert et al., 2018), this is the 
first study to explore the hypothesis that Tip30-copy-number-loss guides an organ-
specific PDAC metastatic seeding event. Our findings show that KrasG12D-positive 
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pancreatic cancer cells (PCCs) seeded the lungs of K30+/-C mice as early as five 
weeks, and K30-/-C liver tissues as early as three months. In K30+/-C mice, this 
early seeding event accelerated inflammation and secondary lesion formation in 
pulmonary tissues. The observed phenomenon is hypothesized to be KrasG12D-
dependent because Tip30-heterozygous (ages two months to six months, n=6) 
and Tip30-null (ages one month to 12 months, n=21) mice, alone, did not fall sick 
nor develop any lung lesions, pancreas nodules, or tumors at necropsy. Tip30-
deficient mice alone also did not exhibited any evidence of micrometastic seeding 
to distant organs when assessed in the dual-fluorescent reporter mouse 
background.  
While our observations are novel, there are inherent limitations due to the 
noncongenic background of the mice. Whether a full-body versus a conditional 
Tip30 genetic ablation contributed to unexpected variability in the data collected 
obtained remains unknown. This variability included acceleration of disease in the 
K30+/+C background and the additional phenomenon of lung adenocarcinoma in 
combination with a PCC seeding event. While these events did not confound the 
overall conclusions, they must be taken into account for future studies that should 
aim to delineate the mechanism for PDAC organotropism and why PCC seeding 
to the lung predominated in KC mice with heterozygous-loss of Tip30. Further 
studies on genetic differences in metastatic cells that seed the lung versus the liver 
in the K30C model could provide further insight on therapeutic targets for PDAC 
patients with TIP30 alterations.  
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5.1 Early Metastatic Seeding in PDAC Precedes PDAC Detection 
The observed pancreatic cancer cell (PCC) pulmonary seeding in K30+/-C 
mice, and micrometastatic liver-seeding in three-month-old K30+/-C mice, before 
detection of PDAC tumor at necropsy, demonstrates the challenges involved in 
PDAC detection. In a report by Rhim et al. (2012), PCC dissemination preceded 
detection of pancreatic ductal adenocarcinoma by histological analysis (Rhim et 
al., 2012). Similar to the Rhim et al. (2012) study, our histopathological analyses 
did not reveal PDAC at such early time points. However, K30+/-C mice with 
pulmonary lesions did exhibit some pancreas pathology and PDAC-associated 
disease that ranged from ductal atypia to PanIN-3. In PDAC patients, there is no 
correlation between metastatic presentation and tumor size (Alteri et al., 2017; 
Hidalgo, 2010; Haeno et al., 2012); therefore, we would expect similar variability 
in mPDAC models. Also, disease reoccurrence is linked to early metastatic events 
that sometimes do not appear at initial diagnosis (Pantel et al., 2008). Metastasis 
evolution studies point to two different models to explain metastatic occurrence: a 
linear progression model (late dissemination) and a parallel progression model 
(early dissemination) (Turajlic and Swanton, 2016). The parallel progression 
model, which assumes that dissemination is more than a one-time occurrence and 
that the clones responsible for establishing metastases seed long before primary 
tumor detection in the clinic, more closely fits our findings (Turajlic and Swanton, 
2016). 
We hypothesized that PCCs seed the lung tissues of Tip30-heterozygous 
K30+/-C mice early, as Tip30-heterozygous-KC mice presented with increased 
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incidence of grossly visible lung lesions as early as five-eight weeks. For KC mice 
that were Tip30-null, both frank tumor presentation and metastatic nodule 
formation, an indication of macrometastasis and the last stage of a tumor cell’s 
metastatic colonization process (Obenauf and Massagué, 2015), was observed at 
later time points (nine to eleven months) with pancreatic tumors as big as 15 mm 
in diameter. A horizontal transfer of information via exosomes is one mechanism 
that could explain our observation of early micrometastatic seeding in the liver of 
three-month-old K30-/-C mice with an overall low incidence of PDAC. One PDAC 
study shows that the formation of the liver pre-metastic niche occurs before PDAC 
lesion formation and is due to pancreatic cancer exosome uptake by hepatic 
stellate cells (Costa-Silva et al., 2015). Further research is required to determine if 
exosomes play a significant role in our model. Of all groups evaluated for our 
studies, the K30+/-C group became moribund early and had the poorest survival 
outcome, although differences did not reach statistical significance. At necropsy, 
42% of K30+/-C mice (n=13/31) had large pulmonary lesions of varying size and 
phenotype. While we did not expect these lesions to be lung adenocarcinoma, the 
finding that 45% (n=5/11) of abnormal lung tissues assessed by histopathological 
analysis had detectable lung adenocarcinoma could be explained by the BALB/c 
mouse strain. Previous investigators reported an increased incidence of 
pulmonary tumors and lung adenocarcinoma in Tip30-deficient BALB/c mice 
compared to Tip30-wild-type mice, albeit at 78 weeks of age (Ito et al., 2013).  
The concept that tumor size does not have to correlate with a tumor’s 
tendency to metastasize was explored in a candidate metastasis suppressor 
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Caveolin-1 (Cav1) study using bone marrow-derived dendritic cells (BMDCs) in a 
breast cancer model (Celus et al., 2017). Investigators reported that mice 
reconstituted with bone marrow from WT or Cav1 knock-out (Cav1KO) mice 
exhibited no difference in primary tumor growth or weight; however, mice 
reconstituted with Cav1KO marrow had a two-fold increase in lung metastases 
compared to WT-marrow mice (Celus et al., 2017). In contrast, and alignment with 
original models for tumor-metastasis dogma, investigators have shown that 
pancreatic cancer cells acquire the genetic mutations necessary for metastasis 
later in evolution and after the development of the primary-tumor-initiating cell 
(Yachida et al., 2010).   
In our model system, we detected pancreatic cancer cell seeding as early 
as two months in the lung, and three months in the liver, of K30C mice with 
heterozygous and homozygous loss of Tip30, respectively. It is important to note 
that the cell tracing/tracking technique, via the dual-fluorescent tdTomato-EGFP 
mouse introduced in this model, enabled the detection of these early metastatic 
seeding events. Also, bright-field analysis of a field of metastatic Tip30+/-PCCs in 
culture confirmed that GFP-positive and GFP-negative cells were 
indistinguishable. We suspect that the PCCs that seeded the lung were dormant 
and did not colonize. Successful colonization requires malignant evolution of either 
the disseminated cell population or the tumor microenvironment (Nguyen et al., 
2009). Use of lineage tracing or a dual method of detection will be critical to identify 
early metastatic seeding events in PDAC. Studying disseminated cells that have 
successfully seeded a target organ early will help uncover differences for why 
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PCCs seed the lung versus the liver. They may also shed insight into the switch 
that allows a dormant tumor cell to become competent for colonization. The 
dormancy switch is not yet understood in pancreatic cancer.  
5.2 PDAC Liver vs. Lung Metastasis: PDAC Metastatic Organotropism 
We found that PCCs in K30+/-C mice predominately seeded the lung while 
PCCs in K30-/-C mice seeded the liver. To understand the role of Tip30 dose in 
mediating organ-specific metastasis, we first considered reported cases of PDAC 
metastases to the liver versus the lung in PDAC patients. In a review article by 
Yachida and Iacobuzio-Donahue, pulmonary and abdominal lymph node 
metastasis is most common in one-third of patients that do not have hepatic 
metastases at autopsy (Yachida and Iacobuzio-Donahue, 2007). Both the liver and 
lung are sites of relapse for pancreatic cancer (reviewed by Nguyen et al., 2009). 
In a recent study hPDAC patients with more poorly differentiated tumors were 
found to associate with liver- over lung-metastasis recurrence; and the cohort of 
PDAC patients with lung recurrence had increased lymph node metastases (Sahin 
et al., 2018). Lymph node spread varies in humans diagnosed with Stage IV 
pancreatic cancer (Alteri et al., 2017; Hidalgo, 2010). How these data are impacted 
by limitations in detection is not clear. Interestingly, in our studies the group of mice 
with more poorly differentiated PDAC (K30-/-C) exhibited increased incidence of 
liver metastasis. In contrast, Tip30-heterozygous-KC mice were the only group of 
K30C mice that presented with an incidence of either lymph node invasion or 
lymph node metastasis in a three-month cohort. However, associations between 
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genotype and our observation of early lymph node metastasis are limited by small 
sample size and experimental design. 
Bypass of liver metastases in PDAC patients can be attributed to 
hepatofugal portosystemic shunting due to obstruction of the splenic vein or to 
aggressive features of the primary carcinoma as is reviewed in Yachida and 
Iacobuzio-Donahue (2007). The results presented herein, including 1) poorer 
survival outcome in K30+/-C mice, 2) detection of increased K30+/-C lymph node 
invasion or metastasis after evaluation of pancreas histology in an age-matched 
cohort, and 3) lack of symmetry and an invadopodia-like protrusions in 3D cultures 
of Tip30+/- PCCs, support our interpretations that Tip30 hetloss induces an 
aggressive subtype of tumorigenesis and PDAC-associated lesions when coupled 
with oncogenic Kras. Our in vitro findings also support an aggressive K30+/-C-
pancreatic cancer cell (PCC)-phenotype; however, studies are still needed to 
confirm the invasive potential of primary and metastatic Tip30+/- PCCs. 
Assessment of more cell lines per group would also strengthen our study. 
Prior and more recent studies on PCC dissemination and metastasis, using 
genetically engineered mouse models (GEMMs) of PDAC, recapitulate the 
phenomenon of PCC metastases to both the liver and lungs (Rhim et al., 2012; 
Reichert et al., 2018). According to findings from Reichert and colleagues (2018), 
the cause for liver versus lung organotropism in the mPDAC model evaluated was 
related to epithelial plasticity and the loss of one versus two copies of p120catenin 
(p120ctn). In these studies, mono-allelic loss of p120ctn, a stabilizer of E-cadherin, 
mediated KrasG12D-driven liver metastasis (Reichert et al., 2018). While we did not 
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assess epithelial cell marker stability, we observed that Tip30-null PCCs had 
markedly decreased levels of E-cadherin, further supporting a role for E-cadherin 
in mediating PDAC metastasis to the liver. However, we note that there was no 
significant difference in E-cadherin protein levels between Tip30-wild-type and 
Tip30-heterozygous PCCs.  
Marked phenotypic differences between Tip30-deficient and Tip30-null 
PDAC tissues by gross and microscopic evaluation supported our Tip30-dose 
dependent metastatic organotropism interpretations. Pancreata from KC mice with 
one-copy-loss of Tip30 were phenotypically different from KC-Tip30-null mouse 
pancreata. In K30+/-C mice with pancreatic nodule presentation that appeared to 
be multifocal, we identified ductal atypia and advanced PDAC precursor lesions, 
commonly pancreatic intraepithelial neoplasia (PanIN). These observations are in 
line with theories that describe cancer origins as multicentric: microscopically 
related but growing independently before coalescing into a single tumor (Slaughter 
et al., 1953). While oncogenic Kras appeared to drive disease progression in the 
K30C model, Tip30 copy number loss enhanced pancreatic tumorigenesis. In 
contrast, K30-/-C mice did not have a more advanced lesion distribution in the 
group of mice assessed. Pancreatic tumor presentation was detected late (nine-
eleven months) in these mice. Overall, K30-/-C mice lived longer than K30+/-C mice, 
but this difference allowed for an increased opportunity for larger pancreatic tumor 
mass formation. Tumors from late K30-/-C mice looked like classic PDAC tumors 
and these tumors were not difficult to discern from normal pancreas at necropsy. 
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Our results suggested that Tip30 gene dosage mediates organotropic differences 
observed in PCC seeding of distant organs.  
In our studies, we based our conclusions on the data as a whole; however, 
it is important to note that even within groups there were differences between mice. 
These differences within each group did not permit differences between groups to 
reach statistical difference, despite examining considerable numbers of animals 
per group. PDAC tumors are very heterogeneous; and each human patient has a 
unique tumor blueprint in addition to commonalities when compared to patients 
with other tumors. The K30C mice in our studies displayed a similar heterogeneous 
tumor landscape. While pancreatic nodules predominated in K30+/-C mice and 
frank PDAC tumor formation or liver metastasis in K30-/-C mice, not all mice 
developed nodules or liver metastasis. Whether these differences were the result 
of differences in TIP30 protein levels between animals within each group or other 
epigenetic changes that affected gene expression is unknown. For example, in the 
Tip30-heterozygous group, there was a variation in Tip30 mRNA levels between 
mice, but analysis of protein levels from the pancreata of the same mice did not 
mirror these differences. The significance of those variations on impacting the 
results is not well understood. Also, whole genome sequencing on PCC lines 
isolated from at least two separate mice from each group did not reveal any 
differences in the Tip30 coding region or additional mutations at the genetic level. 
Moreover, functional activity assays would need to be done to fully understand 
these differences. 
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5.3 Accelerated Pulmonary Seeding of Pancreatic Cancer Cells (PCCs) in 
K30+/-C Mice 
Ito et al. (2003) demonstrated that 18-20-month-old Tip30-deficient mice 
developed increased tumor prevalence, with a slightly higher incidence observed 
in Tip30-heterozygotes. Alternately, Li et al. (2013) reported a 33% incidence of 
lung adenocarcinoma in Tip30-null mice at 19.5-months. In our studies, we 
confirmed an increased pathology affecting both pancreas and pulmonary tissues 
in mice heterozygous for Tip30 compared to Tip30-null mice in the KC background. 
When we introduced the oncogenic Kras murine mouse model of PDAC (KC) into 
the Tip30-deficient background (K30C), we observed increased pancreas 
pathology as well as more advanced disease in both K30+/-C and K30-/-C mice as 
compared to the K30+/+C group. While Tip30-null/KC mice developed frank tumors 
at 9 to 11 months and earlier signs of micrometastatic seeding to the liver, K30+/-
C mice had a phenotype that appeared similar to the Li et al.(2013) study, but at 
an accelerated rate (an average of 3 months compared to 19.5 months). Our data 
support that this increased pathology is the result of PCC dissemination and 
seeding to pulmonary tissues in K30+/-C mice.  
Two methods were used in this study to evaluate PCC seeding to the lungs 
of K30+/-C mice. First, the “Kras G12D Conditional PCR” method (Jacks, 2017) 
which differentiates a wild-type Kras allele, a LSL-KrasG12D transgene, and a 
recombined 1-LoxP-KrasG12D PCR product (Jacks, 2017; Hingorani et al., 2003) in 
pancreas tissues from transgenic mice. The presence of oncogenic Kras in the 
endogenous Kras locus, driven by the tissue-specific promoter Pdx1, to the 
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pancreas, was used to identify PCCs in both primary pancreatic tumors and 
metastatic sites, including lung tissue biopsies using this method. The second 
method utilized GFP-labeling through the incorporation of a dual-fluorescent 
reporter mouse, also driven by Pdx1-Cre. This confirmed the presence of GFP-
positive PCCs in the lung tissue of a K30+/-C mouse. These GFP-positive cells 
were isolated, sorted, and were found to be positive for oncogenic Kras by 1-LoxP-
KrasG12D-positivity. Our findings suggest that PCCs with oncogenic Kras elicit an 
activity (to promote malignant transformation) that likely synergizes with the 
microenvironment where copy-loss of one Tip30 allele persists. This combination 
of events is therefore most likely responsible for the accelerated formation of lung 
adenocarcinoma after PCC dissemination to lung tissues because we observed 
the lung lesion/adenocarcinoma phenomenon on average of 13 months earlier 
than previously reported. The lung adenocarcinoma may have been selected for 
and outcompeted PCC macrometastases, which would have been detected by 
histological analysis (as it was observed for K30-/-C-TP889). We hypothesize that 
our observations in vivo may be linked to the increased EGFR levels observed in 
K30+/-C primary PCCs. 
Results from the original study on the KC mouse model (Hingorani et al., 
2003) suggest that nonspecific recombination of oncogenic Kras in pulmonary 
tissues is highly unlikely. Whole-body GFP imaging and GFP localization after 
Pdx1-Cre mediated recombination supported the specificity of GFP labeling to 
pancreas tissues. Why only one-copy of Tip30 loss resulted in significant 
pulmonary lesion formation in our model is unclear. Lung tissues from K30+/-C mice 
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with grossly visible pulmonary lesions were abundant with inflammation and 
macrophage infiltration. Alveolar macrophages are the first line of defense against 
pathogens that come in contact with the lung (Rubins, 2003); therefore, an 
inflammation storm may have occurred in response to a PCC seeding event in our 
studies. This environment may not have been permissive for true colonization of 
the PCCs, which would explain the lack of detectable macrometastases by gross 
observation or histology. 
We used Kras G12D Conditional PCR (Jacks, 2017) combined with a 
method for visual tracking of PCCs by GFP-labeling (after confirming Pdx1-Cre-
specific GFP-fluorescent pancreas tissues as depicted in Figure 25) to detect 
pancreatic cancer cells that had disseminated to distant organs. The source of 
GFP-labeling utilized was the LoxP-tdTomato-LoxP-EGFP reporter mouse 
(Muzumdar et al., 2007) or “td” after Pdx1-Cre mediated excision of the tdTomato 
cassette. We were able to, therefore, track micrometastatic seeding in compound 
mutant K30Ctd mice. Hingorani and colleagues (2003, Supplemental) originally 
evaluated Pdx1-Cre for driving the pancreas-specific expression of oncogenic 
Kras in KC mice. Hingorani et al. (2003, Supplemental) did not detect Pdx1-Cre 
activity or recombination in the lungs nor the liver of KC mice.  
The significant increase in pulmonary lesions in young K30+/-C mice 
compared to other groups suggested that Pdx1-Cre activity did not lead to 
recombination in lung tissues, in the K30C model. This observed phenotype also 
appeared to be specific to K30C mice with heterozygous loss of Tip30, considering 
13 out of 31 K30+/-C mice were affected compared to only 2 out of 20 K30-/-C mice. 
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Therefore, we hypothesized that pancreatic cancer cells seeded the lung and 
created a microenvironment that promoted lung adenocarcinoma due to Tip30-
heterozygosity. The surrounding lung cells may have become transformed and 
resulted in lung adenocarcinoma selection and outgrowth, over a pancreatic 
cancer metastatic event. After the PCCs disseminated to the lung, they may have 
been unable to colonize and form detectable metastases if the environment was 
not favorable for growth proliferation or if their proliferative growth properties were 
not sufficient to allow for metastasis. Metastastic colonization at distant tissues is 
an inefficient process (reviewed by Gay and Malanchi, 2017). The metastatic niche 
or microenvironment must be permissive or else disseminated tumor cells can 
exist in a state of dormancy (Gay and Malanchi, 2007; Chambers et al., 2002). 
Additionally, studies show that the organ microenvironment can influence cancer 
cell gene-expression patterns (reviewed by Chambers et al., 2002).  
Although we uncovered pancreatic cancer cell dissemination to the lung 
tissues of K30+/-C mice, it was not clear if the migration and dissemination of the 
pancreatic cancer cells caused a change in the pulmonary environment or if Tip30-
heterozygous loss in the lung primed the pulmonary environment for pulmonary 
lesion formation. It would be interesting to evaluate if the latter resulted in a specific 
molecular landscape that attracted pancreatic cancer cells. When cancer cells 
seed a site, they have a potential to exert their malignant growth signature on and 
transform surrounding cells via the field effect. A field effect, referred to initially as 
“field characterization” in a 1953 study, refers to the preconditioning and influence 
that a cell has on its environment (Slaughter et al., 1953). These influences can 
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manifest in the form of irreversible changes in a particular cell’s environment. In 
cancer, this concept helps discern between individual, original cancer cells and the 
once-unaffected peripheral cells that incorporate cancer-inducing alterations 
based on their proximity and location (Slaughter et al., 1953). Reports of non-cell 
autonomous effects of mutant KRAS have previously been published (Bao et al., 
2017; Beckler et al., 2012; Grabocka and Bar-Sagi, 2016). In the study by Beckler 
et al. (2012), investigators reported that exosomes released from KRASG13D-
mutant colorectal cancer (CRC) cells were internalized by isogenically-matched 
wild-type KRAS colorectal cancer cells and resulted in the enhanced three-
dimensional growth in soft agar of both KRAS WT CRC cells and rat intestinal 
epithelial cells (Beckler et al., 2013). Therefore, mutant KRAS was transferred from 
mutant cells to wild-type cells via exosomes (Beckler et al., 2013). In addition, 
according to TCGA, genetic alterations in which one allele of KRAS is lost and the 
second allele mutated is common in human PDAC (J. Gao et al., 2013; Cerami et 
al., 2012). Our studies support the idea that the metastatic seeding event observed 
was an oncogenic Kras-driven event, as metastasis was not observed in mice that 
did not have the KrasG12D mutation. 
The absence of recombined DNA in the normal lung tissue biopsies and the 
presence of GFP-positive cells in the lung tissue of the K30+/-C-TP852 mouse at 
two months led us to hypothesize that PCCs were seeding the lungs. The absence 
of conditional LSL-KrasG12D allele recombination in the lung and liver tissues of the 
KC model, as reported by Hingorani et al. (2013, Supplemental), supported our 
interpretations of this metastatic seeding phenomenon. Further investigation is 
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needed to study whether pulmonary Tip30-heterozygosity resulted in increased 
metastatic lung-seeding or if Tip30-heterozygosity synergized with Tip30-
heterozygous PCC activity, which then resulted in accelerated secondary lesion 
formation. The ratio of GFP-positive to GFP-negative cells visualized in culture 
may be representative of the distribution of PCCs and lung cells in the pulmonary 
lesion; predictably, it would be a high lung cell-to-PCC ratio. Also, the presence of 
two populations of cells also became evident in the DNA analysis of GFP-positive 
versus GFP-negative sorted cells, cultured from the lung lesion of the K30+/-Ctd+/-
-TP852 mouse. 
Since our observations were in mice whose average ages were three 
months, the likelihood for an off-target recombination event in the lung tissues of 
KC mice was low (Hingorani et al., 2003, Supplemental). Accelerated lung lesion 
formation, in the Tip30-heterozygous K30C model, was probably driven by 
paracrine or autocrine signaling between the disseminated PCCs and surrounding 
alveolar cells or lung resident cells (Obenauf and Massagué, 2015). An 
accelerated metastatic seeding event to pulmonary tissues, in our observations, 
was supported by the identification of pancreatic lesions in the pancreas tissues 
and detectable lymph node invasion and metastasis as early as three months in 
K30+/-C mice. PDAC patients with lymph node metastasis have a poorer prognosis 
(Kanda et al., 2011). Also, mice overexpressing the lymphangiogenic growth factor 
VEGF in the pancreas islets, develop lymph node metastases while VEGFC-
deficient mice do not (reviewed by Stacker et al., 2002). While the KC model alone 
typically results in a long latency to tumor development with a low frequency of 
 199 
metastasis, metastases to both the lung and liver were nevertheless reported 
(Hingorani et al., 2003). Therefore, metastasis is a plausible phenomenon in 
GEMMs that utilize the KC mouse model. In our hands, we observed an 
accelerated progression to PDAC for K30+/+C mice alone, compared to what was 
reported in the literature, and were able to confirm no interference of contaminating 
transgenes based on validation studies (Appendix A). K30+/+C mice presented 
with tumors at six months, and PDAC was detected in n=2/2 of these mice by 
histopathological analysis.  
Future experiments are needed to determine whether the PCCs isolated 
from K30+/-C lungs or KrasG12D-positive DNA found in biopsied pulmonary lesions 
in K30+/-C mice are not of pulmonary origin. These studies, and additional staining 
for pancreatic cancer cell markers in the lung tissue, will further confirm that these 
cells are of pancreatic origin. Testing for the presence of bone morphogenetic 
protein 7 (BMP7), a protein involved in the dormancy of metastatic prostate cancer 
cells, may also shed light on the state of disseminated PCCs in the lung (Kobayashi 
et al., 2011). In a review on organ-specific metastasis, BMPs secreted by lung 
resident cells resulted in breast cancer cell differentiation and dormancy (Obenauf 
and Massagué, 2015). However, as evident by the data in our studies, 
disseminated pancreatic cancer cell presentation might not evolve into a classic 
colonization or macrometastatic event, both of which are easily detected by gross 
observation. It is possible, however, that TP852 may have fallen sick at two months 
due to complications unrelated to PDAC seeing that PDAC had not yet developed 
in this mouse, and PDAC precursor lesions were not detected. 
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In addition, one K30+/-C mouse had 1-LoxP-KrasG12D positive DNA in a 
pulmonary region that appeared healthy and not yet affected. The third mouse 
without any symptoms and of the KC genotype was also found to have GFP/1-
LoxP-KrasG12D-positive PCCs in a culture of cells isolated from its lung. Even in 
the pancreas, recombination is not 100% efficient, as reported in Hingorani et al. 
(2003). This is a limitation of the Pdx1 promoter, and was observed in pancreas 
tissues from K30C mice by the Kras G12D Conditional PCR analysis (see 
Pancreas in Figure 24, Appendix C2.C). 
5.4 Copy Number Loss of Tumor Suppressor Tip30: Translational 
Relevance and Therapeutic Potential 
We expected to see the poorest survival outcomes in K30C mice that were 
Tip30-null. However, our findings were inconsistent with that expectation. Instead, 
complete loss of Tip30 was protective, allowing prolonged survival and bypass of 
detectable disease by gross evaluation at earlier time points (three months). The 
initial differences in survival outcome observed (in KC mice with heterozygous loss 
in Tip30 compared to homozygous loss) led us to initially hypothesize that Tip30 
was functioning as a haploinsufficent tumor suppressor in our model. Further, 
monoallelic loss of Tip30 would result in the poorest disease outcome, similar to 
Beclin 1 (Qu et al., 2003). In vivo, tumor-initiating cells could have been 
compensating for Tip30-/- loss resulting in slowed disease progression to PDAC. 
Although we did not characterize the tumor microenvironment during PDAC 
initiation in our model, we suspect that there may be enhanced fibroblast and 
pancreatic stellate cell activation and recruitment based on our observation of 
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dense, fibrotic tumors with marked desmoplasia in the K30-/-C group. Both 
pancreatic stellate cells (Bachem et al., 2004) and activated cancer associated 
fibroblasts or CAFs (reviewed in Wang et al, 2017) contribute to extracellular matrix 
(ECM) deposition and remodeling; studies have also demonstrated that CAFs are 
the only cell type required to initiate tumor growth (reviewed in Wang et al., 2017). 
At this time we cannot explain why two-copy loss of Tip30 resulted in frank PDAC 
tumor development in K30-/-C mice as compared to the other K30C groups, but we 
did confirm that PCCs from Tip30-null K30-/-C PDAC tumors had a two-dimensional 
and three-dimensional growth advantage. Further studies are needed to 
understand the mechanism. An alternative hypothesis is that complete loss of 
Tip30 eventually leads to the activation of EGFR-independent tumor growth 
promoting mechanisms. Further studies are needed to evaluate these proposed 
claims.  
K30+/-C mice had an average 50% decrease in pancreatic Tip30 mRNA 
level as compared to age-matched controls; and whole genome sequences of two 
Tip30+/- PCCs isolated from K30+/-C mice displayed an intact wild-type Tip30 
sequence (data not shown). However, the difference in TIP30 protein levels 
between the two groups appeared to be greater than a 50% decrease. While the 
explanation for this differential was not clear, it may contribute to the poor survival 
and early disease outcome observed in K30+/-C mice, as compared to K30-/-C 
mice. Perhaps, the complete loss of Tip30 leads to one pathway in our mPDAC 
model while loss of one copy induces a post-translational modification that results 
in aberrant TIP30 protein function.  
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We observed that decrease in Tip30-gene dose led to an associated 
increase in pancreatic cancer cell growth in 2D and 3D growth. A similar trend in 
growth was reported by Ito et al. (2003) for Tip30+/+, Tip30+/-, Tip30-/- immortalized 
mouse embryonic fibroblasts (MEFs). However, we did not observe a gene dosage 
effect when analyzing EGFR and N-cadherin protein levels. Instead, one copy loss 
of Tip30 led to increased EGFR levels in cell lines derived from our model, while 
loss of both copies of Tip30 did not significantly impact EGFR levels when 
compared to Tip30-wild-type PCCs. Lack of detectable EGFR levels in Tip30-null 
PCCs may have been due to a negative feedback loop after complete loss of 
TIP30. A compensatory pathway may have triggered this feedback loop after the 
complete loss of Tip30 gene expression. Also, loss of both copies of TIP30 may 
not be a biologically occurring event in PDAC. These ideas would also further 
investigation to confirm the role of TIP30. 
Interestingly, monoallelic deletions (TIP30-HETLOSS) make up all TIP30-
copy number loss alterations in human PDAC cases (hPDACs) (Witkiewicz et al., 
2015). The Cancer Genome Atlas (TCGA) does not show any hPDAC cases with 
homozygous deletions in TIP30 in either the UTSW or the TCGA Provisional 
datasets (Witkiewicz et al., 2015; J. Gao et al., 2013; Cerami et al., 2012). 
Therefore the K30-/-C observations in our studies may be due to the 
microenvironmental selective pressure of our genetically engineered mouse model 
(see review by Ben-David et al., 2018). Comparatively, we do not know if TIP30-
HETLOSS PDAC cases have an epigenetic modification that negatively affects the 
remaining wild-type allele. Hypermethylation of the second allele could lead to total 
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loss of TIP30. While there are instances of missense mutations in TIP30 across 
various cancers, a genetic alteration of homozygous deletion in TIP30 is 
uncommon (J. Gao et al., 2013; Cerami et al., 2012). For instance, in a cohort of 
963 breast cancer patient samples sequenced and reported in the TCGA 
Provisional database in cBioPortal, there were only two cases of TIP30 
homozygous deletion (J. Gao et al., 2013; Cerami et al., 2012). Complete loss of 
Tip30, plus oncogenic Kras-driven PDAC initiation in our model may have selected 
for tumor formation and the pathology we observed in K30-/-C mice.  
Because a subset of PDAC patients exhibit heterozygous loss, according 
to TCGA data (Witkiewicz et al., 2015) our observations and findings have a 
potential for translational relevance. This group of TIP30-deficient patients may 
benefit from therapies that target TIP30 loss; however, the data obtained from 
TCGA first needs to be validated. Although the RPKM (reads per kilobase per 
million mapped reads) measure is widely used and accepted for high-throughput 
sequencing data interpretation, there are some in the field who do not consider it 
to be an accurate measure of relative molar RNA concentration (Wagner et al., 
2012). On the other hand, although the TCGA data from our studies were not 
validated, microarrays were conducted in a cohort of 106 PDAC patient samples 
from the Pancreas Disease Center of Changhai Hospital, and a scoring system 
determined that while 50.9% of PDAC cases in the cohort were TIP30-high, 
TIP30-low patient samples were associated with lymph node metastasis (Guo et 
al., 2014). Therefore, pancreatic cancers with TIP30 loss may represent a unique 
subclass which requires novel therapeutic strategies. 
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5.5 EGFR-KRAS Signaling Axis, Kras-Induced Aggressiveness in the 
K30+/-C Model 
In one K30+/-C mouse, the genomic DNA from the pulmonary lesion tissue 
biopsy tested positive for full recombination of the conditional LSL-KrasG12D allele 
with loss of the wild-type Kras allele. One thought in response to such an 
observation is that a loss of heterozygosity occurred. Loss of the wild-type Kras 
allele, also known as “loss of heterozygosity (LOH) at Kras”, has been reported to 
promote metastasis in the p16flox/flox;LSL-KrasG12D;Pdx1-Cre mouse model, and 
was found in cell lines derived from metastases compared to matched primary 
tumors (Qiu et al., 2011). The investigators confirmed that this LOH phenomenon 
had occurred in vivo (Qiu et al., 2011).  
In the case of esophageal squamous cell carcinoma (ESCC), although 
decreased TIP30 expression was not reported to be associated with increased 
tumor size, it did significantly correlate with lymph node metastasis and 
differentiation (Dong et al., 2014). After mining TCGA data, we did not find a 
significant association between TIP30 copy number loss and PDAC survival in 
hPDAC cases (Witkiewicz et al., 2015). Patients with low TIP30 levels may not 
have had a poorer survival outcome when compared to PDAC patients with high 
TIP30 levels. It is possible that the limited number of available patient samples in 
the dataset, including PDAC patients with normal levels of TIP30, and disease-
free controls (or limitations in sample quality) skewed survival results. Any 
treatment that patients may or may not have received before tumor sequencing 
may also play a role in survival outcome. In the Li et al. (2013) study, TIP30-low-
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expressing lung adenocarcinoma patients had a higher median survival compared 
to TIP30-high-expressing lung adenocarcinoma patients; the investigators 
attributed this result to TIP30-low patients having a better response to EGFR-
targeted therapy (Li et al., 2013). Tip30 loss is reported to sustain EGFR signaling 
(Zhang et al., 2010; Li et al., 2013; Zhang et al., 2011). Whether Tip30 loss 
cooperates with Kras activity has not yet been studied. KC mice are reported to 
have increased GTP-bound Ras protein levels in the pancreas when compared to 
littermate controls (Hingorani et al., 2003). The functional relevance of the Kras 
mutation for both the KrasG12D/+ and Tip30-/- or Tip30+/- genotypes in our mouse 
models can be assessed using a Ras activity assay. Ras activity has been linked 
to metastatic outcome in PDAC (Muzumdar et al., 2017); therefore, these 
additional studies could reveal the function or mechanism behind some of our 
novel observations in Tip30-deficient K30C mice.  
EGFR has been an attractive target in cancer research due to the increased 
EGFR expression in various tumors have, including PDAC (Korc et al., 1992; 
Navas et al.; 2012; Fjӓllskog et al., 2003; Tobita et al., 2003). To add to this, 
oncogenic Kras-driven PanIN lesions and PDAC is dependent on EGFR signaling 
(Navas et al., 2012). In our studies, we found that mPCCs positive for mutant Kras 
with Tip30-heterozygosity resulted in a seven-fold increase in EGFR protein levels 
when compared with mPCCs with mutant Kras alone. The human pancreatic 
cancer cell line, AsPC-1, also exhibited an increase in basal EGFR levels with miR-
10b overexpression. miR-10b directly represses TIP30 mRNA (Ouyang et al., 
2014, Dong et al., 2014). Constitutive EGFR overexpression leads to neoplasia, 
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and EGFR ablation in the KC mouse model abolishes pancreatic transformation 
(reviewed by Crawford et al., 2019). EGFR has been proposed to be required for 
the initial Kras loading of GTP or that it activates the protein product of the 
remaining wild-type Kras allele (Crawford et al., 2019). In 2007, a large randomized 
phase III clinical trial for the EGFR inhibitor erlotinib plus gemcitabine modestly 
improved median survival of PDAC patients when compared to gemcitabine alone, 
with p=0.038 (Moore et al., 2007). Other EGFR inhibitors or combinatorial 
therapies targeting EGFR and insulin growth factor receptor (IGFR) have had 
mixed efficacy in clinical trials. For instance cetuximab plus gemcitabine did not 
lead to statistical significance in overall survival (Philip et al., 2009), while gefitinib 
plus gemcitabine had promising results for patients with PTEN expression 
(Fountzilas et al., 2008). While one study linked an increase in EGFR with PDAC 
liver metastasis, another study reports that PDACs with family member ERBB2 or 
HER2 overexpression lacked liver metastases and were associated instead with 
lung and brain metastasis (Chou et al., 2013). In a clinical trial for HER2 
overexpressing metastatic pancreatic cancer patients, targeting HER2 
overexpression with trastuzumab plus chemotherapeutic capecitabine did not lead 
to improvements in median overall survival (Harder et al., 2012). One limitation of 
the study was the small patient sample and patients with HER2 expression 
(reviewed by Adamska et al., 2017), however the investigators do not recommend 
HER2 targeting to treat metastatic PDAC. In a cohort of 469 PDAC patients, the 
prevalence of a HER amplification was 2% (Chou et al., 2013). Overexpression of 
HER2 was observed in one out of three Tip30-heterozygous K30C cell lines. 
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Protein levels in this cell line were low when compared to the other two cell lines 
from that group, however both EGFR and HER2 levels were elevated when 
compared to Tip30-wild-type and Tip30-null PCCs. Study into the circumstances 
that lead to an increase in EGFR levels versus HER2 levels could provide further 
insight into TIP30’s mechanism of action in PDAC. Also, the subset of PDAC 
patients with TIP30 heterozygous loss may be more responsive to EGFR or HER2 
targeted therapy.  
5.6 Questions of Leakiness and Pdx1-Cre Specificity 
Pancreatic duodenal homeobox 1 (Pdx1) is expressed in the pancreas 
epithelium and is required for pancreas development and differentiation as early 
as embryonic day 8.5; Pdx1 is also expressed in regions that will give rise to the 
duodenum and stomach (Green et al., 1992; Offield, 1996; Gu et al., 2003; Gannon 
et al., 2001; reviewed in Babu et al., 2007). In the field of pancreatic cancer 
modeling, Pdx1-Cre is not known to have off-target effects in the lung or liver 
(Magnuson and Osipovich, 2014). However, limitations exist in all model systems. 
For instance LSL-KrasG12D; Pdx1-Cre mice were reported to have mucocutaneous 
papillomas in addition to intestinal metaplasia as early as two months (Hingorani 
et al., 2003). LSL-KrasG12D;Pdx1-Cre mice are reported to develop sporadic 
mucocutaneous papillomas, intestinal metaplasia, and hyperplastic polyps of the 
duodenum (Hingorani et al., 2003, p.441). These observations still raise questions 
about more precise control in experimental models and suspicions of leakiness in 
mouse model systems. For this reason, we generated controls from within the 
colony for these studies. Also, the organotropic metastases observed in these 
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studies did not appear at random, but was linked to the genetic dose of Tip30. 
Although unlikely, we acknowledge the possibility of leakiness in all experiments 
that utilize genetically engineered mouse models. To combat these concerns, 
other in vivo model systems use a two-step control of conditional expression to 
minimize leakiness and off-target effects (Collins et al., 2012; Feil et al., 2009; 
reviewed in Herreros-Villanueva et al., 2012). Since hPDAC is a disease of the 
adult pancreas, conditional aberrant expression in adult mouse pancreas tissues 
may not only address issues of leakiness but may also be more relevant. In 
addition, use of an orthotopic model whereby labeled pancreatic cancer cells are 
directly injected into the pancreas may serve as another alternative to more 
confidently link metastatic seeding in distant organs with primary tumor formation.  
While the use of a beta-galactosidase reporter to assess Pdx1-Cre 
expression in all tissues was not performed in these studies, recombination-based 
lineage tracing has been shown previously (Kawaguchi et al, 2002; Gu et al., 2002; 
Hingorani et al., 2003). Both Pdx1 localization and Pdx1-Cre activity has been 
thoroughly investigated (Offield et al., 1996; Gu et al., 2002; Kawaguchi et al, 2002; 
Hingorani et al., 2003); and KC mouse model (Hingorani et al., 2003) is commonly 
used for murine PDAC studies (Guerra and Barbacid, 2013). For instance, through 
the use of a LacZ-PDX1 fusion allele, Pdx1 was first detected at embryonic day 
E8.5 (Offield et al., 1996). At E9.5, it was visible in the dorsal and ventral pancreatic 
buds and the duodenal endoderm (Offield et al., 1996). At E18.5, just before birth, 
Pdx1 expression was reported to be restricted to the developing pancreatic islet 
(Offield et al., 1996). Pdx1-null embryos lack islet differentiation and mature 
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pancreatic beta cells and acinar cells (Offield et al., 1996). Perinatal stages had 
similar boundaries and expression levels of PDX1 (Offield et al., 1996). In situ 
hybridization studies by Gu et al. (2002), in mesenchymal, endothelial, and smooth 
muscle cells, revealed human placental alkaline phosphatase (HPAP) reporter 
expression in pancreas acini, islets and ducts in four and eight-week-old Pdx1-
Cre/Z/AP reporter mice as well as in a tamoxifen-induced Cre mouse model 
system, with Cre induction at E9.5 (Gu et al, 2002). Consequently, there is no 
literature precedent for extra-pancreatic/duodenal expression of PDX1.  
To date, there have been no reports in the literature of Pdx1 expression or 
Pdx1-Cre activity in tissues in the liver or lung in LSL-KrasG12D; Pdx1-Cre mice 
(reviewed by McKinnon and Docherty, 2011; Hingorani et al., 2003). In Hingorani 
et al. (2003, Supplemental) recombination was not detected in lung or liver tissues 
in KC mice by a PCR method to detect the recombined KrasG12D allele. 
Nevertheless, we cannot exclude the possibility that a recombination event early 
in embryogenesis occurred in a progenitor cell of developing liver or lung with a 
different fate than that of the pancreas. The pre-pancreatic ventral foregut 
endoderm, the lung bud, the trachea, and the hepatic diverticulum all are derived 
from the ventral foregut endoderm (Serls et al., 2005). However, pancreas-, liver-, 
and lung-specific genes are required for hepatic and lung bud development (Serls 
et al., 2005). In addition to the expression of specific transcription factors, growth 
factors, such as the fibroblast growth factor (FGF), and their concentration 
thresholds determine cell fate (Serls et al., 2005). In theory, it would only take one 
molecule of Cre recombinase expression to result in a recombination event in a 
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cell fated to become lung tissue, leading to a source of oncogenic Kras in the lung. 
Reports of Pdx1-Cre leakage to the brain do exist (Song et al., 2010). 
5.7 Limitations in Detection by Histology 
In addition to the discussion in section 5.1, it is possible that histological 
evaluation alone may not be sufficient to detect PDAC metastasis or metastatic 
pancreatic cancer cells. We only examined one slice of lung tissue, and even so, 
sites of metastasis can easily be missed during sectioning and slide preparation. 
Further staining with a more rigorous panel of markers and examination of lung 
sections for GFP-labeled pancreatic cancer cells would allow for more thorough 
characterization of the lung microenvironment. 
5.8 Whole-Body Tip30-Deficiency  
We cannot exclude the possibility that Tip30-deficiency in the lung 
contributed to lung adenocarcinoma formation or even to metastatic seeding 
because the Tip30-deficient K30C mouse used in these studies had a whole-body 
Tip30-deficiency. Tip30-deficient mice alone did not show any signs of pulmonary 
lesions in our model, and in the literature lung adenocarcinoma and gross lesion 
formation did not occur until 19-20 months (Li et al., 2013). The BALB/c 
background is known to have a propensity to develop lung tumors and 
adenocarcinoma; according to the Mouse Tumor Biology (MTB) Database there 
are at least six separate reports of the BALB/c strain developing a high incidence 
of lung adenocarcinoma (Begley et al., 2012). In addition multiple reports have 
documented BALB/c mice developing an increased incidence of lung adenoma 
(Begley et al., 2012). MTB is based out of Jackson Laboratory and is a National 
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Institutes of Health (NIH)-driven and continuously updated repository of tumor 
biology data (Begley et al., 2012). Both studies documenting the Tip30-deficient 
mouse model (Ito et al., 2003; Li et al., 2013) did not report any incidence of 
pancreatic tumor formation, however we recognize that studies in a conditional 
Tip30-deficient mouse model would be more clinically relevant for studies of 
PDAC. It is even plausible that without a whole-body deficiency in Tip30, 
pancreatic cancer cells may be limited in their metastatic potential.  
5.9 Strain Effect on Tumor Incidence: The Importance of a Congenic 
Background 
Mouse strain and genetic background influence phenotype in studies that 
utilize transgenic mouse models (Berghe et al., 2015; Gerlai, 1996; Simpson et al., 
1997). Therefore, either the use of one strain for backcrossing to create a purer 
background or generation of controls from within the mouse colony under 
investigation is recommended. Investigators commonly backcross transgenic mice 
ten generations to attain a congenic background, i.e., backcrossing ten 
generations to the C57BL/6J mouse strain (Berghe et al., 2015). Ten generations 
of backcrossing results in a 0.1% chance that the locus from the donor strain 
remains (Lusis et al., 2007). For mice made of multiple strains (i.e., more than four, 
and referred to as “stock” by The Jackson Laboratory), there is no method to detect 
the sequence percentage of all strains involved (e.g., on four different loci). In an 
attempt to select for the strain of interest, there remains a chance of transfer of the 
donor strain with each crossing. Where there is an influence of an additional strain, 
there is a chance for an influence on phenotype. In mouse models for cancer 
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research, where certain strains have been reported to be contaminated or led to 
an increased incidence of tissue-specific tumor formation, this circumstance could 
contribute to variability in results or even novel-appearing findings. There is a risk 
for phenotypes that may or may not be attributed to the gene of interest. For 
example, the Tip30-deficient mouse in the C57BL/6 background showed an 
increase in tumors of the liver at 18-20 months (Ito et al., 2003), while the Tip30-
deficient mouse in the BALB/c background had an increase in lung tumors at 19.5 
months (Li et al., 2013). Lung tumors are known to occur at a high rate in BALB/c 
mice as they are reported to be more susceptible to adenocarcinoma of the lung 
(Begley et al., 2012; Li et al., 2013). 
Attaining background purity takes time, can be costly and challenging; 
however, doing so could prevent variations in research outcomes, lead to 
increased reproducibility, and potentially allow for smaller sample sizes to reach 
definitive conclusions in research studies. Pure genetic background, which can be 
achieved by after ten generations of backcrosses is reported to minimize variability 
in tumor penetrance, disease onset kinetics, lesion phenotype, and propensity for 
metastasis (Lee et al., 2016). Although a congenic background is exceptionally 
close to a pure background, in transferring a mutation of interest from one mouse 
background to another the region that flanks the selected gene will always remain 
donor material (Lusis et al., 2007). These genes in these flanking regions are 
termed “passengers” and can influence traits of interest (Lusis et al., 2007). 
The mice generated for these studies were the result of crosses between 
mice on a background of three or more different strains, including three different 
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sources of strain 129 (129P2), 129S4 and other strains of 129. The genetic 
variation in the 129 strain is well documented and results in phenotypic differences 
(Simpson, 1997; Threadgill, 1997). The 129 strain is also associated with a light 
tan chinchilla color, which we also observed after a few interbreedings of Tip30-
deficient mice. Although the original coat color of the mice should have been white 
(95% BALB/c background), this phenotype points to the impact that a small 5% in 
the genetic background can have when selected for accidentally through crosses. 
Crossbreeding the B6;129-Kras2tm4Tyj (KrasG12D/+ or KrasG12D mice) strain with 
B6.FVB-Tg(Ipf1-cre)1Tuv mice has resulted in vulvar and periauricular papilloma 
presentation in as many as 40% of progeny (Gades, 2008). We also observed 
rectal and vulvar masses in our studies. Phenotypic variability also highlights the 
need for increased sample size to meet statistical significance. Indeed, the 
phenotypic results in the mice that developed tumors were so variable that even 
when using our results as preliminary data to perform a power analysis for future, 
the number of mice needed was unpractical. 
Lymphoma is the most common tumor in GEMMs, and BALB/c background 
is highly susceptible to lung adenomas (Percy and Barthold, 2008; Ward, 2006). 
Lymphoma prevalence in the B6;129 strain can also be found through the MTB 
Database (Begley et al., 2012). The background of the Tip30-deficient mouse 
model that was used to generate each group of mice in this colony consisted of 
roughly 5% of the 129P2(B6) background that is referenced in Ward, 2006, 
according to The Jackson Laboratory. This small percentage is enough to 
contribute and pass on strain-related predispositions. One limitation of using mice 
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from a stock strain is that these mice consist of more than four different strains, 
according to Jackson Laboratory. Therefore identification of all of the strains 
present in one’s experimental group of mice is difficult to discern. It is important to 
note that a near pure genetic background, which can be achieved after ten 
generations of backcrosses, can minimize variability in tumor penetrance, disease 
onset kinetics, lesion phenotype, and propensity for metastasis (Lee et al., 2016). 
These data on the influence of genetic background on tumor penetrance are well 
documented for mouse models of mammary (Guy et al., 1992; Lifsted et al., 1998) 
and colon cancers (Beckwith et al., 2005; Mahler and Leiter, 2002; Bristol et al., 
2000) and are beginning to be mentioned for GEMM research of pancreatic cancer 
(Lee et al., 2016).   
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CHAPTER 6. CONCLUSION AND FUTURE DIRECTIONS 
We hypothesized that loss of Tip30 would result in poor PDAC prognosis 
based on evidence of TIP30’s proapoptotic and metastasis suppressive functions. 
Here we describe a novel genetically engineered mouse model (GEMM) of PDAC 
where we employed previously established mouse models, KC (Hingorani et al., 
2003), and the Tip30-deficient mouse (Xiao et al., 2003) to generate a novel K30C 
mouse model to study PDAC. Our results in this murine model of PDAC support a 
tumor- and metastasis- suppressive role for Tip30 in PDAC progression. Based on 
our observations, we concluded that Tip30-heterozygous pancreatic cancer cells 
(PCCs) had more aggressive features than do Tip30-wild-type and Tip30-null 
PCCs. We report a pattern of preferential metastasis of pancreatic cancer cells 
(PCC’s) to lung or liver tissue mediated by single Tip30 genetic loss.  
In conclusion, we found that Tip30 loss and heterozygosity accelerated 
organ-specific pancreatic cancer cell (PCC) metastasis. We observed a delayed 
onset of frank PDAC tumor formation in KC mice that were Tip30-null with an 
increased prevalence of micrometastatic seeding compared to K30+/-C 
heterozygous mice, KC (n=3), or Tip30-null control mice (n=22). We concluded 
that the K30+/-C group of mice had more aggressive pancreas lesions by 
histopathological analysis in a three-month cohort when compared to K30+/+C and 
K30-/-C mice, and increased distribution of PanIN-2/3 lesions and PDAC. Just as 
phenotypic differences were observed in pancreata of K30+/-C versus K30-/-C mice, 
differences between PCCs isolated from pancreas tissues from both groups were 
visible in 3D cell cultures. Although PCCs from K30+/-C mice had a more 
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aggressive phenotype and increased EGFR levels compared to PCCs from KC 
and K30-/-C mice, they had less proliferative potential and less 2D and 3D colony 
area formation when compared to Tip30-null PCCs. The trend of increase in 
growth with increasing Tip30 copy number loss was first reported by Ito and 
colleagues and in immortalized mouse embryonic fibroblasts (MEFs) (Ito et al., 
2003). We expected a dose-dependent increase in EGFR levels as Tip30 copy 
number decreased. However, we observed that only the K30+/-C PCCs had 
increased EGFR levels. Our finding that EGFR levels were increased only in PCCs 
with both oncogenic Kras and Tip30-heterozygous loss was novel; this increase in 
EGFR did not appear to have an impact on proliferation in two-dimensional or 
three-dimensional growth culture conditions. In regards to epithelial-mesenchymal 
transition (EMT), we observed that Tip30-null PCCs had decreased E-cadherin 
protein levels without an increase in N-cadherin. It would be interesting to 
investigate if the metastatic PCCs that seeded the liver had increased levels of E-
cadherin and underwent the reverse of EMT, mesenchymal-epithelial transition 
(MET) to regain epithelial properties. Future RNA sequencing studies comparing 
the gene expression between Tip30-heterozygous and Tip30-null primary and 
metastatic PCCs would likely reveal gene-dose dependent effects of Tip30 on 
signaling pathways. 
In addition, lung lesions and lung adenocarcinomas (as early as five and 
eight weeks in predominately K30+/-C mice, n=13/31, compared to the reports of 
presentation of such events at 78 weeks from the original Tip30-deficient mouse 
model and predominately in Tip30-/- mice), alerted us to a different phenomenon 
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than previously published. It is possibly that what we observed in our model was 
due to the addition of the PDAC-initiating KrasG12D mutation that was conditionally 
targeted to the pancreas epithelium during embryogenesis. Heterozygous loss of 
Tip30 resulted in lung or pulmonary seeding of pancreatic cancer cells in KC mice 
as detected by LoxP-KrasG12D DNA by PCR and tracking of GFP+ cells. On the 
other hand, homozygous loss of Tip30 resulted in liver micrometastatic seeding as 
detected by GFP analysis, and increased incidence of liver metastasis in KC mice 
compared to K30+/+C and K30+/-C mice. Interestingly, Tip30-null PCCs had 
increased two-dimensional and three-dimensional growth properties when 
compared to both wild-type and Tip30-heterozygous PCCs. In vivo, Tip30-null 
K30C mice were able to grow larger PDAC tumors, as Tip30-heterozygous K30C 
mice succumbed to disease early. Later time points revealed Tip30-dosage-
mediated differences in pancreatic tumor phenotype. 
DNA from the lung lesions tested positive for LSL-KrasG12D recombination, 
further suggesting that the advanced pulmonary lesions observed as early five 
weeks, although secondary events, were a result of PCCs migrating from the 
pancreas. Experiments using a GFP-sorted cell line established from a two-month-
old KC mouse with Tip30 hetloss (TP852) further supported that pancreatic cancer 
cells migrate to the lung. Micrometastatic seeding to the lung of this mouse was 
visible, but very faintly. It is possible that in mice with more advanced pulmonary 
lesions, an increased infiltration of immune cells resulted in increased pathology 
and masked the visibility of GFP-positive PCCs. Gross pulmonary lesions were 
observed in one of five three-month-old K30+/-Ctd+/- mice. However, GFP-positive 
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micrometastatic seeding was not visible by gross observation upon further analysis 
and the lesion was not GFP-positive. This was in contrast to the micrometastatic 
seeding visible in the two-month-old K30+/-Ctd+/- mouse. The lung tissue of K30+/-
Ctd+/--TP852 was not assessed for the presence or absence of microscopic PDAC 
metastasis lesions. However, the presence of metastatic lesions would have 
preceded gross nodule formation based on what was observed in the liver of 
Tip30-null mice. A 12-month-old Tip30-heterozygous KC mouse did develop a 
visible lung nodule; however, the histology for that tissue was not assessed. One 
three-month-old KC mouse from the TP30 colony also had GFP-positive and 
oncogenic-Kras positive PCCs cultured from lung tissue. GFP-positivity was visible 
only in culture. Future studies can assess micrometastatic seeding in all lung 
tissues and the capacity for colonization and macrometastatic outgrowth versus 
dormancy. More importantly, analysis of additional mice with conditional KrasG12D 
and Tip30 mutations or of an orthotopic model mirroring the system used for these 
studies will be necessary to further elucidate the role of Tip30 gene dose on PCC 
organotropic metastasis. 
Future directions would involve looking at lung tissues at earlier time points 
to detect total GFP+ PCCs to evaluate if metastatic seeding preceded the lesion 
formation we observed in pulmonary tissues. For example, an orthotopic study 
whereby fluorescently-labeled K30+/-C PCCs are injected orthotopically into the 
pancreas tissues of syngeneic or nude mice would allow for an alternative 
approach to monitor Tip30-deficient PCC metastatic seeding. We could also use 
this model to observe if lung metastasis still occurs in the event of Tip30 wild-type 
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lung tissues. This design would allow for the analysis of far fewer animals and 
would also shed insight to the differences in the phenotype of tumors that we 
originally observed in K30+/-C mice compared to K30-/-C mice. The following 
experiments could then uncover the mechanism of action for Tip30 copy loss in 
PDAC metastatic organotropism: 
1. RNAsequencing of Tip30+/- and Tip30-/- PCCs to uncover specific 
signaling pathways involved in mediating PDAC. 
2. Analysis of human PDAC tissue samples to validate TCGA databases 
of genetic alterations, and TIP30 gene expression both at mRNA and 
protein levels.  
3. Migration and invasion assays to understand the role of increased EGFR 
levels in Tip30+/- PCCs in mediating PDAC metastasis to the lung. 
4. Analysis of Tip30+/- PCCs with increased EGFR levels for sensitivity to 
EGFR inhibition.  
Also, if Tip30+/- metastatic PCCs isolated from the lung are more migratory than 
primary PCCs, and if this is due to increased EGFR activity, then targeting EGFR 
in combination with therapeutic regimens to treat PDAC may help better target or 
prevent metastatic disease in the subset of PDAC patients with TIP30-
heterozygous loss.  
How and why differences in Tip30 gene dose mediate organ-specific PDAC 
metastasis requires further investigation. We predict that the immune system is 
heavily involved in the observations from our studies, and impacted by the 
heterozygous loss of Tip30. Chemokines and chemokine receptors are reported 
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to play a role in organ-specific metastasis by recruiting lymphocytes and 
haematopoietic cells to certain organs (Chambers et al., 2002). K30+/-C mice with 
pulmonary lesions had an abundance of inflammation noted during 
histopathological evaluation. Therefore, further studies on the role of the immune 
response and the tumor microenvironment in the context of Tip30 loss would be 
beneficial in order to understand if Tip30 loss allows for PCC evasion of the 
immune response, as observed with the increase in macrophage infiltration in the 
lung tissues of the K30+/-C mice.  
In summary, we have generated and characterized a novel model of 
mPDAC and found that Tip30-deficiency, when coupled with the pancreas-specific 
oncogenic KrasG12D background, enhanced the overall tumor progression of K30+/-
C and K30-/-C mice and influenced organ-specific metastatic seeding. The genetic 
and phenotypic differences observed in K30C mice with either heterozygous or 
complete loss of Tip30 were translated in in vitro systems. We observed a trend of 
increased pancreatic cancer cell growth with increasing Tip30 copy loss, as well 
as increased levels of the epidermal growth factor receptor (EGFR) in primary 
PCCs derived from our most aggressive model. Our findings of enhanced basal 
EGFR using murine PCCs isolated from K30C mice were replicated using a human 
PDAC cell line that was genetically engineered to overexpress microRNA (miR)-
10b. miR-10b directly targets TIP30 mRNA for degradation (Ouyang, 2013; Dong 
et al., 2014). In these analyses, we also observed increase in downstream 
signaling markers, including AKT and phosphorylated ERK1/2, both of which play 
an important role in cell survival (Amaravadi and Thompson, 2005; Mebratu and 
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Tesfaigzi, 2010). Overall, these observations were further supported by the subset 
of patients with TIP30 hetloss according to data from The Cancer Genome Atlas 
(Witkiewicz et al., 2015). The findings from these studies combined with the 
available literature suggest that it would be useful to assess these patients’ 
metastatic status, and explore if TIP30 or its downstream targets can be 
investigated for therapies designed to target metastasis. Additionally, as a vast 
majority of cancers, including PDAC, have amplifications in TIP30 according to 
TCGA (J. Gao et al., 2013; Cerami et al., 2012), it would be equally important to 
understand the role of TIP30 overexpression in PDAC, in the context of wild-type 
miR-10b levels. Gene dose-dependent effects of TIP30 uncovered in this study 
illustrates complexities involved in pancreatic cancer progression and the difficulty 
in establishing a linear relationship between genomic aberrations, disease 
progression, and potentially therapeutic response. 
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APPENDICES 
APPENDIX A. GENOTYPING FOR ADDITIONAL MOUSE MODELS 
mp53 Genotype PCR  Rb Genotype PCR 
TP151 KC 8/4/2017  TP151 KC 8/3/2017 
TP177 KC 1/23/2015  TP151 PCCs KC 8/25/2017 
TP177  KC 4/17/2015  TP177  KC 1/23/2015 
TP180 KC 1/23/2015  TP180 KC 1/23/2015 
TP180 KC 4/17/2015  TP182 KC 1/23/2015 
TP182 KC 1/23/2015  TP184 KC 1/23/2015 
TP182 KC 4/17/2015  TP196 KC 11/10/2014 
TP184 KC 1/23/2015  TP197 KC 11/10/2014 
TP184 KC 4/17/2015  TP503 KC 5/23/2018 
TP196 KC 10/31/2014  TP545 KC 6/6/2018 
TP197 KC 10/31/2014  TP577 KC 6/6/2018 
TP578 KC 10/12/2016  TP578 KC 10/12/2016 
TP579 KC 10/12/2016  TP579 KC 10/12/2016 
TP580 KC 10/12/2016  TP580 KC 10/12/2016 
TP581 KC 10/12/2016  TP581 KC 10/12/2016 
TP711-Re KC 12/9/2016  TP711-Re KC 12/9/2016 
TP713-Re KC 12/9/2016  TP711 PCCs KC 8/25/2017 
TP715-Re  KC 12/9/2016  TP713-Re KC 12/9/2016 
TP912 KC 8/11/2017  TP715-Re KC 12/9/2016 
TP431 K30+/-C 4/1/2016  TP715 PCCs KC 8/25/2017 
TP448 K30+/-C 4/1/2016  TP834 KC 9/8/2016 
TP452 K30+/-C 4/1/2016  TP881 KC 8/11/2017 
TP473-Re K30+/-C 4/1/2016  TP912 KC 8/11/2017 
TP477 K30+/-C 4/1/2016  TP1016-Re KC 6/28/2017 
TP555 K30-/-C 4/1/2016  TP431 K30+/-C 4/6/2016 
TP573 K30+/-C 4/1/2016  TP448 K30+/-C 4/6/2016 
TP576  K30+/-C 4/1/2016  TP609 K30+/-C 4/6/2016 
TP609 K30+/-C 4/1/2016  TP622 K30+/-C 4/6/2016 
TP622 K30+/-C 4/1/2016  TP627 K30+/-C 4/6/2016 
TP627 K30+/-C 4/1/2016  TP630 K30+/-C 4/6/2016 
TP630 K30+/-C 4/1/2016     
TP881 K30-/-C 8/11/2017     
TP368 K30-/- 4/1/2016  Bmal Genotype PCR 
TP392 KT30+/- 4/1/2016  TP177 KC 1/23/2015 
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TP450-Re K30+/- 4/1/2016  TP180 KC 1/23/2015 
TP502-Re 30+/-C 4/1/2016  TP182 KC 1/23/2015 
    TP184 KC 1/23/2015 
    TP711-Re KC 12/9/2016 
miR-155 Genotype PCR  TP713-Re KC 12/9/2016 
TP912 KC 8/11/2017  TP715-Re  KC 12/9/2016 
TP881 K30-/-C 8/11/2017     
 
miR-21 (OX 
(eGFP), KO (TK, 
CK) Genotype PCR  tet-Smad7 Genotype PCR 
TP151 KC 8/4/2017  TP711-Re KC 12/9/2016 
TP177 KC 8/4/2017  TP713-Re KC 12/9/2016 
TP180 KC 8/4/2017  TP715-Re  KC 12/9/2016 
TP182 KC 8/4/2017     
TP184 KC 8/4/2017  Smad7 Genotype PCR 
TP503 KC 8/4/2017  TP711-Re KC 12/8/2016 
TP545 KC 8/4/2017  TP713-Re KC 12/8/2016 
TP577 KC 8/4/2017  TP715-Re  KC 12/8/2016 
TP711-Re KC 8/4/2017     
TP713-Re KC 8/4/2017  Ink4a Genotype PCR 
TP715-Re KC 8/4/2017  TP177 KC 1/23/2015 
TP912 KC 8/4/2017  TP180 KC 1/23/2015 
TP592 K30-/-C 8/4/2017  TP182 KC 1/23/2015 
TP647 K30+/-C 8/4/2017  TP184 KC 1/23/2015 
TP852 K30+/-C 8/4/2017  TP711-Re KC 12/9/2016 
TP892 K30-/-C 8/4/2017  TP713-Re KC 12/9/2016 
    TP715-Re  KC 12/9/2016 
       
Agr2 Genotype PCR  HER3 Genotype PCR 
TP477 K30+/-C 11/18/2015  TP151 KC 8/21/2017 
TP576-Re K30+/-C 11/18/2015  TP578 KC 3/23/2018 
TP711 KC 12/9/2016  TP579 KC 3/23/2018 
TP713 KC 12/9/2016  TP580 KC 3/23/2018 
TP715 KC 12/9/2016  TP581 KC 3/23/2018 
    TP711-Re KC 12/30/2016 
    TP713-Re KC 12/30/2016 
Smad4L/L Genotype PCR  TP715-Re  KC 12/30/2016 
TP151 KC 3/30/2017  TP912 KC 8/21/2017 
TP177 KC 3/30/2017  TP1016 KC 8/21/2017 
 224 
TP180 KC 3/30/2017  TP431 K30+/-C 3/23/2018 
TP182 KC 3/30/2017  TP452 K30+/-C 3/23/2018 
TP184 KC 3/30/2017  TP468 K30+/-C 3/23/2018 
TP711-Re KC 3/30/2017  TP473 K30+/-C 3/23/2018 
TP713-Re KC 3/30/2017  TP526 K30-/-C 3/23/2018 
TP715-Re  KC 3/30/2017  TP543 K30-/-C 3/23/2018 
TP834-Re KC 3/30/2017  TP555 K30-/-C 3/23/2018 
TP860-Re KC 3/30/2017  TP569 K30-/-C 3/23/2018 
TP864-Re KC 3/30/2017     
TP912 KC 3/30/2017  p16 Genotype PCR 
TP431 K30+/-C 3/30/2017  TP151 PCCs KC 8/25/2017 
TP448 K30+/-C 3/30/2017  TP177 KC 1/23/2015 
TP609 K30+/-C 3/30/2017  TP180 KC 1/23/2015 
    TP182 KC 1/23/2015 
    TP184 KC 1/23/2015 
Syndecan 4 Genotype PCR  TP711-Re KC 12/9/2016 
TP711-Re KC 12/9/2016  TP711 PCCs KC 8/25/2017 
TP713-Re KC 12/9/2016  TP713-Re KC 12/9/2016 
TP715-Re  KC 12/9/2016  TP715-Re KC 12/9/2016 
    TP715 PCCs KC 8/25/2017 
    TP912 PCCs KC 8/25/2017 
    TP576-panc K30+/-C 3/29/2016 
    TP630-panc K30+/-C 3/29/2016 
    TP630-Lu K30+/-C 3/29/2016 
 
This testing was to ensure that other transgenes in the lab were not mixed into the 
mice of TP30 Colony. Date of genotyping (testing) is listed under "PCR". Updated 
12/1/18. Tail DNA, unless otherwise indicated. Key: Re, tail sample collected at 
endpoint; PCCs-pancreatic cancer cells; Lu, Lung.  
 
 
Primers, Reaction Components, and Thermocycler Conditions 
 
NCOA5  
(S. Gao et al., 2013) 
 
Ncoa5 WT:    GACCGTTATCTGAGGGTGGA 
Ncoa5 Mutant (neo): GCCAGAGGCCACTTGTGTAG 
Ncoa5 Common (C):  TTCACCTGCAACCTTCTCCT 
 
2 µL  10X 
1 µL  MgCl2 
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0.5 µL  dNTPs 
0.1 µL  Common Primer 
0.1 µL  Ncoa5 WT (or Ncoa5 MT (neo)-separate reaction) 
0.1 µL  Taq 
15.2 µL ddH2O 
 
Cycling (Step #, Temperature) 
1. 95°C, 15 min 
2. 95°C, 30 sec 
3. 57°C, 1 min 
4. 72°C, 1 min 
5. Repeat steps 2-4 for 35 cycles. 
6. 72°C, 10 min  
7. 10°C, hold  
 
Ncoa5+/- = 324-bp band in both M and WT reactions 
 
MMTV-Neu  
(Jackson Laboratory, Stock #00237; Zhang et al., 2010) 
 
MMTV-Neu Reverse (R):  TTTCCTGCAGCAGCCTACGC 
MMTV-Neu Forward (F):  CGGAACCCACATCAGGCC 
MMTV-Neu IPC*-F:  CAAATGTTGCTTGTCTGGTG 
MMTV-Neu IPC-R:   GTCAGTCGAGTGCACAGTTT 
*Internal Positive Control 
 
1.8 µL  10X 
1 µL   MgCl2 
0.5 µL  dNTPs 
0.1 µL  Forward primer 
0.1 µL  Reverse primer 
0.1 µL  IPC-F 
0.1 µL  IPC-R 
0.1 µL  Taq 
15.2 µL ddH2O 
 
Cycling (Step #, Temperature) 
1. 95°C, 15 min 
2. 95°C, 30 sec 
3. 60°C, 30 sec* 
4. 72°C, 35 sec, repeat steps 2-4 for 12 cycles. 
5. 95°C, 15 min 
6. 58°C, 30 sec 
7. 72°C, 35 sec, repeat steps 5-7 for 25 cycles. 
8. 72°C, 10 min  
9. 10°C, hold  
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*Decrease -0.5°C/cycle 
 
IPC = 324 bp 
Transgene = 600 bp 
 
IL6  
(Jackson Laboratory, Stock #002650; S. Gao et al., 2013) 
 
IL6 Common (C):   TTCCATCCAGTTGCCTTCTTGG 
IL6 WT Reverse (R): TTCTCATTTCCACGATTTCCCAG 
IL6 MT Reverse (R):  CCGGAGAACCTGCGTGCAATCC 
 
1.8 µL  10X 
1 µL   MgCl2 
0.5 µL  dNTPs 
0.2 µL  Common Primer 
0.1 µL  Ncoa5 WT 
0.1 µL  Ncoa5 MT (neo) 
0.1 µL  Taq 
15.2 µL ddH2O 
 
Cycling (Step #, Temperature) 
1. 95 °C 15 min 
2. 95 °C 30 sec 
3. 62 °C 1 min 
4. 72 °C 1 min 
5. Repeat steps 2-4 for 35 cycles. 
6. 72 °C 10 min  
7. 10 °C, hold  
 
M band (380 bp) 
WT band (174 bp) 
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10 kB Ladder. IL6: WT (174 bp band only); MMTV-Neu: Negative 
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10 kB Ladder. Ncoa5: WT (324-bp band in WT reaction only) 
 
Bmal 
(The Jackson Laboratory 007668) 
Bmal FP: ACT GGA AGT AAC TTT ATC AAA CTG 
Bmal RP: CTG ACC AAC TTG CTA ACA ATT A 
 
2 µL  10X 
1.2 µL  MgCl2 
0.5 µL  dNTPs 
0.1 µL  Common Primer 
0.1 µL  Ncoa5 WT 
0.1 µL  Taq 
15.2 µL ddH2O 
 
Cycling (Step #, Temperature) 
1. 95 °C, 15 min 
2. 95 °C, 30 sec 
3. 60 °C, 30 sec 
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4. 72 °C, 30 sec 
5. Repeat steps 2-4 for 36 cycles. 
6. 72 °C 5 min  
7. 10 °C, hold  
 
M band (431 bp) 
Heterozygote (both 327 bp and 431 bp)  
WT band (327 bp) 
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1.5% gel, 10 kB ladder, 1) Het ctrl tail DNA from mouse ID X617, 2) K30+/+C-
TP177, 3) K30+/+C-TP180, 4) K30+/+C-TP182, 5) K30+/+C-TP184 
 
p16 
 
1 (P3): AGGAGTCCTGGCCCTAGAAA*  
2 (P4): CCAAAGGCAAACTTCTCAGC 
*Against the lac Z-tagged mutant allele Cdkn2a via Blast 
 
 
2 µL  10X 
1.2 µL  MgCl2 
0.5 µL  dNTPs 
0.1 µL  Forward primer 
0.1 µL  Reverse primer 
0.1 µL  Taq 
15 µL  ddH2O 
 
Cycling (Step #, Temperature) 
1. 95 °C, 15 min 
2. 95 °C, 30 sec 
3. 60 °C, 30 sec 
4. 72 °C, 40 sec 
5. Repeat steps 2-4 for 35 cycles. 
6. 72 °C, 2 min  
7. 10 °C, hold  
 
Double band: L/+ 
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Upper: L/L 
Lower: WT 
 
 
 
2% gel, 10 kb ladder. K30+/+C (TP711. TP713, and TP715) mice and tail DNA 
tested negative for the p16 transgene, as compared to the positive control.  
 
mp53 (R172H) 
 
T35:  CTTGGAGACATAGCCACACTG 
T36:  AGCTAGCCACCATGGCTTGAGTAAGTCTGCA 
 
2 µL  10X 
1 µL   MgCl2 
0.5 µL  dNTPs 
0.25 µL Forward primer 
0.25 µL Reverse primer 
0.1 µL  Taq 
14.9 µL ddH2O 
 
Cycling (Step #, Temperature) 
1. 95 °C, 15 min 
2. 95 °C, 30 sec 
3. 56 °C, 1 min 
4. 72 °C, 1 min 
5. Repeat steps 2-4 for 35 cycles. 
6. 72 °C, 2 min  
7. 10 °C, hold  
 
M band (positive) 
WT (negative) 
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2% gel, 10 kB ladder, p16 genotyping PCR: 1) Het ctrl tail DNA from mouse ID 
PD220 (did not show), 2) K30+/+C-TP177, 3) K30+/+C-TP180, 4) K30+/+C-TP182, 
5) K30+/+C-TP184; mp53 genotyping PCR: 1) positive (+) ctrl tail DNA from 
mouse ID TP131, 2) negative (-) Ctrl-Tail TP130, 3) K30+/+C-TP177, 4) K30+/+C-
TP180, 5) K30+/+C-TP182, 6) K30+/+C-TP184 
 
 
 
2% gel, 10 kB ladder. Positive control (L/+) from mouse ID TP131, negative 
control (+/+) from mouse ID TP130. K30+/-C mice (TP431, TP448, TP609, 
TP622, TP627, TP630, TP452, TP573, and TP477) tested negative for the mp53 
transgene. K30/-C mouse TP555 tested negative for mp53. 
 233 
Rb 
 
R007: GGC GTG TGC CAT CAA TG 
R008: AAC TCA AGG GAG ACC TG 
 
2 µL  10X 
1 µL   MgCl2 
0.5 µL  dNTPs 
0.25 µL Forward primer 
0.25 µL Reverse primer 
0.1 µL  Taq 
13.9 µL ddH2O 
+ 2 µL Tail DNA 
 
Cycling (Step #, Temperature) 
1. 95 °C, 15 min 
2. 95 °C, 30 sec 
3. 60 °C, 30 sec 
4. 72 °C, 1 min 
5. Repeat steps 2-4 for 35 cycles. 
6. 72 °C, 5 min  
7. 10 °C, hold  
 
L/L (Upper band)-650 bp 
L/+ (Double band)-650 and 600 bp 
+/+ or WT (Lower band)-600 bp 
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3% gel, 10 kB ladder, positive (L/+) and negative (+/+) controls from mouse ID’s 
as indicated (T2559, and F2137). K30+/-C mice TP431, TP609, TP622, TP627, 
TP630 test negative for the Rb mutant transgene.  
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3% gel, 10 kB ladder, K30+/+ Ctd+/--TP912 and TP881-K30-/-Ctd+/- were negative 
for the Rb transgene. Controls are indicated.  
 
 
miR-155 (KO) 
 
Wild type Forward: GTG CTG CAA ACC AGG AAG G  
Wild type Reverse:  CTG GTT GAA TCA TTG AAG ATG G  
Mutant:   CGG CAA ACG ACT GTC CTG GCC G 
 
2 µL  10X 
1 µL   MgCl2 
0.5 µL  dNTPs 
0.5 µL  WTF Primer 
0.5 µL  WTR Primer 
0.5 µL  MT Primer 
0.1 µL  Taq 
15.2 µL ddH2O 
+ 2 µL Tail DNA 
 
-/- (Upper band) 
+/- (Double band)  
+/+ or WT (Lower band) 
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1.5% gel, 10 kB ladder (not visible), K30+/+ Ctd+/--TP912 and TP881-K30-/-Ctd+/- 
were negative for the miR-155 transgene. Controls are indicated.  
 
miR-21 
 
2 µL  10X 
1.2 µL  MgCl2 
0.5 µL  dNTPs 
0.1 µL  Forward primer 
0.1 µL  Reverse primer 
0.1 µL  Taq 
15 µL  ddH2O 
 
miR-21 conditional (CK) 
miR-21-conditional-Forward:  GCTTACTTCTCTCTGTGATTTCTGTG 
miR-21-conditional-Reverse:  GGTGGTACAGCCATGCGATGTCACGAC 
 
Cycling (Step #, Temperature) 
1. 95 °C, 15 min 
2. 95 °C, 30 sec 
3. 60 °C, 30 sec 
4. 72 °C, 30 sec 
5. Repeat steps 2-4 for 35 cycles. 
6. 72 °C, 2 min  
7. 10 °C, hold  
 
L/L (Upper band) 
L/+ (Double band)  
+/+ or WT (Lower band) 
 
miR-21 KO (TK) 
miR-21-straightKO F:  CCGGCTTTAACAGGTG 
miR-21-straightKO R:  GATACTGCTGCTGTTACCAAG 
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Cycling (Step #, Temperature) 
8. 95 °C, 15 min 
9. 95 °C, 30 sec 
10. 62.3 °C, 30 sec 
11. 72 °C, 1 min 
12. Repeat steps 2-4 for 38 cycles. 
13. 72 °C, 5 min  
14. 10 °C, hold  
 
-/- (Lower band) 
+/- (Double band)  
+/+ or WT (Upper band) 
 
 
2% gel, 10 kB ladder. K30C mice were genotyped for the miR-21 transgenes as 
indicated above. The miR-21 transgene was not detected in any of the mice 
tested. Three tail DNA samples were low in DNA. K30+/+C-TP151, -TP177, -
TP180. -TP182, -TP184, -TP503, -TP545, -TP577, -TP711-Re, -TP713-Re, -
TP715-Re, -TP912; K30+/-C-TP852, -TP647; K30-/-C-TP592, -TP892. 
 
Agr2 
 
flox1: ATCCAACAAGCATCCACTGA 
flox2: CTTTGGCCAAGGTACCAGAA 
flox3: CTGGATCTAATTTGTGCTGAAT 
 
2 µL  10X 
1.2 µL  MgCl2 
0.5 µL  dNTPs 
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0.1 µL  Forward primer 
0.1 µL  Reverse primer 
0.1 µL  Taq 
14.9 µL ddH2O 
 
Cycling (Step #, Temperature) 
1. 95 °C, 15 min 
2. 94 °C, 30 sec 
3. 58 °C, 1 min 
4. 72 °C, 1 min 
5. Repeat steps 2-4 for 35 cycles. 
6. 72 °C, 5 min  
7. 10 °C, hold  
 
-/- (Upper band) 
+/- (Double band)  
+/+ or WT (Lower band) 
 
 
3% gel, 10 kB ladder, 1) K30+/-C-TP477, 2) K30+/-C-TP576, 3) -/- ctrl tail from 
mouse ID U1403, 4) +/- ctrl tail from mouse ID U1420, 5) -/- ctrl tail from mouse 
ID U1480. TP477 and TP576 are negative for the Agr2 transgene. 
 
tet-Smad7 
 
Tet_S7FP ATCCACGCTGTTTTGACCTC 
Tet_S7RP GAGCGCAGATCGTTTGGT 
 
Final Concentration 
1X Buffer 
1.5 mM MgCl2 
0.25 mM dNTPs 
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0.5 µM Forward primer 
0.5 µM Reverse primer 
0.025U/µL Taq 
 
Cycling (Step #, Temperature) 
1. 95 °C, 15 min 
2. 95 °C, 30 sec 
3. 60 °C, 1 min 
4. 72 °C, 1 min 
5. Repeat steps 2-4 for 34 cycles. 
6. 72 °C, 2 min  
7. 10 °C, hold  
 
Smad7 
 
EGFP mut_FP: AAGTTCATCTGCACCACCG 
EGFP mut_RP: TCCTTGAAGAAGATGGTGCG (R):  
 
Final Concentration 
1X Buffer 
1.5 mM MgCl2 
0.375 mM dNTPs 
0.6 µM Forward primer 
0.6 µM Reverse primer 
0.025U/µL Taq 
 
Cycling (Step #, Temperature) 
1. 95 °C, 15 min 
2. 95 °C, 30 sec 
3. 55 °C, 45 sec 
4. 72 °C, 1 min 
5. Repeat steps 2-4 for 34 cycles. 
6. 72 °C, 10 min  
7. 10 °C, hold  
 
M band (380 bp) 
WT band (174 bp) 
 
Ink4a 
 
Forward: CCAAGTGTGCAAACCCAGGCTCC 
Reverse: TTGTTGGCCCAGTGATGCCGACATC 
 
2 µL  10X 
1.2 µL  MgCl2 
0.5 µL  dNTPs 
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0.1 µL  Forward primer 
0.1 µL  Reverse primer 
0.1 µL  Taq 
15 µL  ddH2O 
 
L/L (Upper band): 200 bp 
L/+ (Double band)  
+/+ or WT (Lower band) 
 
 
3% gel, 10 kB ladder, positive L/L ctrl tail DNA from mouse ID 3507, L/+ ctrl tail 
DNA from mouse ID 3508, K30+/+C-TP177, -TP180, -TP182, and -TP184 tail 
DNA. 
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3% gel, 10 kB ladder. K30+/+C mice (TP711, TP713, TP715) are negative for the 
Ink4a transgene, as compared to the positive (L/L) control.  
 
HER3* 
 
SDR3:  CACTGCAGGAAGGAGAGGTC 
CCL1:  GCTATACGAAGTTATTCGAGGC 
 
2 µL  10X 
1.2 µL  MgCl2 
0.5 µL  dNTPs 
0.1 µL  Forward primer 
0.1 µL  Reverse primer 
0.1 µL  Taq 
15 µL  ddH2O 
 
Cycling (Step #, Temperature) 
1. 95 °C, 15 min 
2. 94 °C, 30 sec 
3. 64 °C, 30 sec 
4. 72 °C, 1 min 
5. Repeat steps 2-4 for 35 cycles. 
6. 72 °C, 1 min  
7. 10 °C, hold  
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2 % gel, 10 kB ladder. Tail DNA from K30+/+C mice (TP151, TP711, TP715, 
TP912, and TP1016) does not test positive for the HER3 transgene as compared 
to the positive control.   
 
 
 
2% gel, 10 kB ladder. Tail DNA from K30+/+C mice (TP578, TP579, TP580, 
TP581), K30+/-C mice (TP431, TP452, TP468, TP473), and K30-/-C mice (TP526, 
TP543, TP555, TP569) does not test positive for the HER3 transgene as 
compared to positive (R4111) and negative (R4105) controls. 
 
Smad4L/L 
(The Bardeesy Lab, Bardeesy et al., 2006b 
 
DPC6: GGGAACAGAGCACAGGCCTCTGTGACAG 
DPC9: TTCACTGTGTAGCCCCGCCTGTCCTGGA 
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2.5 µL  10X, 15 mM MgCl2 
0 µL   MgCl2 
0.5 µL  dNTPs 
1.25 µL 20 µM DPC6 
1.25 µL 20 µM DPC9 
0.13 µL Taq 
18.37 µL ddH2O 
 
Cycling (Step #, Temperature) 
1. 95 °C, 15 min 
2. 95 °C, 30 sec 
3. 60 °C, 1 min 
4. 72 °C, 1 min 
5. Repeat steps 2-4 for 33 cycles. 
6. 72 °C, 10 min  
7. 10 °C, hold  
 
M band (400 bp) 
WT band (350 bp) 
 
Smad transgene 
(The Bardeesy Lab) 
 
SM3:  TGCTCTGAGCTCACAATTCTCCT 
DPC9: TTCACTGTGTAGCCCCGCCTGTCCTGGA 
 
2.5 µL  10X, 15 mM MgCl2 
0 µL   MgCl2 
0.5 µL  dNTPs 
1.25 µL 20 µM SM3 
1.25 µL 20 µM DPC9 
0.13 µL Taq 
18.37 µL ddH2O 
 
Cycling (Step #, Temperature) 
1. 95 °C, 15 min 
2. 95 °C, 30 sec 
3. 60 °C, 1 min 
4. 72 °C, 1 min 
5. Repeat steps 2-4 for 33 cycles. 
6. 72 °C, 10 min  
7. 10 °C, hold  
 
200 bp band = Presence of null allele 
No band = Absence of null allele 
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Syndecan-4 
 
Sdc4 Primer 1:  CCCTTCCCTGAAGTGATTGA  
Sdc4 Primer 2:  GACACTGAGCACACCTCGAA 
Neomycin Primer 3: AGACAATCGGCTGCTCTGAT 
Neomycin Primer 4: ATACTTTCTCGGCAGGAGCA 
 
2 µL  10X 
0.8 µL  MgCl2 
0.5 µL  dNTPs 
0.1 µL  neo 3 
0.1 µL  neo 4 
0.1 µL  Taq 
15.4 µL ddH2O 
2 µL  10X 
1.2 µL  MgCl2 
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0.5 µL  dNTPs 
0.1 µL  Sdc4 Primer 1 (WT) 
0.1 µL  Sdc4 Primer 2 (WT) 
0.1 µL  Taq 
15 µL  ddH2O 
 
Neomycin: 261 bp 
Sdc4: 593 bp 
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APPENDIX B. MURINE PANCREATIC CANCER CELL LINE 
AUTHENTICATION AND VALIDATION 
Cell Line ID Genotype Sex Age 
(Months) 
Date Passage 
Number 
Generation 
C57BL/6 
TP151-GFP-D7 K30+/+Ctd+/- F 3 2/17/2017 18-1 0 
TP151-GFP-F5 K30+/+Ctd+/- F 3 2/17/2017 19-2 0 
TP711-C2 K30+/+C M 4 2/17/2017 8 2 
TP711-D5 K30+/+C M 4 2/17/2017 8 2 
TP715-B6 K30+/+C F 4 2/17/2017 7 2 
TP715-E2 K30+/+C F 4 2/17/2017 7 2 
TP573-D5 K30+/-C F 5 2/17/2017 28-22 0 
TP573-E4 K30+/-C F 5 2/17/2017 30-24-1 0 
TP647-E5 K30+/-C F 5 2/17/2017 12 2 
TP647-G5 K30+/-C F 5 2/17/2017 12 2 
TP852-GFP-C5 K30+/-C+/- M 2 6/1/2017 9 3 
TP852-GFP-D4 K30+/-C+/- M 2 6/1/2017 9 3 
TP592-1-D7 K30-/-C F 6 2/17/2017 14 0 
TP592-3-E4 K30-/-C F 6 2/17/2017 21-1 0 
TP735-GFP-E8 K30-/-C+/- M 3 2/17/2017 21-1 0 
TP735-GFP-F6 K30-/-C+/- M 3 2/17/2017 21-1 0 
TP892-GFP-G2* †K30-/-C+/- F 1 6/1/2017 9 3 
TP892-GFP-G4 †K30-/-C+/- F 1 6/1/2017 9 3 
 
Single cell clones (SSCs) from murine pancreatic cancer cell lines isolated from pancreas tissues 
(TP mouse colony) were authenticated by IDEXX BioResearch (Columbia, MO, USA). Date of 
completed authentication report for Single Cell Clone (SCC)-pancreatic cancer cell lines is 
indicated. IDEXX BioResearch Case # 5352-2017 (Received: 2/10/2017, Completed: 2/17/2017) 
and 161651-2017 (Received: 5/25/2017, Completed: 6/1/2017) *Incorrect ID on original report 
(Case # 16151-2017). †Mouse TP892 was produced from two parents with the Pdx1-Cre transgene 
by accident, whether it received two copies has not been validated 
 
.
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C1. List of non-tdTomato K30C control mice necropsied, examined and 
collected  
 
Non-tdTomato (K30C)  
Tip30+/+  Genotype   
TP1043 5-wk-old F K30+/+  
TP1045 5-wk-old M 30+/+C   
TP602 2-month-old F 30+/+   
TP596 2-month-old M 30+/+   
TP632 3-month-old M 30+/+C   
TP629 3-month-old M 30+/+C   
Tip30+/-  Genotype   
TP463 2-month-old F 30+/-   
TP428 4-month-old F 30+/-C   
TP437 4-month-old F K30+/-   
TP357 5-month-old M 30+/-C   
TP604 5-month-old M K30+/-   
TP520 6-month-old M 30+/-C   
Tip30-/-  Genotype   
TP319 1-month-old M K30-/-   
TP353 1-month-old F 30-/-   
TP487 1-month-old M 30-/-C   
TP816 1-month-old M 30-/-   
TP511 2-month-old F 30-/-C   
TP513 2-month-old F K30-/-   
TP518 2-month-old M 30-/-C   
TP595 3-month-old M 30-/-   
TP528 3-month-old F 30-/-C   
TP546 3-month-old M 30-/-   
TP247 4-month-old M 30-/-   
TP301 4-month-old M 30-/-C   
TP299 4-month-old M K30-/-   
TP497 4-month-old F 30-/-   
TP588 4-month-old M 30-/-   
TP593 4-month-old M 30-/-   
TP356 5-month-old M 30-/-C   
TP635 5-month-old F 30-/-   
TP366 6-month-old F K30-/-   
TP488 6-month-old M K30-/-   
TP487 6-month-old M 30-/-   
TP832 12-month old F K30-/-   
Controls Collected for TP30 Project (Tissues). TP427 Ear Tag is the mouse that is the first of the 
new PDX (NCI).  
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C2. Tip30 Genotyping, additional mRNA validation of Tip30 loss, and LSL-
KrasG12D recombination in K30C pancreata 
 
 
(A) DNA from K30C mouse pancreata was analyzed for wild-type (WT) and Tip30 mutant (Mut) 
alleles by genotyping PCR for Tip30. n=3 per group is shown. (B) mRNA from K30C pancreas 
tissues was analyzed for Tip30 exon 6 transcript levels, n=4 (2-3 month old KC-TP578, TP579, 
TP580, TP503; K30+/-C-TP431, TP452, TP473, TP448; and K30-/-C-TP526, TP543, TP555, and 
TP493). One-way ANOVA followed by Tukey post-hoc test was performed and p<0.05 was 
considered significant. (C) Kras G12D Conditional (Jacks, 2017) using 200 ng genomic DNA 
isolated from pancreata of three-month-old K30+/+C, K30+/-C, K30-/-C mice confirmed 
recombination and presence of oncogenic Kras. CTRL, Pdx1-Cre-negative control; 10 kB ladder. 
Red dashed arrow, recombined 1-LoxP-KrasG12D allele (650 bp). Black solid arrow, wild-type Kras 
allele (622 bp). Red solid arrow, unrecombined 2-LoxP allele (500 bp). K30+/+C-TP197, TP228, 
TP578, TP579, TP580, TP581 mice; K30+/-C-TP431, TP452, TP468, TP470, and TP684; K30-/-C-
TP364, TP336, TP400, TP404, TP526, TP543, and TP555. (Unlabeled sample belongs with last 
group but was loaded out of place.)  
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C3. Gross examination of three-month old K30C mice  
 
Total body mass (Weight) just before necropsy is noted in grams (g).   
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C4. Strong alcian blue staining of mucinous K30+/-C pancreas lesions 
 
 
(A-B) K30+/+C mice: TP578 (A) and TP579 (B). (C-D) Representative images from two K30+/-C 
mice: TP452 (C) TP431 (D). Scale bars: 100 μm. 
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C5. Pulmonary lesion incidence in K30C cohorts 
Genotype Mouse 
ID 
Age 
(Mont
hs) 
Sex Pulmonary 
Lesion (+) 
K30+/+C TP503 2 F  
K30+/+C TP545 2 F  
K30+/+C TP577 3 M  
K30+/+C TP578 3 M  
K30+/+C TP579 3 M  
K30+/+C TP580 3 M  
K30+/+C TP581 3 M  
K30+/+C TP584 4 M  
K30+/+C TP711 4 F  
K30+/+C TP713 4 M  
K30+/+C TP715 4 M  
K30+/+C TP597 5 F  
K30+/+C TP625 5 M  
K30+/+C TP1163 5 F  
K30+/+C TP1053 5 F  
K30+/+C TP652 6 F  
K30+/+C TP1062 6 F  
K30+/-C TP576 1.25 M + 
K30+/-C TP440 2 F  
K30+/-C TP448 2 F + 
K30+/-C TP455 2 F  
K30+/-C TP476 2 M  
K30+/-C TP682 2 M + 
K30+/-C TP718 2 M  
K30+/-C TP431 3 M + 
K30+/-C TP452 3 M + 
K30+/-C TP468* 3 M  
K30+/-C TP470 3 F  
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K30+/-C TP473 3 M  
K30+/-C TP684 3 M  
K30+/-C TP775 3 M  
K30+/-C TP477 4 F + 
K30+/-C TP478 4 F  
K30+/-C TP498 4 F  
K30+/-C TP500 4 F  
K30+/-C TP609^ 4 F + 
K30+/-C TP622* 4 F + 
K30+/-C TP627 4 F + 
K30+/-C TP630 4 M + 
K30+/-C TP544 5 F  
K30+/-C TP573 5 F  
K30+/-C TP647 5 F + 
K30+/-C TP686 5 F  
K30+/-C TP752 5 M + 
K30+/-C TP1061 5 F  
K30+/-C TP623 6 F  
K30+/-C TP1004 8 M + 
K30+/-C TP851* 10 F  
K30+/-Ctd+/- TP852 2 M + 
K30+/-Ctd+/- TP728 3 M + 
K30-/-C TP843 1 F  
K30-/-C TP443 2 F  
K30-/-C TP493 2 M  
K30-/-C TP516 2 M  
K30-/-C TP519 2 M  
K30-/-C TP526 3 M  
K30-/-C TP543 3 M  
K30-/-C TP555 3 M + 
K30-/-C TP569 3 F  
K30-/-C TP716 4 F  
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K30-/-C TP717 4 F  
K30-/-C TP587 4 M  
K30-/-C TP590 4 M  
K30-/-C TP634 5 M + 
K30-/-C TP592 6 F  
K30-/-C TP812 8 F  
K30-/-C TP880 8 F  
K30-/-C TP813 9 F  
K30-/-C TP889 9 M  
K30-/-C TP853 11 M  
     
±, subjects that were imaged.  
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C6. Tip30-deficiency induces early onset pulmonary abnormalities and 
lesions in K30C mice 
 
 
 
(A-B) K30+/-C mouse, TP682, lungs in situ. (B) Ex vivo. (C-D) Additional K30+/-C mice in situ and 
ex vivo. (C) TP752 ex vivo. (D)TP647 in situ. (E) One of two K30-/-C to present with a pulmonary 
abnormality. TP634 in situ. (F) Ex vivo.  
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C7(A). Fluorescence-Activated Cell Sorting (FACS) of Tip30-wild-type 
pancreatic cancer cells  
 
 
P4 is the population of cells that was collected to establish the GFP-positive pancreatic cancer 
cells (PCC) lines. P3 was considered to be a GFP-negative population. Gating was to the 
negative control (a non td+/- cell line).  
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C7(B). Fluorescence-Activated Cell Sorting (FACS) of Tip30-deficient 
pancreatic cancer cells (PCCs)  
 
 
P4 is the population of cells that was collected to establish GFP-positive pancreatic cancer cells 
(PCC) lines. P3 is considered to be a GFP-negative population. Gating was to the negative 
control (a non td+/- cell line.   
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C8. Genomic DNA from K30+/-C mouse pancreas and pulmonary lesion 
tissues is 1-LoxP-KrasG12D-PCC positive  
 
 
Recombined 1-Lox-KrasG12D (red dot) is shown for both pancreas and lung lesion biopsies but not 
the adjacent normal lung tissue in five-week-old mouse ID TP576. Kras G12D Conditional PCR 
method (Jacks, 2017). PCR products were run with increased gel electrophoresis separation. 
DNA from the muscle tissue was negative for recombination. Mouse ID TP630 (3.5 months of 
age) has recombined 1-Lox-KrasG12D (red dot) in the pancreas and evidence of DNA that tests 
positive for full recombination (yellow dot) in its pulmonary lesion. The adjacent normal lung 
tissue, although appeared normal by gross observation, was positive for both recombined (1-
LoxP-KrasG12D) and unrecombined (2-LoxP-KrasG12D). This suggested that this tissue biopsy 
consisted of both 1-LoxP-KrasG12D PCCs and lung cells. Pdx1-Cre results in stochastic 
expression of Cre in the pancreas epithelium, hence lack of full recombination for those tissues. 
First two columns under each mouse are controls, the first being a negative control for both the 
LSL-KrasG12D transgene and the Pdx1-Cre transgene, DNA from pancreas tissue of mouse ID 
TP418 (WT); and the second a K30+/+C control (however this sampling of pancreas tissue for this 
mouse (TP228) appears not to be positive for LSL-KrasG12D recombination, although originally 
genotyped as a K30+/+C mice at weaning) is positive for both the LSL-KrasG12D and the Pdx1-Cre 
transgenes (2-Lox) as well as wild-type Kras (WT). Ladder, 10 kB.  
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C9. Micrometastatic seeding detected in two-month-old K30+/-Ctd+/--TP852 
pulmonary tissue 
 
 
Frank pancreatic tumor was not grossly observed (inset, unaltered). Lung tissue was imaged 
using RFP and GFP filters and a fluorescent light box imaging resource. Lung image has been 
brightened and contrasted both by 70% to better allow for visualization of observed 
micrometastatic seeding at necropsy (white arrows). Upon brightening and contrasting the 
captured image one can also see additional sites of potential metastatic seeding (cyan arrows).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
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C10. Detectable GFP positivity in pancreas and small intestine of K30+/+C 
mice using RFP/GFP fluorescent light box imaging  
 
 
(A) TP834 (Generation 0, male, 2 months). (B) TP912 (Generation 3, male, 3 months). (C) TP957 
(Generation 4, male, 3 months). D-F Liver (top row) and pancreas (bottom row) tissues from 
corresponding mice in A-C, TP834, TP912, and TP957, respectively. Generation reflections 
number of backcrosses to the C57BL/6 background.   
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C11. An 11-month old K30-/-Ctd+/- mouse with GFP positive micrometastatic 
seeding in the intestines and liver 
 
 
(A) Pdx1-Cre activity in the intestines. (B) Micrometastatic seeding in the liver. Mouse ID is 
TP746. 
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